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ABSTRACT 
Laminitis, a serious and debilitating disease of the equine foot, is a significant cause of 
wastage in the equine industry. There is no scientifically validated treatment and laminitis 
prophylaxis is currently limited to digital cryotherapy. Several key steps in laminitis 
pathophysiology have been elucidated, resulting in identification of drugs that may prevent 
laminitis (anti-laminitis drugs (ALDs)). Many of these pharmaceuticals are not suitable for 
systemic delivery but may be amenable to either local or nanoparticle delivery mechanisms. 
The aim of this thesis was to evaluate local, systemic and nanoparticle delivery mechanisms, 
using the matrix metalloproteinase (MMP) inhibitor marimastat, to establish a method of 
drug delivery that yields sustained therapeutic lamellar concentrations for experimental and 
potential clinical use.  
 
Firstly, a method was developed for collecting lamellar interstitial fluid using ultrafiltration to 
enable determination of tissue drug concentrations. The ultrafiltration probe placement 
technique was developed using 16 cadaver limbs. Subsequently probes were placed in the 
lamellar tissue of 6 living horses. Lamellar ultrafiltrate (LUF) was collected continuously for 
5 days at 55 [30-63] µL/h (median [interquartile range]).  
 
In order to establish marimastat concentrations necessary for inhibition of lamellar MMPs, 
zymography was performed using lamellar homogenates incubated in increasing 
concentrations of marimastat. Based on this assay, target marimastat concentrations of 177 
ng/mL were set (the concentration necessary to inhibit 90% of lamellar MMP-2 and MMP-9). 
 
Four delivery mechanisms were evaluated for lamellar drug delivery; intraosseous infusion of 
the distal phalanx (IOIDP), constant rate systemic intravenous infusion (CRI), regional limb 
perfusion (RLP) and systemic intravenous bolus (SIVB). IOIDP and CRI with 0.53 
mg/minute marimastat were performed on 5 horses. Steady-state lamellar ultrafiltrate 
marimastat concentrations (LUF[M]) were 139 [88-497] ng/mL and 136 [93-157] ng/mL 
respectively. LUF[M] were not consistently above those considered sufficient to inhibit 
lamellar MMPs in vivo. SIVB and RLP of 0.23 mg/kg marimastat were administered to 6 
horses. The maximum LUF[M] were 264 [195-335] ng/mL and 61,200[16,713-67,746] ng/mL 
respectively. LUF[M] were greater than those considered necessary to inhibit lamellar MMPs 
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for at least 6 h after RLP in all horses. Therefore, RLP was identified as the most suitable 
technique for administration of marimastat during experimentally induced laminitis. 
 
In a following study, the suitability of RLP and lamellar ultrafiltration as a model for 
assessing the efficacy of candidate ALDs was investigated. Oligofructose was administered 
to 10 horses to induce laminitis. Treatment horses received 140 mg marimastat by RLP every 
six hours (n=6), control horses received saline by RLP every 6h. LUF[M] were consistently 
above the concentration considered necessary to inhibit lamellar MMPs in vivo. Therefore, 
RLP with concurrent measurement of LUF[M] was a suitable investigative model for delivery 
and quantification of marimastat concentrations in lamellar tissue during experimental 
laminitis development and may be suitable to investigate candidate ALDs. Marimastat did 
not prevent laminitis pathology in the oligofructose model, which suggests that proteases 
within the inhibitory spectrum of marimastat are not the key factor initiating laminitis 
pathology.  
 
Nanoparticles can be harnessed for targeted drug delivery resulting in sustained high drug 
concentrations at the target site. They may offer a more clinically applicable solution for 
lamellar drug delivery. Production of a tailor-made nanoparticle- formulation for sustained 
local delivery of marimastat was investigated. Marimastat was loaded into 2 nanoparticle 
formulations; nanoemulsions and mesoporous silica nanoparticles. Loading efficiency was 
either low or the marimastat was rapidly released, and was thus deemed unproductive for 
further studies. The biodistribution of 99mTc-labelled liposomes was investigated to evaluate 
whether passively targeted nanoparticles have potential for lamellar drug delivery.  8.5 GBq 
99mTc-liposomes were administered intravenously to 6 horses after dosing with oligofructose 
to induce laminitis and to 4 control horses. The percentage of the injected dose of liposomes 
that accumulated in the lamellar tissue of laminitis horses was significantly higher compared 
to controls (0.21 [0.14-0.3]% vs. 0.07 [0.06-0.11]%, p=0.02). The results of this study 
indicated liposomes have potential for sustained drug delivery to lamellar tissue. If necessary, 
once a successful ALD is identified, subsequent work should focus on utilising 
nanoformulations to optimise delivery, for clinical application. 
 
The novel research described in this thesis demonstrated RLP was a suitable method for 
locally delivering candidate ALDs and developed ultrafiltration for sampling lamellar IF to 
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ensure attainment of therapeutic lamellar concentrations.  Although marimastat was not 
successful in preventing laminitis, the same investigative model can now be applied to 
evaluate the efficacy of alternative candidate ALDs. When laminitis pathogenesis can be 
effectively arrested by the efficacious delivery of a safe, potent ALD genuine progress will 
have been made.   
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Chapter 1: Introduction, literature review and project aims 
 
1.1 Introduction 
Laminitis, a serious and debilitating disease of the equine foot, poses a significant threat to all 
Equidae. It is defined as failure of the attachment of the distal phalanx to the hoof wall. This 
results in clinical lameness and is often accompanied by displacement of the distal phalanx 
within the hoof capsule (Stick et al. 1982). Laminitis pathology is irreversible and the 
affected animal is often permanently debilitated. The only treatment options currently 
available are primarily palliative and include mechanical support of the affected hoof and 
analgesia. Hence, laminitis is a significant cause of wastage in the equine industry. Laminitis 
has been identified as the second largest cause of death amongst domesticated horses, and is 
considered a top research priority by 63% of equine veterinarians (AAEP 2009). A variety of 
conditions predispose horses to laminitis (Parsons et al. 2007). At present laminitis 
prophylaxis is limited to removal of the inciting cause or treatment of the underlying 
condition, and digital cryotherapy. Research into methods of preventing laminitis has been 
hampered historically by lack of understanding regarding the pathophysiology of laminitis, 
and difficulty in drug delivery to the lamellar tissue. Recently, several key steps in laminitis 
pathophysiology have been elucidated, resulting in identification of anti-laminitis candidate 
drugs (pharmaceuticals with potential for laminitis prophylaxis). Many of these 
pharmaceuticals are not suitable for systemic delivery. Regional delivery techniques, such as 
intraosseous infusion of the distal phalanx (IOIDP) may enable local drug delivery directly to 
lamellar tissue and the concurrent ‘nanomedicine revolution’ in human medical research 
yields a panacea of sophisticated drug delivery systems with potential for application to 
laminitis. The aim of this thesis was to evaluate local, systemic and nanoparticle delivery 
mechanisms, using the MMP inhibitor marimastat, to establish a method of drug delivery that 
yields sustained therapeutic lamellar concentrations for experimental and potential clinical 
use. This chapter first provides an overview of laminitis, including its pathophysiology and 
potential therapeutics, then secondly will discuss targeted delivery techniques with a focus on 
the potential of nanoparticle delivery systems. 
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1.2: Clinical and Pathological Events in Laminitis 
Laminitis ultimately results in lamellar dysadhesion and displacement of the distal phalanx 
within the hoof capsule. The progression to this endpoint is generally divided into three 
phases: developmental, acute and chronic (Hood 1999), through which the horse will 
naturally progress unless successful intervention occurs.  
 
The developmental phase is defined as the period between the initial causative insult and the 
first appearance of acute lameness identifiable as laminitis (Hood 1999). The key processes 
that initiate and trigger lamellar dysadhesion occur during the developmental stage. The 
developmental phase has variable duration, ranging from 8-12 hours after black walnut 
administration (Minnick et al. 1987; Galey et al. 1991) and 20-72 hours after carbohydrate 
overload (Garner et al. 1975; Pollitt and Davies 1998; Hood 1999; van Eps and Pollitt 2006). 
In clinical cases, where laminitis exists in association with other diseases, the length of the 
developmental phase may be longer and even more variable.  
 
The acute phase begins with the first signs of lameness and ends after 72 hours, or when there 
is radiographic or physical evidence of lamellar failure (Hood 1999). The clinical signs of 
acute laminitis include increased digital pulse amplitude, a consistent increase in hoof wall 
temperature, a characteristic stance, pain on hoof testing and lameness (Obel 1948; Yelle 
1986; Baxter 1994; Hood 1999). In 1948 Obel described a grading scale for the assessment of 
the clinical severity of laminitis; this has been universally adopted (Obel 1948). It is 
classified as follows: 
Obel Grade I: At rest the horse will alternately and incessantly lift the feet, lameness is not 
evident at the walk, but a short stilted gait is noted at the trot. 
Obel Grade II: The horse moves willingly at the walk, but the gait is characterisitic of 
laminitis. A hoof can be lifted off the ground without difficulty.  
Obel Grade III: The horse moves very reluctantly and vigorously resists attempts to raise a 
forefoot.  
Obel Grade IV: The horse must be forced to move and may be recumbent.  
 
Chronic laminitis is characterized by radiographic or physical evidence of lamellar failure 
accompanied by mechanical collapse of the foot (Hood 1999). Chronic laminitis may present 
in a wide variation in degree of lameness and anatomical derangement (Hunt 1993).   
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1.3 Equine Digital Anatomy 
The weight of the horse is transmitted from the appendicular skeleton, through the lamellae, 
to the outer hoof wall, and thence to the ground.  The hoof wall is comprised of 3 main 
layers: the stratum externum, the stratum medium and the stratum internum. The stratum 
externum is a thin layer of horn confluent with the stratum corneum of the perioplic 
epidermis. The non-living tissue of the stratum medium forms the main bulk of the hoof wall. 
It is responsible for the mechanical strength of the equine foot and is comprised of tubular 
and intertubular horn (Kasapi and Gosline 1998; Bowker 2003). The tubular horn is formed 
by maturing keratinocytes organized concentrically around a central hollow medulla to form 
elongated tubules (Kasapi and Gosline 1998). The intertubular horn is formed at right angles 
to the tubular horn. It provides the stratum medium with most of its strength and stiffness and 
is the strongest component of the hoof wall.  
 
Beneath the stratum medium lies the stratum internum. The stratum internum, is comprised 
of epidermal lamellae (the stratum lamellatum) and together with its interdigitating dermal 
lamellae forms the attachment between the distal phalanx and the stratum medium. This is 
termed the suspensory apparatus of the distal phalanx (SADP).  Approximately, 600 
keratinised primary epidermal lamellae (PEL) project towards the third phalanx in vertically 
orientated parallel rows. Along the perimeter of each PEL are 150-200 folds termed 
secondary epidermal lamellae (SEL) (Pollitt 2010). These greatly increase the surface area of 
the dermo-epidermal attachment to approximately 1 m2 in the average hoof, and are essential 
for normal weight bearing (Linford 1987). Normal SEL have a constant histologic 
appearance (Figure 1.1): They have club-shaped tips and the perimeter of each SEL is lined 
with epidermal basal cells (EBCs). These cells have oval nuclei that are situated at the apical 
pole of the cell at right angles to the keratinized axis of the SEL. The basement membrane 
(BM), a sheet of extra-cellular matrix that lies at the interface of the epidermal and dermal 
lamellae, closely adheres to the EBCs. Secondary dermal lamellae (SDL) interlock with the 
SEL and have pointed tips that lie in close proximity to the keratinized axis of the PEL 
(Pollitt 1996).  
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Figure 1.1: Micrograph of normal hoof lamellae using PAS stain. The SEL tips are 
rounded and the BM (magenta line/ black arrows) is closely adherent to the EBCs. The EBC 
nuclei (*) are oval, positioned away from the BM at the apex of the EBC and the long axis of 
each nucleus is at right angles to the keratinised axis of the SEL. The SDL are filled with 
connective tissue and capillaries. The BM extends close to the keratinised axis of the PEL 
(arrowheads). Scale bar 50µm. 
 
The sub-lamellar dermis consists of a dense matrix of connective tissue containing a network 
of vessels and nerves that attach to the periosteal surface of the distal phalanx. The lamellar 
dermis contains both primary (PDL) and secondary (SDL) dermal lamellae that interdigitate 
with their respective epidermal counterparts. As the epidermal layer is avascular, the 
epidermal lamellae rely on the dermis for gaseous and nutrient exchange. The arterial supply 
to the foot is provided by branches of the medial and lateral digital arteries. These branches 
form the 3 arterial circles of the foot: the coronary circumflex artery, the terminal arch and 
the circumflex artery (Figure 1.2). The lamellar dermis is supplied primarily via branches 
from the coronary circumflex artery and the terminal arch, which lies within the distal 
phalanx. The veins within the lamellar tissue are valve-less, and drain to a dorsal venous 
plexus that lies in the deep part of the sub-lamellar corium, then into the lateral and medial 
digital veins. In the dermal microcirculation are numerous (approximately 500/cm2) 
arteriovenous anastomoses (AVAs) (Pollitt and Molyneux 1990). AVAs have distinct 
complex endothelial cells that are irregularly sized. These cells appear to have high metabolic 
activity; they have microvilli and long cytoplasmic processes, many cytoplasmic vesicles, 
high numbers of ribosomes, mitochondria and lysosome-like bodies in their cytoplasm and 
many pinocytotic vesicles along their basal plasma membrane (Molyneux et al. 1994). AVAs 
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play an important role in temperature regulation, tissue metabolism, microcirculatory 
regulation of blood flow in the hoof and pressure modulation. 
 
 
Figure 1.2: The digital circulation. 
 
The BM is the key structure that attaches the epidermal lamellae to the dermal lamellae, 
enabling suspension of the distal phalanx within the hoof wall. The BM is comprised of a 
collagen IV meshwork ensheathed in glycoproteins, including laminin (McMillan et al. 
2003). Extensions from the BM, including collagen VII anchoring filaments, intermesh with 
collagen I filaments in the connective tissue matrix of the lamellar and sub-lamellar dermis 
(Pollitt and Daradka 1998). Attachment of the EBCs to the BM is reliant on numerous 
electron dense adhesion plaques called hemidesmosmes (HDs, Figure 1.3). The HDs bridge 
the EBC plasmalemma connecting the EBC cytoskeleton to the adjacent BM. HDs are 
composed of 6 key proteins and are assembled and maintained by glucose-consuming 
phosphorylation reactions (French and Pollitt 2004). The HD intracytosplasmic proteins 
BP230 and plectin connect to the intermediate filaments of the cytoskeleton and thus 
attachthe nucleus to adjoining basal and parabasal cells. The transmembrane integrin α6β4 
connects the intracytoplasmic proteins to the extracellular Ln-332 (formerly known as 
laminin-5) protein anchoring filaments. The second anchoring filament, BP180, bridges the 
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plasmalemma and extends as collagen XVII filaments into the BM (Jones et al. 1998; 
Borradori and Sonnenberg 1999).  
 
 
 
Figure 1.3: Diagram of the 
basement membrane zone. BP180 
and α6β4integrin interact with the 
anchoring filaments (laminin 332) 
in the basement membrane zone. 
The α6β4 integrin associates with 
the keratin cytoskeleton via the 230 
kDa bullous pemphigoid antigen 
(BP230 and plectin. The latter two 
proteins are plakin family members 
that mediate the indirect linkage of 
keratin to α6β4 integrin.  
 
 
 
 
 
1.4 Histologic and ultrastuctural laminitis pathology 
Sepsis related laminitis results in a consistent pattern of histological changes. A histological 
grading system developed by Pollitt, demonstrated that the severity of histological changes 
correlates with clinical severity (Pollitt 1996). This grading scheme also seems to correlate 
with the temporal changes that occur during clinical laminitis progression; however there is 
some individual variation in the histological changes between horses (Croser 2006; Visser 
2009).  
  
Grade 1 lamellar lesions are the mildest histological grade (Pollitt 1996). Grade 1 changes 
are typified by narrowed, elongated SEL with pointed tips; rounded and abnormally located 
EBC nuclei; detachment of the BM at the SEL tips to form teat-shaped bubbles and loss of 
BM staining at the base of the SEL. Lamellar lesions present during the developmental phase, 
between 18 and 30 hours post induction with OF, are often consistent with Grade 1 lesions 
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(Croser 2006; Nourian et al. 2007). However, histological changes that are milder than 
typical Grade 1 lesions have been detected at 12 hours post OF induction. These included 
rounding and rotation of the EBC nuclei, mild pointing of the tips of the SEL, thinning of the 
SDL and a reduction in BM staining intensity at the tips of the SEL (Croser 2006). 
 
Grade 2 lesions are similar to Grade 1 only more extensive. The major difference between 
grade 1 and grade 2 lesions is that the BM at the base of the SEL, and the tips of the SDL, 
are no longer close to the keratinized axis of the PEL. Additionally, there is no connective 
tissue between the SEL and the PEL tips acquire a stretched, wavy appearance. Rounding of 
the EBC nuclei is more obvious, and the EBC nuclei are situated close to the BM in a now 
pale, cloudy and vacuolated cytoplasm (Pollitt 1996). 
 
Grade 3 lesions are characterized by extensive separation of the BM from the SEL.  There is 
extreme elongation and stretching of the SELs. The axial cores of the SELs are barely 
recognizable as distinct architectural structures and most of the epidermal cells form an 
amorphous mass between alternating PEL and PDLs. The few SELs that are recognizable are 
devoid of connective tissue attachments. Some of the EBC nuclei are pyknotic and their 
cytoplasm is light, cloudy and vacuolated. The PEL tips are tapered and shrunken and consist 
of wavy empty tubes surrounded by BM, resembling the fingers of empty gloves. In the mid-
PEL region the BM is stripped from the EBCs and lies free, adjacent to the connective tissue 
of the PDL. Blood vessels adjacent to the PELs are surrounded by leukocytes. PAS positive 
neutrophils are present surrounding the PEL tips and some appear within the epidermal 
compartment between layers of the BM (Pollitt 1996). 
 
Recently a fourth grade was described defined as complete physical separation of lamellar 
epidermis from dermis, with no association between dermal and epidermal tissues (van Eps et 
al. 2013). 
 
Investigations into the ultrastructural BM changes at 48 hours post induction reveal loss and 
destruction of key BM components. Lysis of the BM commences between the bases of the 
SELs with disappearance of type IV collagen and laminin from the BM along with loss of 
type VII collagen from the BM-dermal interface (Pollitt and Daradka 1998).  In addition to 
the BM lysis occurring at the base of the SEL, the BM detaches from the tips of the SEL in 
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intact sheets, suggesting loss of Ln-332 anchoring filaments (Pollitt and Daradka 1998; 
French and Pollitt 2004). On transmission electron microscopy, at this time-point, there is a 
loss of both anchoring filaments and EBC cytoskeletal filaments, along with a reduction the 
number of HDs. The intracytoplasmic plaques of some of the remaining HDs are pale and 
disorganized, as if in the process of disassembling. BM separation occurs adjacent to areas 
where HDs are absent or faint, but remains attached in zones where HDs survive, implicating 
HD failure as a mechanism of dermo-epidermal detachment (French and Pollitt 2004). 
Similar ultrastructural lesions are present at 24 hours post-OF-induction (Nourian, Baldwin et 
al. 2007).  
 
Using immunohistochemistry French and Pollitt probed further into the hemidesmosomal 
changes occurring at 48 hours post OF. They discovered intermittent loss of BP230 and a 
reduction of immunofluorescence for integrin α6β4, and BP180 proteins. However, these 
proteins remained localised within their normal positions in the EBCs (French and Pollitt 
2004). Ln-332 immunofluorescence was also diminished, and interestingly Ln-332 remained 
associated with the BM rather than being co-localised with BP180 as seen in control samples, 
suggesting either cleavage or detachment of this AF from the HD. Utilising temporal biopsies 
Visser demonstrated consistent loss of collagen IV and Ln-332 in the BM accompanied by 
appearance of reactivity for the γ2 subunit of Ln-332 in the BM as early as 12 hours post-OF 
induction (Visser 2009). Collagen IV loss between the bases of SELs or in mid SEL regions 
often preceded Ln-332 loss. This pathology resulted in fragmentation of the BM. The loss of 
Ln-332 and appearance of γ2 reactivity occurred primarily at SEL tips and appeared to be a 
second type of pathology. Where separation of the EBC from the BM occurred γ2 reactivity 
co-localised with the detached SDL tissue. No proteolytic Ln-332 fragments were detected, 
indicating that Ln-332 disengages with integrin α6β4 during laminitis development rather 
than being directly cleaved. Decreased expression of the integrin α6β4 subunit in the acute 
phase of laminitis also occurs (French 2002), thus loss and dysfunction of the α6β4 subunit 
may contribute to Ln-332 disengagement and subsequent lamellar failure. Whilst, no 
consistent change in integrin α6β4 gene expression has been detected (Visser 2009), changes 
may be occurring at the protein level and this theory fits with the reduction in HD numbers in 
areas of dermo-epidermal separation (French and Pollitt 2004; Nourian, Baldwin et al. 2007).  
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1.5 Theories on laminitis pathogenesis 
A diverse variety of diseases predispose horses to laminitis. These can be grouped into 
different syndromes as follows; i) laminitis associated with endotoxaemia/ sepsis, ii) laminitis 
associated with unilateral weight bearing, and  iii) laminitis associated with metabolic 
disturbances. The pathophysiology of any single syndrome has yet to be fully elucidated. 
Whilst the existence of a single underlying initiating mechanism present in all forms of 
laminitis cannot be definitively ruled out, current data suggests that each syndrome has its 
own unique aetiopathogenesis leading to the same end result of lamellar failure.  
 
Several experimental induction models have been utilized in order to study the developmental 
phase of laminitis in a uniform manner. Laminitis associated with endotoxaemia and sepsis 
can be studied using either carbohydrate overload (CHO) models  that result in the 
development of colitis (Garner et al. 1975; van Eps and Pollitt 2006), or the black walnut 
extract model (BWE) which is similar to the endotoxin bolus model of human sepsis 
(Minnick et al. 1987; Galey et al. 1991). A framework for studying metabolic laminitis is 
provided by the hyperinsulinaemic and hyperglycemic models (Asplin et al. 2007; de Laat et 
al. 2010).  
 
Horses with clinical signs of endotoxaemia/ sepsis are predisposed to developing laminitis 
(Parsons et al. 2007), and laminitis prophylaxis can be instituted in conjunction with the onset 
of primary disease. Therefore, this thesis will focus on developing a pharmaceutical agent for 
laminitis prophylaxis in horses with primary diseases that result in endotoxaemia/sepsis. Both 
the BWE and CHO models fit this category of laminitis.  The BWE model is characterized by 
rapid (within 1.5 hours of dosing), multisystemic neutrophil margination and activation, 
along with marked upregulation of inflammatory cytokines and evidence of oxidative stress 
in lamellar tissue (Belknap et al. 2007; Belknap 2010; Burns et al. 2011; Hurley et al. 2011). 
Laminitis, which occurs within 8 to 12 hours after BWE administration, is relatively mild, 
potentially reversible, and rarely results in displacement of the distal phalanx (Minnick et al. 
1987). In contrast, the CHO model results in moderate to severe colitis in dosed animals, with 
severe laminitis and distal phalangeal displacement. This is more relevant to clinical disease, 
hence will be focused upon in this review. 
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The original CHO model of laminitis was the starch induction model (Obel 1948; Garner et 
al. 1975). In this model laminitis is induced by nasogastric administration of a bolus dose of 
corn starch and wood flour or rye flour. The excess starch rapidly ferments within the hindgut 
with a subsequent increase in Gram positive bacteria and lactic acidemia (Garner et al. 1978). 
There is a resultant decrease in hindgut pH, which causes death of Gram negative bacteria 
and liberation of endotoxin (Garner et al. 1977; Garner et al. 1978). There is an increase in 
intestinal permeability and destruction of the caecal mucosal barrier (Krueger et al. 1986; 
Weiss et al. 1998). Laminitis develops between 32 and 48 hours post-dosing (Garner et al. 
1975). The drawbacks of the starch induction model are the associated high incidence of colic 
and mortality amongst experimental horses, and the inconsistency in laminitis development 
(Harkema et al. 1978; Linford 1987; Trout et al. 1990; Pollitt and Davies 1998). In 2006, van 
Eps and Pollitt reported a model of CHO using oligofructose (OF), which is similar to the 
nonstructural plant storage carbohydrate fructan (van Eps and Pollitt 2006). In this model 10 
g/kg OF administered via nasogastric tube results in development of colitis within 12 hours, 
resolution of the diarrhoea at 24 to 32 hours and development of lameness between 24- 36 
hours. There is a reduction in fecal pH and accompanying lactic academia similar to that 
reported with the starch induction model (Garner et al. 1977). 
 
The exact mechanisms that cause laminitis are unclear and there are multiple hypotheses 
regarding the pathophysiology of laminitis. Traditionally researchers hypothesised laminitis 
was a form of ischaemia reperfusion injury (Robinson 1990; Trout et al. 1990; Hood et al. 
1993; Molyneux et al. 1994; Eaton et al. 1995; Hinckley et al. 1995; Bailey and Elliott 1998; 
Ingle-Fehr and Baxter 1998; Ingle-Fehr and Baxter 1999; Schneider et al. 1999; Rosenstein et 
al. 2000; Bailey et al. 2002; Elliott et al. 2003; Berhane et al. 2006). However, the variation 
in techniques for measuring lamellar perfusion (Hood, Amoss et al. 1978; Allen, Clark et al. 
1990; Trout, Hornof et al. 1990; Eaton, Allen et al. 1995; Hinckley, Fearn et al. 1995; Adair, 
Goble et al. 2000; Hood, Wagner et al. 2001) along with the use of different experimental 
models for laminitis induction yielded conflicting results. Whilst the studies of Coffman, 
Hood and Adair (Coffman et al. 1970; Hood et al. 1978; Adair et al. 2000; Hood et al. 2001) 
implicate decreased lamellar perfusion; three studies, (Robinson et al. 1976; Trout et al. 1990; 
Pollitt and Davies 1998), report increased digital blood flow during developmental and acute 
laminitis. The fundamental question of whether lamellar ischaemia is a triggering event in 
laminitis pathogenesis was addressed by Loftus et al. (Loftus et al. 2007) in the BWE model: 
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the authors were unable to demonstrate molecular biochemical or metabolic evidence of 
ischaemia during the developmental phase. These studies, combined with the growing 
evidence of inflammation and enzymatic degradation as key early pathophysiological events, 
led to many researchers disregarding ischaemia-reperfusion as a key initiating factor in 
laminitis development. Instead, similarities are frequently drawn to human sepsis, where 
inflammation, enzymatic degradation and cellular bioenergetic failure are the purported 
mechanisms of end organ damage (Belknap et al. 2009). 
   
Whilst there is no evidence of ischaemia during laminitis development, non-ischemic bio-
energetic failure secondary to sepsis may occur during laminitis development as in human 
sepsis related organ dysfunction (Belknap et al. 2009). A number of sepsis induced 
disturbances in cellular energy pathways have been described including alterations in 
pyruvate dehydrogenase activity, reductions in Kreb’s cycle enzyme function, inhibition of 
electron flow along the electron transport chain, uncoupling of oxidative phosphorylation and 
impaired transport of ATP out of mitochondria (Singer 2008).  The reduction in energy 
availability appears to trigger a metabolic shutdown that impairs normal functioning of the 
cell. HDs require energy for structural maintenance, and withdrawal of glucose in the 
lamellar explants model causes a loss of HDs accompanied by lamellar separation (Pollitt et 
al. 1998; French and Pollitt 2004). Therefore the hemidesmosomal structural changes seen 
during laminitis development may be associated with impaired energy production and 
metabolic shutdown of EBCs. Further work is necessary to demonstrate the validity of this 
hypothesis in relation to laminitis.  
 
Much of the evidence suggesting a   central role of inflammation in the pathogenesis of 
laminitis originates from the BWE model (Fontaine et al. 2001; Waguespack et al. 2004; 
Waguespack et al. 2004; Black et al. 2006; Blikslager et al. 2006; Black 2009; Faleiros et al. 
2009; Faleiros et al. 2009; Belknap 2010; Faleiros et al. 2011). However, recent evidence also 
implicates inflammation in CHO induced laminitis. Dysregulation of inflammatory 
signalling, including STAT-3 activation, increased expression of inflammatory cytokines 
(TNF-α, IL-1β, IL-2, IL-6,IL-10, IL-12p35, IL-8 and IFN-γ), COX-2, inducible nitric oxide 
synthase 2 (iNOS-2) and adhesion molecules (E-selectin, P-selectin, L-selectin and ICAM-1) 
are present at the onset of lameness in horses with CHO induced laminitis (Ingvastlarsson et 
al. 1992; Belknap et al. 2007; Leise et al. 2011; Leise et al. 2012; Leise et al. 2012; Kwon et 
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al. 2013). Cytokines can regulate protease expression and activation, and may be involved in 
initiating the excessive protease activation that occurs during laminitis development (Mauviel 
1993). Incubation of lamellar explants with IL-6 results in focal BM loss and separation, as 
well as destruction of some EBCs, but no change in dermo-epidermal separation force and no 
evidence of MMP-2 activation (Visser 2009). However, IL-6 could be activating other 
unexamined cytokines or proteases and thus contributing to BM destruction. The fundamental 
question with regard to determining whether inflammation initiates laminitis pathophysiology 
is; do inflammation and leukocyte emigration into lamellar tissue occur prior to structural 
BM damage, or occur as a result of this damage? Early evidence of BM damage and IL-6 
mRNA expression has been documented at 12 hours post OF induction, followed by 
leukocyte infiltration at 18 hours (Visser 2009). However, lamellar leukocyte accumulation 
has also been documented prior to histological evidence of BM degradation using the starch 
induction model (Visser 2009; Faleiros et al. 2011). In either scenario, once leukocytes have 
emigrated into the lamellar tissue, they produce reactive oxygen species, enzymes and pro-
inflammatory cytokines that contribute to the cascade of events that result in lamellar failure. 
Hence blocking these inflammatory pathways with targeted pharmaceutical agents may 
reduce lamellar damage. 
 
Enzymatic degradation of the BM-epidermal attachment was first proposed by Pollitt as a 
potential pathogenesis for laminitis ((Pollitt 1996; Mungall et al. 1998; Pollitt 1999). Initially, 
increased matrix metalloproteinase enzyme (MMP) expression was implicated as the primary 
causative agent resulting in lamellar destruction (Johnson et al. 1998; Pollitt et al. 1998; 
Kyaw-Tanner and Pollitt 2004; Kyaw-Tanner et al. 2008). Matrix metalloproteinases are a 
family of at least 25 zinc and calcium dependent proteinases involved in degradation of the 
extracellular matrix (Wojtowicz-Praga et al. 1997). They can be broadly subdivided into six 
groups: stromelysins (MMP-3,-10 and -11), collagenases (MMP -1, -8, -13 and -18), 
gelatinases (MMP -2 and -9), matrilysins (MMP -7 and -26), membrane type MMPs (MT-
MMPs -1 through -6) and others that demonstrate unknown or unique domains and substrate 
specificity. MMPs are secreted in a latent, proenzyme form and require activation to digest 
the ECM, this activation can be accomplished by other proteolytic enzymes including other 
MMPs (Fridman et al. 1995). Physiologic tissue maintenance requires controlled MMP action 
to degrade ECM components. The rate of degradation is controlled by endogenously 
produced MMP inhibitors known as tissue inhibitors of metalloproteinases (TIMPs), to 
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maintain equilibrium between degradation and re-synthesis. Disruption of this natural balance 
results in catastrophic tissue damage and excessive MMP activation has been associated with 
tumour metastasis, arthritis and colitis (Konttinen et al. 1999; Ferazzini et al. 2002; Hritz et 
al. 2011).  Both MMP-2 and MMP-9 are capable of degrading collagen IV.  Zymography of 
lamellar tissue from experimental and clinical cases of acute and chronic laminitis shows 
increased activation of MMPs 2 and 9 (Johnson et al. 1998; Mungall et al. 1998; Pollitt et al. 
1998; Mungall and Pollitt 1999).  Marked upregulation of MMP-2 transcription is present in 
OF induced laminitis (Kyaw-Tanner and Pollitt 2004). Increased transcription of MMP-9 
occurs at 12 hours post OF induction, and accumulation of pro-MMP-9 occurs early during 
laminitis development, between 18-24 hours (Visser 2009). Incubation of lamellar hoof 
explants with an MMP activator causes a laminitis-like separation at the dermo-epidermal 
junction (Pollitt et al. 1998), with loss of hemidesmosomal anchoring filaments on 
transmission electron microscopy (French and Pollitt 2004). This forms an in vitro model of 
laminitis against which the MMP inhibitors batimastat and marimastat are preventative 
(Pollitt et al. 1998). 
 
Whilst MMPs undoubtedly play a role in perpetuating the laminitis lesion recent evidence has 
drawn into question their role in initiating lamellar damage. Using temporal hoof biopsies 
during OF induction Visser placed MMP-2 production and activation at least 12 hours after 
initiation of BM changes (Visser 2009).  Additionally, there is no zymographic evidence of 
active MMP-9 for 48 hours after OF induction or between 36-48 hours after starch induction 
(Loftus et al. 2009; Visser 2009). Caesin zymography indicates that MMP-3, MMP-7, MMP-
10 and MMP-11 do not play a role in acute laminitis (Visser 2009). MMP-14 (MT1-MMP) is 
able to cleave a variety of BM membrane components including collagens and Ln-332 
(Udayakumar 2003; Visse 2003; Koshikawa, Schenk et al. 2004; Koshikawa et al. 2005). 
Activation of MMP-14 releases MMP-2 from inhibition by TIMP-2 and precipitates a 
cascade of matrix degradation, including proteolytic cleavage of laminin-332 (Koshikawa et 
al. 2003). MMP-14 (MT-MMP1) has been implicated in initiating BM degradation (Kyaw-
Tanner et al. 2008). However, this study did not investigate activation of MMP-14 in 
laminitic tissue. Subsequently Visser did not identify smaller active MMP-14 fragments 
during OF induction and did not identify any consistent changes in MMP-14 gene expression 
during laminitis development (Visser 2009).  This data does not rule out other MMPs, 
particularly MT-MMPs, e.g. MT-MMP-6, that are able to cleave BM components from 
15 
 
playing a role in BM degradation, buthave yet to be studied (Hernandez-Barrantes, et al. 
2002), nor does it rule out the involvement of MMP-1 and MMP-13; both of which have 
increased gene expression in carbohydrate-induced laminitis and may play a role in laminitis 
pathophysiology (Wang et al. 2014).TIMPs are multifunctional proteins and can act both as 
MMP activators and inhibitors (Zhao, et al. 2004). TIMP-2 is able to bind and inhibit all MT-
MMPs (Lambert et al., 2004). TIMP-2 gene repression occurs as early as 12 hours post 
induction with OF (Visser 2009). If a corresponding early change in TIMP-2 protein 
expression occurs during laminitis development, this may allow for activation of additional 
MT-MMPs resulting in BM degradation.  
  
Additional enzymatic mediators of BM degradation are the ADAMTS (a disintegrin and 
metalloproteinase with thrombospondin motifs) proteases, many of which are involved in 
cartilage degradation in osteoarthritis (Hofkens et al. 2011). ADAMTS-4 is capable of 
processing and destabilising the proteoglycans and glycoproteins of the lamellar BM.  A 
marked increase in the expression of ADAMTS-4 mRNA is present at the developmental 
(12-24 hours post induction) and acute phases (48 hours post induction) of experimental 
laminitis development, as well as in natural cases of the disease (Budak et al. 2009; Coyne et 
al. 2009; Visser 2009; Wang et al. 2012). This is accompanied by an increase in activity of 
ADAMTS-4, an increase in the low molecular weight ADAMTS-4 cleavage fragments of 
versican and depletion of versican from the EBCs (Wang et al. 2012). This may result in a 
change in the physiology of EBCs with consequent detachment from the BM. Therefore 
ADAMTS-4 enzyme may play a central role in initiating the laminitis lesion, and may be a 
potential target for anti-laminitis drugs.   
 
Recent work has investigated the role of regulatory pathways responsible for the reduction in 
versican gene expression in laminitic horses (Wang et al. 2013).  The canonical Wnt 
signalling pathway is one of the fundamental pathways controlling cell development and 
differentiation. Positive regulation of the Wnt-signaling pathway is necessary for 
maintenance of the epithelial phenotype and epithelial cell function. In horses with CHO 
laminitis, negative regulation of the canonical Wnt-signaling pathway in EBCs is 
accompanied by a reduction in components of the adherens junctions (β-catenin) and 
hemidesomes (integrin β4), hence may contribute to failure of the dermal-epidermal junction 
in laminitis (Wang et al. 2013). Determination of the importance of the Wnt-signalling 
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pathway requires additional studies. If negative regulation of the Wnt-pathway does play a 
key role in laminitis development, Wnt-agonists, such as GSK3, may have potential for 
laminitis prophylaxis.  
 
Although the exact pathophysiologic mechanism of laminitis has not been fully elucidated, 
based  on the current  evidence it is clear that a combination of proteolytic enzymes, further 
upregulated by inflammatory cytokines, act at the dermo-epidermal interface prior to the 
onset of clinical signs and marked structural histological changes. Therapeutic targeting of 
these factors using anti-inflammatories or protease inhibitors may inhibit catastrophic 
lamellar destruction and the associated lameness.  
 
1.6 Laminitis prophylaxis  
Once the marked structural histological changes of acute, sepsis-related laminitis occur they 
are irreversible. Therefore, for the purpose of this review the discussion of treatment is 
focused on prevention of disease progression in high risk patients. At present laminitis 
prophylaxis is limited to distal limb cryotherapy (Van Eps and Pollitt 2004; van Eps and 
Pollitt 2009; van Eps et al. 2013). There is no effective, scientifically proven pharmaceutical 
laminitis prophylactic. Great potential exists for targeting the currently identified mechanistic 
pathways associated with laminitis pathophysiology. 
 
Based on the vascular theory of laminitis,treatments aimed at increasing lamellar blood flow 
have not resulted in successful prevention nor treatment of sepsis-related laminitis.  
Isoxuprine (Ingle-Fehr and Baxter 1999) and topical nitroglycerine (Gilhooly et al. 2005) 
have been shown to have no effect on digital perfusion.  Although acepromazine effectively 
increases total blood flow to the digit, there is little evidence to support this as being 
beneficial in the prevention or treatment of sepsis-related laminitis (Leise et al. 2007). A 
platelet aggregation inhibitor appeared to reduce the incidence of laminitis in a single study 
of starch induced laminitis in ponies (Weiss et al. 1998).  A recent report showed an apparent 
reduction in laminitis incidence after colic surgery in horses administered low molecular 
weight heparin however the control group in this study was historical and the total incidence 
of laminitis was low (de la Rebiere et al. 2008). Additionally, other reports have shown no 
beneficial effect of heparin for laminitis prophylaxis (Belknap and Moore 1989; Uberti et al. 
2010). 
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The strong evidence that inflammation plays a significant contribution to the pathogenesis of 
developmental and acute laminitis highlights the potential for use of anti-inflammatory 
agents.  There is anecdotal evidence that high doses of flunixin meglumine have potential 
benefit for laminitis prophylaxis (Belknap 2010); however there is no experimental evidence 
to support this.  Pentoxifylline exerts anti-inflammatory effects via inhibition of inflammatory 
mediators (particularly TNF-α) in addition to anti-MMP activity. Recent evidence suggests a 
possible beneficial effect in reducing the severity of starch induced laminitis, however small 
numbers of horses were evaluated and some of the results may have been attributable to the 
variations seen with starch induction (Eades 2009).  Lidocaine has anti-inflammatory 
properties (Cook et al. 2009), yet intravenous infusion failed to have an effect on lamellar 
inflammation in a recent study of BWE induced laminitis (Williams, Lin et al. 2010). 
Corticosteroids are potent inhibitors of both the COX and lipoxygenase pathways of 
inflammation. Evidence suggests that early treatment with dexamethasone reduces mortality 
among human septic shock patients (Cicarelli et al. 2007). Recent evidence demonstrates 
glucocorticoids reduce protease (MMP and ADAMTS-4) expression and inhibit cartilage 
destruction in a mouse model of rheumatoid arthritis (Hofkens et al. 2011). The link between 
systemic corticosteroid administration and the development of laminitis (Bailey 2010), and 
concern that their immunosuppressive effects may be detrimental to any concurrent septic 
disease has precluded their systemic use in clinical and experimental laminitis. The potential 
of pharmaceuticals such as chemokine antagonsists (Faleiros et al. 2011) and STAT-3 
inhibitors (Leise et al. 2012) have been identified, however these are impractical for systemic 
delivery in horses and have yet to be investigated (Yue and Turkson 2009; Schall and 
Proudfoot 2011). 
 
Enzymatic degradation of epidermal-dermal attachments by proteases (including MMPs and 
ADAMTSs) contributes to lamellar failure in acute laminitis. In the human field, protease 
inhibitors have been developed as chemotherapeutic agents for the treatment of cancer and 
arthritis (Li and Wu 2010).  Marimastat is a synthetic, low molecular weight peptidomimetic 
inhibitor that binds to the zinc ion in the active site of MMPs (Millar et al. 1998; Barlaam et 
al. 1999).  It has been used in multiple oncologic clinical trials (Rosenbaum et al. 2005; Levin 
et al. 2006), has anti-inflammatory properties (Bruce and Thomas 2005; Nenan et al. 2007) 
and protects against ischaemia reperfusion injury (Novak et al. 2010) in preclinical trials. 
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Marimastat and its chemical analogue, batimastat, prevent lamellar separation in an in vitro 
laminitis explant model (Pollitt et al. 1998). In addition to anti-MMP activity marimastat 
demonstrates ADAMTS-4 inhibition (Tortorella et al. 2009), and thus had potential for 
blocking the excessive protease activation associated with laminitis development. This, in 
combination with its proven anti-laminitis characteristics in vitro made it an ideal candidate 
drug for laminitis prophylaxis in vivo. Unfortunately, marimastat is impractical for systemic 
administration in horses due to expense, systemic side effects, lack of oral bioavailability and 
rapid clearance after intravenous administration (Barlaam et al. 1999; Levin et al. 2006, 
Pollitt and Pass, unpublished data). Musculoskeletal side effects include tendonitis like 
fibromyalgia and arthritis and affect >90% of patients in some studies; additional side effects 
such as headache, nausea, diarrhoea, coughing, pharyngitis and fatigue have also been 
reported (Millar et al. 1998, Miller et al. 2002, Peterson 2006).   However, marimastat has 
great potential for laminitis prophylaxis if a suitable method of local delivery that yields 
sustained lamellar drug levels can be established. 
 
1.7 Lamellar delivery techniques 
There is an obvious need for a practical effective method for delivering high concentrations 
of pharmaceuticals to lamellar tissue for laminitis prophylaxis. Local drug delivery, defined 
as target tissue concentrations greater than plasma concentrations (Collins 1984), may be the 
most practical way to achieve therapeutic lamellar drug concentrations. Once successfully 
established, a local delivery system could be used to investigate the efficacy of 
pharmaceuticals whose expense or negative side effects preclude systemic use. 
 
Intraosseous infusion of the distal phalanx (IOIDP) has been developed and validated for 
local lamellar drug delivery using gentamicin as a pharmaceutical marker (Nourian, Mills et 
al. 2010). Continuous IOIDP has the potential to yield sustained drug levels in lamellar tissue 
throughout the period of the infusion. However, insulin delivery by IOIDP, although not 
assayed at the lamellar level, failed to achieve hyperinsulinaemia in veins of the treated foot, 
and resulted in foot pain (de Laat 2011). Further investigation was required to determine if 
long-term IOIDP resulted in regional lamellar delivery and whether the technique could be  
tolerated by the subject   
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A somewhat less invasive option for local lamellar delivery is retrograde intravenous infusion 
of the distal limb also termed regional limb perfusion (RLP). This technique has been 
validated for antimicrobial delivery to distal limb synovial structures, bone and subcutaneous 
tissues, and is in frequent clinical use (Parra-Sanchez et al. 2006; Rubio-Martinez et al. 2006; 
Levine et al. 2010; Beccar-Varela et al. 2011; Kelmer et al. 2013; Kelmer et al. 2013; 
Lallemand et al. 2013; Mahne et al. 2013). Previously reported complications of RLP include 
phlebitis, perivasculitis (Parra-Sanchez et al. 2006), cellulitis, mild limb swelling and 
hematoma formation (Beccar-Varela et al. 2011), occurring at rates of  12-27% in horses 
receiving multiple RLPs (Kelmer et al. 2012; Rubio-Martinez et al. 2012). The efficacy of 
RLP for targeted delivery to the lamellar tissue is unknown, but is worthwhile to investigate 
as it has potential as a simple technique for lamellar delivery.  
  
An unfortunate drawback of both IOIDP and RLP is that both methods only treat one limb, 
therefore the procedure has to be repeated twice, or four times to achieve laminitis 
prophylaxis in both forefeet or all four limbs respectively. An ideal anti-laminitis therapy 
would be administered systemically but then target all four feet, or be of a slow release 
formulation thus allowing reduced dosing frequency. This may be achievable by harnessing 
some of the novel delivery techniques offered by recent advances in nanotechnology. 
 
1.8 Establishing tissue drug concentrations 
In order to assess the efficacy of a pharmaceutical it is often necessary to measure drug 
concentrations at the site of action or target site (Collins 1984).  Therefore, a means of 
repeatedly sampling the lamellar tissue was key to the success of this work. This section 
briefly reviews the options available for sampling tissue for pharmacokinetic analyses.  
 
Techniques available to determine tissue drug concentrations include implanted tissue cages, 
biopsies, microdialysis and ultrafiltration (Papich et al. 2002; Davis et al. 2006; Voermans et 
al. 2006; Nourian et al. 2010). Due to its small depth and anatomical location beneath the 
hoof capsule, lamellar tissue is not amenable to tissue cage implantation. Serial lamellar 
biopsies (Visser and Pollitt 2011) potentially allow measurement of lamellar drug 
concentrations. However, only a limited number of samples can be obtained and the 
technique is invasive resulting in inflammation (Visser 2009), which may affect drug 
distribution (Barza and Cuchural 1985).  The combination of blood, interstitial fluid (IF) and 
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intracellular fluid in homogenised the biopsy samples may under- or over-estimate drug 
concentrations, and complicated homogenisation and extraction procedures reduces the 
accuracy of the technique (Cars and Ogren 1985; Nix et al. 1991). 
 
Microdialysis is a minimally invasive technique that has been applied to investigate local 
tissue metabolism and has been used in pharmacokinetic studies (Ingvastlarsson et al. 1992; 
Chou et al. 2001).  Microdialysis has been applied to the lamellar tissue to measure lamellar 
drug concentrations (Nourian et al. 2010) and tissue metabolites (Medina-Torres et al. 2013). 
It uses small, implantable probes that cause minimal tissue damage. However, because 
microdialysis relies on passive diffusion over a concentration gradient between tissue and 
dialysate, the recovery of the substance of interest is often low (Linhares and Kissinger 1993) 
hence sensitive analytical techniques and complex calculations are required to establish 
actual drug concentrations (Nourian et al. 2010). 
 
Ultrafiltration is a minimally invasive technique for directly sampling interstitial fluid (IF), 
and appears to be the most suitable technique for lamellar sampling. Ultrafiltration probes 
consist of loops of semi-permeable membrane tubing connected to a single collection tube.  A 
negative pressure gradient is applied across the probe by connecting the collection tubing to a 
vacuum tube or peristaltic pump.  Once placed in the tissue, IF is drawn across the probe 
membrane and collected for direct analysis. The recovery of small molecules is typically 
greater than 95% (Linhares and Kissinger 1992). Following implantation, ultrafiltration 
probes can be used in unrestrained animals over extended time periods (Linhares and 
Kissinger 1992). Extensive pharmacokinetic analyses of drugs have been conducted  using 
ultrafiltration probes in equine bone marrow and subcutaneous tissues (Linhares and 
Kissinger 1992; Linhares and Kissinger 1993; Spehar 1998; Davis et al. 2005; Davis et al. 
2006; Parra-Sanchez et al. 2006), canine subcutaneous tissues (Bidgood and Papich 2002; 
Bidgood and Papich 2003; Bidgood and Papich 2005),  rodent subcutaneous tissues (Linhares 
and Kissinger 1992; Linhares and Kissinger 1993), porcine intramuscular, subcutaneous and 
intrapleural tissues (Messenger et al. 2011) and bovine subcutaneous tissues (Davis et al. 
2007).  
 
Although ultrafiltration is a minimally invasive technique, it remains possible that the host 
response to the probe may affect pharmaceutical recovery.  There are over 40 studies using 
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ultrafiltration to measure drugs or metabolites concentrations, yet very few investigate the 
tissue response to probe placement histologically (Huinink 2007). In those that do, the 
responses encompass varying degrees of foreign body reaction, from a small sheath of fibrous 
tissue around the probe to marked granulomatous inflammation dependent on the species, 
probe material, tissue and duration of implantation (Janle-Swain et al. 1987; Clark et al. 
2000; Imsilp et al. 2000; Wisniewski et al. 2001).  Along with biofouling (the adhesion of 
proteins and cells on the outer surface of the UF probe that obstruct filtration) the host 
reaction to an implanted probe can significantly affect substance recovery (Clark et al. 2000; 
Wisniewski et al. 2001). This effect has been demonstrated with microdialysis, but not with 
ultrafiltration.  As ultrafiltration relies on bulk flow across the membrane, it is probable that 
substance recovery will be unaffected by host tissue response (Janle and Kissinger 1996), 
however, studies investigating the use of ultrafiltration for measurement of lamellar drug 
concentrations would need to consider and explore the extent of this caveat. 
 
1.9 Nanoparticle delivery systems 
Nanotechnology is redefining human medicine, imaging and drug delivery, leading to the 
development of a new generation of medical products.  For over 30 years nanoparticles, 
defined as ordered structures with diameters smaller than 1,000 nm (Brigger et al. 2002), 
have been engineered to develop novel diagnostic methods and targeted therapies (Figure 
1.3). In multiple studies, nanoparticles have demonstrated remarkable efficacy for targeting 
delivery of anti-neoplastic agents (Hofheinz et al. 2005), antimicrobials (Cordeiro et al. 
2000), analgesics (Rose et al. 2005) and anti-inflammatory agents (Metselaar et al. 2003). 
There are over 200 nanoparticle drug delivery systems in development, with at least 30 nano-
particle based therapeutic products approved for clinical use in humans and similar numbers 
in clinical trials (Wagner et al. 2006; Bawa 2008). Several nanoparticle formulations are 
available on the veterinary market, e.g. Surpass® and as nanoparticle production facilities are 
scaled up for commercialisation, nanoparticle preparations become more affordable for 
veterinary application. This section will focus on the basic principles behind the use of 
nanoparticles for drug delivery, Common forms of nanoparticle are discussed, along with 
their clinical applications, limitations, and potential for targeted delivery of therapeutic agents 
to the lamellar tissue. Further information on nanoparticles and their potential for application 
to veterinary medicine is detailed in the published review article in Appendix 1 (Underwood 
and van Eps 2012). 
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Figure 1.4. A schematic diagram depicting the relative size of a typical nanoparticle 
compared to an erythrocyte, an E. coli bacterium and a molecule of fibrinogen. Whilst 
nanoparticles are defined as being less than 1,000 nm in diameter, most nanoparticles used 
in medical applications are between 50 and 200nm in diameter. 
 
1.9.1 Nanoparticles in targeted drug delivery 
The use and efficacy of many currently available pharmacologic agents are limited by low 
bioavailability and unwanted side effects.  Approximately 95% of all potential therapeutic 
agents have poor bioavailability and pharmacokinetics (Brayden 2003). Nanoparticle drug 
delivery systems can be engineered to overcome these issues and thus improve the 
therapeutic indexes and safety profiles of the substances they carry. Nanoparticles have found 
widespread use in drug delivery, with indications including cancer, infection and analgesia. 
In addition to the intravenous administration route, nanoparticle delivery systems improve the 
pharmacokinetics of ocular, inhalational, intra-articular, peri-neural, epidural, oral and topical 
pharmaceuticals, primarily via increasing drug penetration to the target tissue, increasing the 
concentration of drug in that tissue, and increasing the retention time in that tissue (Shek et al. 
1994; Aly 2008; Gershkovich et al. 2008). Unless otherwise mentioned, this review focuses 
on nanoparticles administered by the intravenous route. 
 
Nanoparticles improve the therapeutic index of the pharmaceutical agents they carry through 
four key mechanisms. Firstly, they enable the use of drugs that would otherwise be insoluble 
or unstable. Secondly, they increase the concentration of pharmaceutical at its intended site of 
action, resulting in increased efficacy. Thirdly, because of preferential accumulation at target 
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sites, they lower systemic toxicity and drug concentration healthy tissues. Fourthly, 
nanoparticles have reduced clearance compared to the parent drug and thus provide a method 
of sustained controlled release over a period of days or even weeks. (Sahoo and Labhasetwar 
2003; Bakker-Woudenberg et al. 2005; Fahmy et al. 2005). As a consequence of these 
mechanisms nanoparticle formulations require a reduced dose compared to free drug. This is 
particularly pertinent as it may facilitate clinical application of expensive pharmaceuticals, 
such as MMP inhibitors, whose use for anti-laminitis therapy would otherwise be precluded 
by the cost of dosing. 
 
To form a successful drug delivery system, the nanoparticle must be loaded with a sufficient 
amount of pharmaceutical, carry this to the target tissue and then release the pharmaceutical 
at the target site. Nanoparticles can be loaded with drugs via encapsulation within the particle 
or via surface attachment (Lu et al. 2007). The method of drug loading depends upon the type 
of nanoparticle, and upon drug type and target. By loading a drug into the nanoparticle, 
delivery of the drug essentially depends on the external properties of the nanoparticle until 
the particle is destroyed. 
 
Targeting of nanoparticles to specific sites is achieved by passive targeting (based on the 
innate properties of the nanoparticle) and/or active targeting (the coupling of a targeting 
moiety to a nanoparticle). The archetypical mechanism of passive targeting occurs via the 
‘enhanced permeability and retention (EPR) effect’, which is demonstrated almost 
ubiquitously by nanoparticles due to their small size (Maeda 2010). Optimal nanoparticle size 
for the EPR effect is 50-200nm.  The EPR effect relies on the ability of intravenous 
nanoparticles, which are normally retained in the circulation, to extravasate at sites of 
increased vascular permeability. This results in accumulation of nanoparticles at sites of 
increased vascular permeability (e.g. tumours, infections and areas of inflammation), hence 
targeting of the agents they carry to these sites (Ishihara et al.).  Opsonisation and subsequent 
uptake of nanoparticles by the mononuclear phagocyte system  (MPS) reduces the number 
remaining in circulation and able to extravasate (Laverman et al. 2000). To overcome this, 
nanoparticles can be coated with hydrophilic substances, the most commonly used being 
polyethylene glycol (PEG). This reduces opsonisation and prolongs circulation time 
(Arulsudar et al. 2004). In addition to a PEG coating, nanoparticle characteristics, such as 
size, surface charge, hydrophobicity and architecture can be engineered to passively target 
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certain tissues or cell types (Adiseshaiah et al. 2010). In fact, MPS, rendering them ideal for 
targeting intracellular parasitic, bacterial, fungal and viral infections (Schiffelers et al. 2001).  
 
In addition to passive targeting, active targeting may be necessary to increase the interaction 
between nanoparticles and target tissues. This is achieved via attachment of a targeting 
moiety to the nanoparticles, causing them to adhere to a particular receptor/cell type and thus 
increasing their concentration at the site of interest (Goutayer et al. 2010). Ligand-mediated 
binding is particularly valuable todrugs that are not easily taken up by cells, and require 
facilitated fusion, endocytosis or another uptake processes to access intracellular active sites. 
Significant progress has been made by actively targeting nanoparticles to inflammatory 
markers, adhesion molecules and abnormal cell surface receptors (Guccione et al. 2004; 
Winter et al. 2010). By targeting liposomes to ICAM-1 on inflamed endothelial cells Kang 
(Kang et al. 2011) achieved preferential and specific uptake by these cells. As inflammatory 
adhesion molecules are expressed during CHO laminitis development this technique may 
have potential for targeted lamellar delivery.  However, as the use and development of 
antibodies to target nanoparticles to a particular tissue or cell type can be expensive, targeting 
nanoparticles to specific tissues simply by altering their charge, or coating them in a 
substance that is naturally taken up by that tissue is a more cost-effective approach. This 
method has been successfully utilized to target nanoparticles to the vascular endothelium in 
order to increase uptake across the blood-brain barrier in treatment of neurological diseases 
(Lu et al. 2006; Weiss et al. 2008). Targeting of nanoparticles to the vascular endothelium is 
a comparatively novel area in nanoparticle development. It has potential for application to 
laminitis therapy, as nanoparticles targeted to the digital vascular endothelium could be 
administered by RLP, to enhance uptake and provide a depot supply of the pharmaceutical 
they carry in the lamellar tissue. Therefore, the cellular uptake mechanisms and potential 
surface coatings that have been applied in this area will now be considered. 
 
Nanoparticles are targeted to the vascular endothelium on the basis of their charge, size, and 
surface characteristics (Kreuter et al. 2002; Lockman et al. 2003; Lu et al. 2006; Kratzer et al. 
2007; Hombach and Bernkop-Schnurch 2009; Huang et al. 2009; Huang et al. 2010; Ulbrich 
et al. 2011). Once successful targeting is achieved, nanoparticle internalisation occurs rapidly 
(within minutes); the nanoparticle’s fate is then ultimately determined by the endocytic 
pathway used to internalise the particle. This is also affected by nanoparticle charge, size and 
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surface characteristics. Therefore, in designing an efficient trans-endothelial drug delivery 
system it is critical to understand and identify the uptake mechanisms that transport particles 
from the endothelial surface to intracellular sites or subluminal targets.  
 
Endothelial cellular uptake mechanisms are broadly grouped into receptor- dependent and 
receptor-independent mechanisms. Receptor mediated pathways include clathrin mediated 
endocytosis, caveolae-mediated endocytosis and cellular adhesion molecule (CAM)-mediated 
pathways (Huang et al. 2010). Receptor-independent pathways that depend on membrane 
cholesterol and lipid raft domains have been identified in the uptake of larger-sized particles, 
as well as macropinocytosis. After being internalized, nanoparticles are trafficked into several 
pathways dependent on mechanism of endocytosis. These include: delivery to the cytosol, 
transport across the cell (transcytosis) and delivery to the lysosome (Huang et al. 2010). The 
key challenge to intra/transcellular drug delivery is in avoiding cellular degradation processes 
(via the lysosome). To avoid acidic lysosomal degradation nanoparticles must either escape 
from the endosomes destined for lysosomal fusion or utilize endocytic mechanisms that 
generate vesicles that do not traffic to the lysosome (transcytosis). Clathrin-dependent 
endocytosis generally delivers nanoparticles to the lysosome (Bareford and Swaan 2007). 
Clathrin-independent endocytic pathways, i.e. caveolae mediated endocytosis, lipid raft-
mediated endocytosis and macropinocytosis lead to cytosol localization or transcytosis 
(Rejman et al. 2004; Huang et al. 2010). Transcytosis is a mechanism whereby molecules are 
transported across the cell in discrete vesicles (Simionescu et al. 2009). This process is 
particularly prominent in vascular endothelial cells and is the target pathway for nanoparticles 
that need to be delivered to the underlying tissue, such as the EBCs for laminitis therapy. 
Transcytosis takes place either by a receptor independent process, or a receptor dependent 
mechanism. Receptor-dependent transcytosis entails the binding of plasma molecules to 
specific sites or receptors localized on caveolae; it applies to several molecular species, 
including low-density lipoproteins, transferrin, insulin, metalloproteinases and albumin. 
Plasma solutes and macromolecules e.g. glycogen, dextran, and ferritin, generally perform 
receptor independent transcytosis (Simionescu et al. 2009).    
 
Nanoparticles smaller than 500 nm are typically internalized via receptor-mediated 
endocytosis; particles less than 200 nm via clathrin-mediated endocytosis and others mostly 
via caveolae-mediated mechanisms (Rejman et al. 2004). Nanoparticles engineered to have a 
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positive charge appear to be superior for trans-endothelial delivery: charged nanoparticles 
typically show higher uptake rates compared to neutrally-charged particles (Yue et al. 2011) 
and cationic nanoparticles are internalized more readily than anionic nanoparticles (likely due 
to their better interaction with the negatively charged plasma membrane and clathrin coated 
pits of the endothelium). In addition to having an increased uptake rate, cationic particles 
avoid degradative lysosomal pathways (Harush-Frenkel et al. 2008). In addition to optimizing 
nanoparticle size and charge, in order to target transcytotic pathways, the majority of 
nanoparticle formulations developed for trans-endothelial drug delivery are modeled after/ 
coated in macromolecules naturally transported across the endothelium via transcytosis. 
Chitosan, thiamine, Polysorbate 80, transferrin, lactoferrin, cationic BSA, apolipoprotein E 
and insulin have all been successfully employed to aid nanoparticle uptake, with transcytosis 
across the blood brain barrier occurring within 20 minutes of systemic intravenous injection 
(Kreuter et al. 2002; Lockman et al. 2003; Lu et al. 2006; Kratzer et al. 2007; Hombach and 
Bernkop-Schnurch 2009; Huang et al. 2009; Huang et al. 2010; Ulbrich et al. 2011). 
 
Once at the target site the next essential step is drug release. A myriad of mechanisms for 
drug release/ nanoparticle uptake may occur. These differ based on the properties and surface 
characteristics of the nanoparticle in question (Georgieva et al. 2009). Possible mechanisms 
of drug release include: i) liberation due to nanoparticle disintegration, or enzymatic 
breakdown, ii) diffusion from the intact nanoparticle; iii) release from the surface of the 
nanoparticle; iv) fusion of the nanoparticle with the cell surface membrane and subsequent 
release of contents into the cell; v) endocytosis of the nanoparticle with subsequent release of 
contents into the endoplasmic reticulum; vi) triggered release initiated by application of an 
external factor, e.g. application of a magnetic field, a change in temperature or pH (Couvreur 
1993; Liu et al. 2007). In many scenarios a combination of these processes coexist, and 
particles can be engineered to have optimal and controllable release kinetics. 
 
In addition to successfully delivering their payload to the target site, nanoparticles and their 
degradatory products must be successfully cleared from the body without inciting adverse 
effects. Nanoparticle toxicity, adverse reactions and a lack of knowledge regarding the 
clearance and long term effects of some nanoparticles formulations have slowed their 
application to human medicine (Maurer-Jones, Bantz et al. 2009). In order to minimise the 
risk of adverse effects nanoparticles should be formed from bio-degradable or bio-inert 
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materials, and close monitoring for adverse reactions is necessary at all stages of nanoparticle 
development. Toxicity issues with respect to individual nanoparticle formulations will be 
discussed further below. 
 
1.9.2 Nanoparticles in imaging 
Harnessing similar delivery principles as those for nanoparticle drug delivery systems, 
nanoparticle platforms can be loaded with imaging agents to detect pathological tissues and 
specific cell types (Bentolila et al. 2009; Matteucci and Thrall 2000). Imaging can be based 
upon both a macroscopic scale and on a molecular level where nanoparticles are used to 
visualise, characterize and measure cellular processes in living organisms. Ligand directed 
nanoparticles, such as fluorescent quantum dots can identify diseased tissues and molecular 
processes providing unprecedented information on disease pathophysiology (Bentolila et al. 
2009).  Initial work focused on macroscopic use of nanoparticles with conventional imaging 
modalities, such as radiography, MRI, nuclear scintigraphy, PET and CT, for diagnosis of 
tumours and inflammatory foci. Utilising the ‘EPR effect’ nanoparticles extravasate in areas 
of pathology leading to increased signal from the imaging contrast agent they carry at that 
site.  Nanoparticle based imaging techniques have been used extensively to evaluate the 
biodistribution of potential nanoparticle-drug delivery systems; much of the information 
available regarding nanoparticle clearance, degree of uptake by the MPS and tissue 
localization is based on the results of studies with imaging agents conjugated to the potential 
nanoparticle delivery system. It is likely they will prove useful for assessing nanoparticle 
based lamellar delivery.  
 
1.9.3 Nanoparticles 
There are a variety of nanoparticles in use (Figure 1.5); each varies in its ease of manufacture, 
the type and amount of pharmaceutical it can incorporate, ease of targeting, stability, adverse 
effects, duration within the body and cost. Below is a brief description of different 
nanoparticle formulations, with more elaborated discussion of the formulations that will be 
applied to laminitis drug delivery in this thesis. 
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Figure 1.5: A schematic of some typical nanoparticle systems: a) a polymeric dendrimer 
typical size range 100-200nm; b) a liposome, typical size range 50-200nm; c) a 
nanoemulsion, typical size range 50-500nm; d) a phospholipid micelle typical size range 5-
50nm 
1.9.3.1 Polymeric nanoparticles 
Polymeric nanoparticles are prepared by combining the active substance/drug with a polymer.  
The active components are dissolved in, entrapped in, or adsorbed to the surface of the 
polymer nanoparticle. Polymeric nanoparticles exist in a variety of forms ranging from 
nanospheres to dendrimers (Figure 1.5a), and utilise both natural and synthetic polymers. 
Polymer delivery characteristics, surface properties, morphology and composition can be 
readily tailored and optimized to achieve the desired drug loading, biocompatibility, 
targeting, degradation and controlled release kinetics (Yang 2000). Primary limitations to the 
development of polymeric nanoparticles include toxicity, irritancy, the need for a 
biodegradable soluble material and a lack of large scale production methods (Muller and 
Keck 2004).   
 
1.9.3.2 Solid Lipid Nanoparticles 
Solid lipid nanoparticles (SLNs) are composed of lipids that are solid at room temperature, 
stabilised by surfactant and suspended in an aqueous solution (Souto 2009). The 
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pharmaceutical agent is dissolved or dispersed within the lipid, therefore they are most 
suitable for lipophilic pharmaceuticals. SLNs exhibit several advantages over polymeric 
nanoparticles: they have comparatively higher drug entrapment efficiency, can be 
administered by multiple routes (orally, topically, and intravenously), hydrophobic drugs are 
stable in their lipid matrix, they protect sensitive drugs from the external environment, they 
have minimal toxicity and they do not require the use of organic solvents in their production 
which is easily scaled up to commercial level (Blasi et al. 2007; Mishra et al. 2009). 
Additionally SLNs can provide controlled release lasting up to several weeks, adhere to 
mucosal surfaces, promote the absorption of orally administered drugs and have particular 
potential for drug delivery to the brain as they are capable of transporting pharmaceuticals 
across the blood brain barrier (Muller and Keck 2004; Blasi et al. 2009).  However, as the 
current candidate anti-laminitis drugs are hydrophilic, SLNs will not be utilised in this 
project. 
 
1.9.3.3 Liposomes 
Liposomes are vesicles in which an aqueous core is encapsulated within one or more 
phospholipid bilayers (Figure 1.5b). They have been used as drug delivery systems since the 
1960s, with their first market appearance in 1986 in a cosmetic formulation by Dior, and are 
somewhat considered the archetypical nanoparticle (Muller and Keck 2004). Liposomes are 
highly flexible delivery systems, able to load high quantities of both hydrophobic and 
hydrophilic substances, be conjugated to antibodies or ligands and have their size, the number 
of phospholipid bilayers, lipid composition, surface characteristics and charge engineered to 
optimize their suitability for an intended use. Liposomes are suitable for topical, intravenous 
and intramuscular administration, but are susceptible to degradation in the gastrointestinal 
tract so are rarely suitable for oral preparations. They have been investigated for targeted 
drug, imaging agent, vaccine and gene delivery with promising results (Dams et al. 2000; 
Bakker-Woudenberg et al. 2005). Several commercially available liposome formulations are 
on the market and there are multiple studies on their application in veterinary species 
(Khanna et al. 1997; Caldwell et al. 2004; Mathes et al. 2006; Paul-Murphy et al. 2009). 
However, their application has been slowed somewhat by stability issues, difficult 
manufacturing technique and expense. In recent years, the upscaling of liposome production 
for commercial applications has resulted in the availability of liposomes that have a 
reasonable shelf life (up to two years) and are an affordable, practical option for veterinary 
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application. Liposomes have biodegradable constituents so toxicity is rarely an issue; 
however, complement mediated hypersensitivity reactions may occur in response to 
intravenous liposome administration (Muller and Keck 2004; Szebeni et al. 2007). These 
reactions occur in 5-45% of human patients (Szebeni et al. 2007) and can be prevented by 
slow infusion, anti-histamines and anti-inflammatories.  The severity and dose dependence of 
liposomal CARPA reactions varies between species, with rats being two-to-three orders of 
magnitude less sensitive than pigs and humans (Szebeni et al. 2007). The safety and 
biodistribution of 99m Tc-PEG-liposomes has already been evaluated in horses (Underwood et 
al. 2011). In comparison to the hypersensitivity reactions demonstrated in humans, pigs and 
dogs, horses appear relatively insensitive to liposome administration with clinical signs and 
complement activation levels similar to those seen in rats (Szebeni et al. 2007; Underwood et 
al. 2009). Further work by the author has established that intravenous liposomes extravasate 
at sights of focal inflammation in the horse with a 24 fold increase in liposome levels in 
inflamed muscle compared to normal muscle at 24 hours post-injection (Underwood et al. 
2011). A recent report has described the successful application glucocorticoid liposomes in a 
mouse rheumatoid arthritis model (Hofkens et al. 2011). In addition to clinical and 
histological improvement, ADAMTS-4 and MMP production by synovial cells was inhibited. 
There is strong evidence that inflammation occurs early in the development of laminitis 
(Belknap et al. 2007; Visser 2009). Therefore it is hypothesised that liposomes will 
extravasate into lamellar tissue during laminitis development, providing a potential 
mechanism for targeted drug delivery. 
 
1.9.3.4 Nanoemulsions 
Nanoemulsions are meta-stable dispersions of nano-sized droplets of one liquid in a different 
immiscible liquid (Fryd and Mason 2012). The dispersed droplets are stabilised with an 
interfacial layer composed of surfactant and co-surfactant (Lawrence 2000; Karasulu 2008; 
He et al. 2010). Most commonly, drugs are loaded into the dispersed phase where the droplet 
size is typically 20-200 nm. An oil-in-water emulsion consists of dispersed oil droplets within 
an aqueous solution (Figure 1.5c). Water-in-oil emulsions and water-in-oil-in-water 
emulsions (double emulsions) have also been formulated for biomedical application. 
Advantages of nanoemulsions include simple, inexpensive preparation, high stability, the 
ability to solubilise lipophilic substances and the ability to protect substances from 
degradation. Nanoemulsions are versatile and can be prepared by many different aqueous 
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solutions, surfactant and oil constitutes. According to the properties of their constituents, they 
exist in a wide range of compositions and thus perform a wide variety of tasks. Whilst the 
high concentrations of surfactants and co-surfactants in some nanoemulsion formulations can 
result in toxicity (Karasulu et al. 2007), low-cost, solvent free nanoemulsions have been 
produced for use in veterinary species (Vandamme and Anton 2010) and promising results 
have been achieved using nanoemulsions for drug delivery (Kawakami et al. 2002; Kang et 
al. 2004; Ke et al. 2005). As they are easily produced and readily tailorable, addition of a 
surface coating to target nanoemulsions to certain cell types e.g. vascular endothelial cells, 
can readily be achieved. The high tailorability of some nanoemulsion formulations stems 
from bottom up design and the use of pepfactant in the interfacial layer. Recently a versatile 
biocompatible tailorable oil-in-water nanoemulsion has been developed by Chuan (Chuan et 
al. 2012) for administration of a lipophilic anti-inflammatory agent. As marimastat is a 
weakly hydrophilic drug (soluble to 10 mM in water, 20 mM in ethanol and 100 mM in 
dimethylsulfoxide (DMSO)), use of a double emulsion system is necessary. Double emulsion 
formulation is somewhat challenging (Fryd and Mason 2012).  Water/oil/water double 
microemulsions can be prepared using microfluidic mass-transfer control (Zhao and 
Middelberg 2009). Combination of the two previously described techniques may yield 
development of a double nanoemulsion that can transport hydrophilic pharmaceuticals and 
has surface characteristics that can be readily tailored to target the lamellar vascular 
endothelium. 
 
1.9.3.5 Micelles 
Polymeric micelles have a unique structural composition characterized by a hydrophobic core 
stabilized by a hydrophilic shell (Blanco et al. 2009; Kim et al. 2009; Yokoyama 2010).  Due 
to their hydrophilic shell they are highly water soluble and evade MPS clearance. Thus, 
micelles have long circulation times and exhibit the EPR effect. Hydrophobic substances are 
stored in the micelle core, where they are solubilised and protected from enzymatic 
degradation. Micelles can be easily prepared, have low toxicities and have the potential to be 
a versatile system for effective delivery of different classes of therapeutic agent, with at least 
six micelle formulations currently in clinical trials (Matsumura and Kataoka 2009; Saif et al. 
2009). However, careful engineering of the micelle in necessary to ensure their long-term 
stability and drug loading capacity (Blanco et al. 2009).  
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1.9.3.6 Inorganic Nanoparticles 
The most intensively studied inorganic nanoparticles are reviewed in brief below. In early 
studies, inorganic nanoparticles demonstrated great potential. However, their clinical 
application is limited by concerns over toxicity, lack of biodegradability and persistent tissue 
accumulation (Fadeel and Garcia-Bennett 2010).  
 
Ceramic nanoparticles made of materials such as silica, alumina and titania, have several 
advantages over polymeric nanoparticle systems. Namely, they are easy to prepare and 
engineer to a desired shape, size and porosity, are biocompatible, have large surface to 
volume ratios, have high surface tailorability and are extremely inert (Lai et al. 2003; Trewyn 
et al. 2007; Liong et al. 2008; Mamaeva et al. 2013). Additionally they protect the adsorbed 
particles they carry against denaturation induced by extreme pH and temperature. However, 
titania nanoparticles appear to possess considerable in vivo toxicity. Mesoporous silica 
nanoparticles (MSNs) are the most commonly investigated of the ceramic nanoparticles. 
MSNs can be functionalised for sustained or stimuli responsive drug release by either 
covalent linking of the drug to the silica framework through cleavable bonds (Mamaeva et al. 
2013), or the addition of cap systems that cover the pores and hence prevent loaded drug 
molecules from leaving the pore (Lai et al. 2003). These cap systems can be removed under 
various triggers such as pH (Zhao et al. 2010), enzymatic and chemical reactions 
(Schlossbauer et al. 2009; Luo et al. 2011), light (Ferris et al. 2009), and molecular 
interactions (Coll et al. 2011). 
 
Carbon nanoparticles include fullerenes, carbon nanotubes and carbon nanohorns.  They have 
been investigated as drug carriers, and have potential for vaccine delivery as they amplify the 
immunological response (Pantarotto et al. 2003).  However, toxicity and biodegradability are 
a significant concern in clinical application (Lamprecht 2009; Surendiran et al. 2009). 
 
Various metals have been used to prepare nanoparticles. Gold, silver and copper are the most 
common metals used, with gold nanoparticles being studied most intensively (Ghosh et al. 
2008; Mishra et al. 2009). The main applications of metal nanoparticles lie in biosensing/ 
imaging and cancer thermotherapy, although they are also being explored for targeted drug 
delivery (Jain 2007; Saha 2007). Metal nanoparticles can easily be synthesized with a range 
33 
 
of sizes (1nm-150nm), are stable and can be modified by conjugation with various functional 
groups (Jain 2007), but are often expensive.  
 
Magnetic nanoparticles are commonly composed of iron oxide due to its high in vivo 
degradability. They have been investigated for use as biosensors, for imaging and for drug 
delivery (Banerjee et al. 2010). In addition performing targeted drug delivery by passive and 
active targeting, magnetic nanoparticles can be pulled out of suspension in the blood stream 
and into localized disease sites by application of a high gradient magnetic field over that 
tissue (Mishima 2007; Nishijima 2007). Despite having many characteristics that make them 
excellent agents for drug delivery and imaging, concerns over toxicity and the accumulation 
of metal-based particles are a significant barrier to the clinical application of magnetic 
nanoparticles (Veiseh et al. 2009).  
 
Quantum dots are semi-conductor nanoparticles that measure approximately 2-10nm and 
fluoresce when stimulated by light. They are comprised of an inorganic core, an inorganic 
shell and an aqueous coating to which biomolecules can be conjugated. The size of the core 
determines the colour of light emitted. Biomedical applications of quantum dots are primarily 
focused on their use as imaging agents (Bentolila et al. 2009). Quantum dots can be targeted 
to various biomarkers providing a highly sensitive diagnostic and research tool (Halfpenny 
and Wright, 2010).  However, clinical application of quantum dots is limited by their 
potential cytotoxicity and slow elimination (Iga et al. 2007; Hauck et al. 2009). 
 
1.10 Conclusions 
Whilst the precise pathophysiologic mechanism of laminitis has yet to be fully elucidated, 
multiple pharmaceuticals with potential for laminitis prophylaxis have been identified. Many 
of these are impractical for systemic delivery; hence a suitable method of local lamellar 
delivery is required for experimental validation of their efficacy. Once established, this local 
delivery method can be used to investigate the efficacy of drugs forlaminitis prophylaxis. The 
reviewed literature suggests that enzymatic degradation and inflammation are key pathogenic 
factors in laminitis; hence their suppression may prevent clinical disease. Pharmaceutical 
agents that inhibit enzymatic degradation, such as the MMP-inhibitor marimastat, have been 
identified as a potential anti-laminitis drugs and validated using in vitro models. This, in 
combination with the broad spectrum MMP and ADAMTS-4 inhibitory properties of 
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marimastat makes it an ideal candidate drug for laminitis prophylaxis. Concurrent 
development of nano-particle based delivery systems may provide a practical means of drug 
delivery to all four feet and a further platform for experimental administration of anti-
laminitis drugs 
 
1.11 Project hypotheses and aims 
The principal aim of this project was to compare different methods of lamellar drug delivery 
and establish the optimal method for delivery of candidate ALDs to equine digital lamellar 
tissue.  This would enable evaluation of their efficacy for laminitis prophylaxis. Throughout, 
marimastat was used as an example candidate ALD. The central hypothesis was that a local 
or targeted delivery method would be necessary to achieve therapeutic lamellar drug 
concentrations. The major hypotheses tested were: 
 
1. Ultrafiltration can be employed as a minimally invasive method of collecting lamellar 
interstitial fluid for pharmacokinetic studies 
 
2. Intraosseous infusion of the distal phalanx with marimastat results in higher lamellar 
marimastat concentrations than systemic marimastat delivery by constant rate infusion 
 
3. Regional limb perfusion with marimastat results in higher lamellar marimastat 
concentrations than a systemic intravenous bolus 
 
4. The optimal regional delivery technique can be applied to evaluate the efficacy of 
marimastat in preventing oligofructose-induced laminitis 
 
5. A nanoparticle formulation will enable targeted drug delivery to the lamellar tissue 
and provide a more clinically applicable means of lamellar drug delivery.. 
 
To test these hypotheses the following four key objectives were set, each forming major 
themes of the project:  
 
Part II: To develop a minimally invasive technique to collect lamellar interstitial fluid 
for pharmacokinetic studies. 
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Part III: To assess the efficacy and suitability of systemic and local delivery 
techniques for delivery of marimastat to lamellar tissue, focusing primarily on the systemic 
delivery technique of intravenous constant rate infusion (CRI) and intravenous bolus dosing 
(SIVB), and the regional delivery techniques of IOIDP and RLP. 
 
Part IV: To determine whether the optimal delivery technique from part III remains a 
suitable mechanism for lamellar drug delivery during experimental laminitis induction, and to 
evaluate the efficacy of marimastat in preventing oligofructose-induced laminitis. 
 
Part V: To investigate whether nanoparticle formulations offer alternative means of 
targeted lamellar drug delivery. 
 
1.8 Ethical considerations 
The experimental protocols used during this project were approved by the Animal Ethics 
Committee of the University of Queensland (approval numbers: SVS/027/11, SVS/117/11, 
SVS 337/11, SVS/418/12), which ensured compliance with the Animal Welfare Act 2001 of 
Queensland and the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes (current edition). All horses were continuously monitored throughout the 
experimental period by a registered veterinarian. Live animal experiments were an essential 
part of this project, but every effort was made to reduce the number of horses used. The 
terminal nature of the experiments meant that the three R’s of the Code of Practice (reduce, 
refine and replace) were observed as much as possible by minimising animal usage. 
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PART II: LAMELLAR SAMPLING FOR PHARMACOKINETIC 
STUDIES 
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Part II: Introduction 
 
Comparison of delivery techniques necessitates collecting samples for determination of tissue 
drug concentrations. In lamellar tissue, this presents a unique challenge due to its small depth 
and its anatomical location between the hoof capsule and the distal phalanx. Traditional 
techniques such as implanted tissue cages and serial biopsies are impractical and traumatic. 
Lamellar microdialysis has been developed (Nourian, Mills et al. 2010), but pharmaceutical 
recovery is low hence lack of detection at low tissue concentrations is a concern.  Capillary 
ultrafiltration overcomes this limitation by directly sampling interstitial fluid (Linhares and 
Kissinger 1992).   
 
The first hypothesis of this thesis, that ultrafiltration could be employed as a minimally 
invasive method of collecting lamellar interstitial fluid for pharmacokinetic studies, is tested 
in Chapter Two. In order to accept this hypothesis the following key objectives were set:   
(1) To develop a technique for ultrafiltration probe placement within the confines of the 
hoof wall and the distal phalanx that results in neither pain, discomfort nor 
destabilisation of the suspensory apparatus of the distal phalanx.  
(2) To collect of sufficient fluid for analysis by UPLC or HPLC 
(3) To establish that the composition of the fluid collected was stable and did not vary 
with time  
This section focuses on addressing these objectives; a preliminary step in developing and 
validating lamellar ultrafiltration for repeated, direct sampling of lamellar interstitial fluid as 
lamellar ultrafiltrate (LUF). 
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2.1 Abstract 
Laminitis is a crippling disease of the equine digit. Currently, there are no experimentally 
validated pharmacologic means of preventing laminitis. Pharmaceutical agents with the 
potential to prevent laminitis have been identified. Demonstrating therapeutic drug 
concentrations are achieved in the lamellar tissue is key to experimentally evaluating the 
efficacy of these agents. The aim of this current study was to develop an experimental 
technique for repeatedly sampling lamellar interstitial fluid (IF) using ultrafiltration. 
 
A technique for placing ultrafiltration probes in lamellar tissue was developed in vitro using 
15 cadaver limbs. Subsequently, ultrafiltration probes were placed in the lamellar tissue of 6 
living horses. The horses were monitored twice daily for discomfort associated with the 
ultrafiltration probe. Ultrafiltrate was collected continuously for 4 (n=4) or 14 day (n=2) 
study periods. The fluid was sampled every 12 hours and the rate of collection calculated. 
Biochemical analyses were performed on ultrafiltrate collected on night 1 (12 to 24 hours 
post implantation) and night 4 (84 to 96 hours post implantation). Sections surrounding the 
probe and control tissue from the contralateral limb were harvested at the end of the study 
and stained with H&E and Masson’s Trichrome and scored based on the tissue response to 
the probe.  Data were analysed non-parametrically with significance set at P<0.05 
 
Ultrafiltration probes were placed in the lamellar tissue in all 6 horses. Ultrafiltrate was 
collected at 55[30-63] µL/h (median [interquartile range]). Fluid production decreased 
significantly with time from night 3 onwards. There was no significant change in the 
constituents of the ultrafiltate between nights 1 and 4. The technique was well tolerated and 
the horses showed minimal signs of discomfort.  
 
This study demonstrates that ultrafiltration can be used to sample equine digital lamellar IF, 
and has potential for measuring lamellar drug levels. 
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2.2 Introduction 
Acute laminitis is a common sequela to a variety of primary diseases in the horse (Parsons et 
al. 2007). Whilst, there are three broad aetiologic categories of laminitis (endocrinopathic, 
sepsis and severe contra-lateral limb lameness), they all result in lamellar separation at the 
dermo-epidermal interface (van Eps and Pollitt 2009; de Laat et al. 2010; van Eps et al. 
2010). Once the lamellar attachment is sufficiently weakened, mechanical failure of the 
lamellar tissue is unavoidable. The ensuing displacement of the distal phalanx and traumatic 
tissue damage is irreversible. Therefore, whatever the aetiology, laminitis prophylaxis is key.  
 
Digital hypothermia prevents laminitis in the oligofructose model (a sepsis model)(van Eps 
and Pollitt 2009).  However, there is currently no evidence to support an effective 
pharmaceutical means of laminitis prophylaxis. Inflammation, proteolytic enzymatic 
activation and basement membrane disintegration have been implicated in the 
pathophysiology of sepsis-related laminitis (Pollitt et al. 1998; Belknap et al. 2007; Visser 
2009). There are pharmaceutical agents that could block these pathways at the lamellar level, 
including protease inhibitors, Wnt pathway agonists, and STAT3 inhibitors (Pollitt et al. 
1998; Leise et al. 2012; Wang et al. 2013). The first step in evaluating their potential for 
laminitis prophylaxis is to establish a delivery mechanism that yields sustained therapeutic 
concentrations in the lamellar tissue.  This requires a means of repeatedly measuring lamellar 
drug concentrations.   
 
Measurement of drug concentrations within the lamellar tissue presents a unique challenge. 
Techniques to determine tissue drug concentrations include implanted tissue cages, biopsies, 
microdialysis and ultrafiltration (Papich et al. 2002; Davis et al. 2006; Voermans et al. 2006; 
Nourian et al. 2010). Due to its small depth and anatomical location beneath the hoof capsule, 
lamellar tissue is not amenable to tissue cage implantation. Serial lamellar biopsies (Visser 
and Pollitt 2011) potentially allow measurement of lamellar drug concentrations. However, 
only a limited number of samples can be obtained and the technique is invasive resulting in 
inflammation (Visser 2009), which may affect drug distribution (Barza and Cuchural 1985).  
The combination of blood, interstitial fluid (IF) and intracellular fluid in homogenised biopsy 
samples may under- or over-estimate drug concentrations (Cars and Ogren 1985; Nix et al. 
1991).  Microdialysis has been used to measure lamellar drug concentrations (Nourian et al. 
2010). Microdialysis uses small, implantable probes that cause minimal tissue damage. 
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However, because microdialysis relies on passive diffusion over a concentration gradient 
between tissue and dialysate, the recovery of the substance of interest is often low (Linhares 
and Kissinger 1993) hence sensitive analytical techniques and complex calculations are 
required to establish  actual drug concentrations (Nourian et al. 2010). Ultrafiltration also 
uses small implantable probes, but directly samples the IF, facilitating direct analysis of 
tissue drug concentrations without the need for complicated homogenisation and extraction 
processes (Linhares and Kissinger 1992; Bidgood and Papich 2002). 
 
Ultrafiltration probes consist of loops of semi-permeable membrane tubing connected to a 
single collection tube.  A negative pressure gradient is applied across the probe by connecting 
the collection tubing to a vacuum tube or peristaltic pump.  Once placed in the tissue, IF is 
drawn across the probe membrane and collected for direct analysis. The recovery of small 
molecules is typically greater than 95% (Linhares and Kissinger 1992). Ultrafiltration probe 
placement is minimally invasive.  Following implantation, ultrafiltration probes can be used 
in unrestrained animals over extended time periods (Linhares and Kissinger 1992). 
Pharmacokinetic analyses of drugs have been conducted  using ultrafiltration probes in 
equine bone marrow and subcutaneous tissues (Linhares and Kissinger 1992; Linhares and 
Kissinger 1993; Spehar 1998; Davis et al. 2005; Davis et al. 2006; Parra-Sanchez et al. 2006), 
canine subcutaneous tissues (Bidgood and Papich 2002; Bidgood and Papich 2003; Bidgood 
and Papich 2005),  rodent subcutaneous tissues (Linhares and Kissinger 1992; Linhares and 
Kissinger 1993), porcine intramuscular, subcutaneous and intrapleural tissues (Messenger et 
al. 2011) and bovine subcutaneous tissues (Davis et al. 2007).  
 
Whilst ultrafiltration has been used successfully in other tissues (Davis et al. 2005; Davis et 
al. 2006; Parra-Sanchez et al. 2006) there are particular challenges associated with probe 
implantation in equine digital lamellar tissue. The stratum medium of the hoof wall and 
adjacent lamellar tissue are essential for weight-bearing (Pollitt 2010). Hence, placement 
technique must not involve excessive removal of hoof wall or result in significant pain. The 
rate of fluid collection is proportional to the length of the probe membrane (0.5 to 2 µL/cm 
membrane length/ hour) (BASi 2012). To collect enough ultrafiltrate (50uL) for hourly 
pharmacokinetic analysis by ultra-performance liquid chromatography (UPLC), 3 loops each 
containing at least 8 cm of probe membrane are required. The depth of the lamellar tissue is 
not sufficient for this length probe to be positioned in a dorsopalmar plane. Therefore the 
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probe must be oriented proximodistally, from coronary band to toe.  Probe implantation in the 
digit faces the challenge of maintaining sterility during implantation and cleanliness post-
implantation, to prevent infection. As laminitis development occurs over a 72 hour period it is 
necessary that the probes function, without causing pain, for that period of time.  
 
The primary aim of this study was to develop a technique for ultrafiltration probe placement 
in, and collection of IF from, equine digital lamellar tissue. Objectives included: 1) To 
establish whether ultrafiltration probes could be placed in a proximodistal direction in the 
lamellar tissue; 2) To establish whether ultrafiltrate could be collected in sufficient volume 
for analysis by UPLC or high-performance liquid chromatography (HPLC) over a 96 hour 
period; 3) To assess whether probe placement resulted in lameness or discomfort; 4) To 
assess whether the constituents of the fluid collected varied with time; and 5) To establish 
whether biochemical analytes in the ultrafiltrate differed from those in plasma.  
 
2.3 Materials and methods 
2.3.1 Development of probe placement technique 
To establish the maximum ultrafiltration probe length that could be accommodated in the 
lamellar tissue, the proximo-distal length of the lamellar tissue was measured on sagittal 
sections of six Standardbred cadaver limbs. Measurements were confined to the dorsal 
midline of the forefeet. A further 15 cadaver limbs were used to develop the placement 
technique. The hoof wall was resected to the white line at the dorsal, distal toe immediately 
cranial to the point of the frog. A custom made introducer, fashioned from the stylet of a 12G 
catheter (EquiCath Fastflow, B. Braun Vet Care), containing a custom made chisel tip stylet 
(Figure 2.1), was inserted into the lamellar layer at the centre of the resection. The introducer 
was advanced proximally through the lamellar tissue for a distance equivalent to the length of 
the lamellae. At this point the chisel tip stylet was replaced with a curved tip stylet and the 
introducer was advanced until it exited the skin. The curved tip stylet was removed and 3 ml 
of coloured polyurethane (Plasticast, Dalchem Pty Ltd) was injected through the introducer as 
it was withdrawn. The feet were sectioned to enable visualization of the polyurethane. 
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Figure 2.1: Photograph of ultrafiltration probe placement instruments, showing the 
custom-made introducer, the chisel tip stylet used when the introducer is passed through the 
lamellar tissue and the curved tip stylet used to pass the introducer through the skin at the 
coronary band. 
 
2.3.2 In vivo ultrafiltration probe placement 
Six clinically normal Standardbred horses (4-12 year old geldings) with healthy feet and no 
lameness (based on physical examination) were used in this study. The animals were housed 
in stalls, were free to move and had ad libitum access to food and water. All procedures were 
approved by The University of Queensland Animal Ethics Committee (approval number: 
SVS/027/11/TRUST/RIRDC).  
 
The ultrafiltration probes were soaked in sterile distilled water for 12 hours prior to 
placement using aseptic technique, according to the manufacturer’s guidelines. The hoof was 
cleaned and trimmed to remove excess horn then soaked for 12 hours in a poultice of 
povidone–iodine solution (PVP-iodine, Vetsense).  The limb was clipped of hair to the level 
of the metacarpophalangeal joint. Perineural analgesia was performed by injecting 3 mL 2% 
mepivacaine hydrochloride (Mepivacaine Injection, Naturevet) at the distal aspect of the 2nd 
and 4th metacarpal bones and at the level of the proximal sesamoid bones. A rubber 
Esmarch’s bandage was applied as a tourniquet at the metacarpophalangeal joint. The hoof 
wall was resected (20x20mm) down to the white line at the dorsal toe. A surgical scrub was 
performed using chlorhexidine (Hexawash, Apex Laboratories) and methylated spirits at the 
resection site and at the coronary band on dorsal midline. The hoof and distal limb were 
wrapped in an antimicrobial surgical incise drape (Ioban, 3M).  The limb was extended 
cranially and placed on a hoof stand.  The introducer was inserted as described in cadaver 
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limbs. The curved tipped stylet was withdrawn and a custom-made 3-8 ultrafiltration probe 
with a polyacrylonitrile (PAN) membrane (Bioanalytical Systems Inc) was threaded 
distoproximally through the introducer. When the probe membrane was positioned at the mid 
lamellar level the introducer was withdrawn, leaving the probe in the lamellar tissue, with the 
tubing exiting at the coronary band (Appendix 2). The resection site was packed with 
sterilised dental putty (Coltene Lab Putty, Coltene) and covered with adhesive tape. The limb 
was placed on the ground and the tourniquet removed. The plastic tubing of the ultrafiltration 
probe was secured to the pastern and a sterile bandage was applied from the hoof to the 
metacarpophalangeal joint. The foot was placed in a hoof boot (SIMPLE Boot, Cavallo Horse 
and Rider Inc.). The ultrafiltration tubing was connected to a 3 ml glass vacutainer using a 
commercially supplied vacutainer holder (Bioanalytical Systems Inc) and flanged tubing 
connectors. The vacutainer holder was taped to the metacarpus and covered with a stable 
bandage. The vacutainers were changed every 12 hours. The volume of the sample collected 
was measured and rate of fluid collection was calculated for each 12 hour period. Samples 
were stored at -80 ̊C for further analysis. Blood was collected at 96 hours post implantation 
(end of night 4) and plasma was stored at -80 ̊C prior to analysis. The probes were maintained 
for 14 days in the initial 2 animals, then for 4 days in the final 4 animals to simulate the 
maximum length of time required for development of experimental acute laminitis (van Eps 
and Pollitt 2006; de Laat et al. 2010), and hence the time over which pharmaceuticals with 
potential for laminitis prophylaxis would need to be evaluated.  
 
2.3.3 Pain and lameness evaluation  
A complete physical examination including a pain evaluation was performed on the horses 
twice a day throughout the experimental period. Lameness was assessed as part of the pain 
evaluation. Lameness assessment included observation of the horses when unrestrained in the 
stall and at the walk on a concrete surface. The pain evaluation was based on a numerical 
scale of various pain behaviours (van Eps 2010). Horses were scored from 1 to 4 based on 
their heart rate (score 1= heart rate < 40 beats/ minute, score 2 = heart rate 41-60 beats/ 
minute, score 3 = heart rate 61-80 beats/minute; score 4 = heart rate > 80 beats/minute); 
lameness (score 1= no signs of lameness; score 2 = occasional weight shifting, score 3= 
walks with slight pain; score 4 = walks if forced); attitude (score 1= bright, alert and 
responsive; score 2= quiet, alert and responsive; score 3= depressed, score 4= obtunded); 
appetite (score 1 = eating normally, score 2 = eating intermittently, score 3 = eating 
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occasional mouthfuls, score 4 = not eating); recumbency (score 1= mostly standing, score 2 = 
frequently recumbent but gets up, score 3= recumbent most of the time, in lateral and sternal 
recumbency, score 4 = recumbent most of the time, in lateral recumbency); and non-specific 
pain behaviours e.g. teeth grinding (score 1= none, score 2= occasional, score 3= frequent, 
score 4 = constant). The total score for all pain evaluation parameters in each horse at each 
observation period was calculated by adding the scores of each parameter (maximum 24, 
minimum 6). The individual and total pain scores were compared to baseline (Day 0) to 
establish whether there was an increase in pain behaviours after probe implantation. 
 
2.3.3 Fluid analysis 
Biochemical analyses were performed on ultrafiltrate collected between 12 and 24 hours post 
implantation (night 1), ultrafiltrate collected between 84 and 96 hours post implantation 
(night 4) and plasma collected at 96 hours post implantation (the end of night 4) using a 
chemistry analyser (Beckman Coulter AU400, Beckman Coulter Inc.). The concentrations of 
total protein (TP), albumin, globulin, alkaline phosphatase (ALP), aspartate aminotransferase 
(AST), cholesterol, gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH), 
creatinine kinase (CK), total bilirubin, carbon dioxide (CO2), creatinine, glucose, 
triglycerides, urea, sodium, chloride, potassium, calcium, magnesium and phosphate in 
plasma were measured in triplicate using the plasma application, with plasma control and 
calibration samples (Olympus Life and Material Science Europa GmbH), as per the 
laboratory’s standard method for running equine clinical chemistry samples. Due to the lack 
of calibration and control samples in interstitial fluid, where possible cerebrospinal fluid 
(CSF) and urine protocols, were used for measuring the concentrations of analytes in 
ultrafiltrate as these are a more similar matrix to interstitial fluid. The concentrations of TP 
and glucose in ultrafiltrate were measured using the CSF application with CSF calibration 
and control samples (Olympus Life and Material Science Europa GmbH). The concentrations 
of creatinine, urea, calcium, magnesium, sodium, potassium and chloride in ultrafiltrate were 
measured using the urine application with s urine calibration and control samples (Olympus 
Life and Material Science Europa GmbH). The remaining analytes in ultrafiltrate were 
analysed using plasma calibration samples. All ultrafiltration samples were measured in 
triplicate providing sufficient fluid volume was collected.   
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2.3.5 Tissue collection 
At the end of the study (day 14 for the first 2 horses and day 5 (96 hours post implantation) 
for the remaining 4 horses) each horse was euthanased with pentobarbital sodium (20 mg/kg 
bwt i.v.). The forelimbs were removed rapidly by disarticulation at the pastern. Sagittal 
sections were cut with a bandsaw leaving a 1cm margin either side of the ultrafiltration probe. 
The dorsal lamellae were dissected from the hoof and third phalanx. The sagittal section was 
then sectioned transversely into 6 segments, along the length of the probe from the skin at the 
coronary band to the toe. Control sections were obtained from the contralateral limb. A 
section from each segment was fixed using 10% neutral buffered formalin, processed by 
routine paraffin embedding, sectioned at 4 µm and stained with H&E and Masson’s 
Trichrome for light microscopy as previously described (Pollitt 1996). The sections were 
interpreted by a board-certified veterinary pathologist (REA) blinded to all factors except 
study duration. The lamellar section showing the most severe histological changes in each 
horse and its corresponding control section were scored using a semi-quantitative method 
based on the degree of epidermal hyperplasia, flattening of the secondary epidermal lamellae 
(SEL), the presence of mitotic figures in the lamellar epidermis, the inflammatory cell count, 
endothelial reactivity, fibroplasia, collagen bundle formation, lamellar necrosis and the 
amount of cellular debris around the probe (Table 2.1). The skin sections from each horse 
were scored based on inflammatory cell count, endothelial reactivity, fibroplasia, collagen 
bundle formation and cellular debris. The types of inflammatory cells around the probe were 
recorded.  If relevant sections other than the scored section showed notable morphologic 
changes not otherwise recorded these were additionally noted.  
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Table 2.1: The semi-quantitative histologic scoring system applied to the lamellar slides 
 
 
0 1 2 3 
Epidermal basal cell and parabasal cell 
hyperplasia: expressed as fold increase in 
thickness of epidermal cell layer 
Normal  2 fold  3 fold ≥ 3 fold  
Flattening of secondary epidermal lamellae 
(SEL): expressed as % of length of unaffected SEL 
remaining 
100% 66-99% 50-66% <50% 
Mitotic figures: per high power field at 200x 
magnification in the most affected area 
0 1  2 ≥3 
Inflammatory cell count surrounding the probe 0 1-50 50-100 >100 
Fibroplasia: thickness of the fibrous tissue around 
the probe compared to the width of  unaffected 
primary epidermal lamellae (PEL) 
0 <1 PEL 
width 
1 PEL 
width 
>1 PEL 
width 
Collagen bundle formation Absent Mild  Moderate Marked  
Cellular debris  Absent Mild  Moderate Marked  
Endothelial reactivity: The number of vessels with 
reactive endothelium around the probe 
0 1-20 21-50 >50 
Lamellar necrosis: The number of necrotic PEL 0 1 2 3 or more 
 
2.3.6 Statistical Analyses 
Data were analysed using a statistical software package (Graphpad Prism 6). Due to the small 
numbers the data were assumed to be non-normally distributed. Hence non-parametric 
statistical tests were used throughout. The rates of collection of ultrafiltration fluid in each 12 
hour period were compared by Friedman test with Dunn’s post-test (objective 2). The pain 
score data were analysed to establish whether probe placement resulted in lameness or 
discomfort (objective 3). Pain scores were compared to baseline by Friedman test. The 
concentrations of biochemical analytes in UF fluid collected on night 4 were compared to 
those on night 1 using a paired Wilcoxon-Signed Rank Test (objective 4). The biochemical 
analytes in ultrafiltrate were compared to those in plasma by Mann-Whitney U test 
(Objective 5). Histologic scores in lamellar sections containing the ultrafiltration probe were 
compared to control tissue and skin section scores using paired Wilcoxon-Signed Rank Tests. 
Significance was set at P≤0.05. Unless otherwise stated, data are expressed as median 
[interquartile range (IQR)]. 
 
2.4 Results 
The proximo-distal length of the lamellar tissue ranged from 3.8 cm to 5.2 cm. Custom- made 
ultrafiltration probes were manufactured to fit into the introducer.  These probes had three, 8 
cm long, semi-permeable membranes looped into the connection tubing resulting in a 
membrane loop length of 4 cm (Figure 2.2).  
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Figure 2.2: Photograph of ultrafiltration equipment showing the 3, 8cm long loops of 
ultrafiltration probe membrane and its associated tubing, connected by a flanged tubing 
connector to a vacutainer holder. The vacutainer is inserted onto a needle within the 
vacutainer holder in order to apply a vacuum to the membrane. 
 
Transverse sectioning of the cadaver limbs in which the placement technique was evaluated 
showed polyurethane successfully marking the location of the introducer parallel to the long 
axis of primary epidermal lamellae in all 15 feet (Figure 2.3). There was no penetration of the 
distal interphalangeal joint. The technique was judged feasible for in vivo studies. 
 
 
Figure 2.3: Transverse section of the lamellar tissue 
from a cadaver limb after injection of polyurethane cast 
material in the location of the introducer. The 
polyurethane cast material is situated between the primary 
epidermal lamellae. 
 
 
 
 
Ultrafiltration probes were placed in the lamellar tissue of all 6 horses. Implantation took 
approximately 45 minutes, photographs demonstrating the technique are available in 
Appendix 2. Fluid was collected successfully from five of the six horses. Fluid could not be 
collected from horse 2 (in the 14 day study group). The median fluid collection rate over the 
first 4 days of the experiment was 55[30-63] µL/h. Fluid production was significantly 
different to baseline (day 1) from night 3 onwards (Figure 2.4) (P=0.03). In the horse that 
was maintained for 14 days and produced fluid, production ceased completely at day 7.  
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Figure 2.4: Box and whisker plot showing the median rate of ultrafiltrate collection over 
time (error bars represent range). There was a significant decrease (P<0.05) in fluid 
production compared to baseline from night 3 onwards (*). 
 
The median pain evaluation lameness score after probe implantation was 1[1-1.5] out of 4. 
There was no significant variation in the lameness score from baseline (day 0) over the 
experimental period (Figure 2.5). However, there was subjective variation between individual 
horses with time. Horse 5 was sound for the entire study period (lameness score 1 at each 
time-point). Horses 1, 3 and 4 demonstrated occasional weight shifting (lameness score 2) for 
≤24 hours then returned to soundness. Horses 2 and 6 both became lame at the walk on a hard 
surface (lameness score 3): Horse 2 was lame at the walk on night 4. This persisted for 24 
hours when the packing was removed from the toe to allow drainage. As the horse did not 
exhibit any other pain behaviours, appeared comfortable in the stall, and had a normal heart 
rate (36-40 beats/minute), anti-inflammatory therapy was not administered at this time. 
Within 24 hours (day 7) the horse was sound at the walk and remained comfortable until day 
14. Horse 6 was lame at the walk on night 4 (lameness score 3). This horse was enrolled in 
the 5 day group so was euthanized on day 5 without returning to soundness. The median heart 
rate score after probe implantation was 1 (range 1-2). There was no significant change in 
heart rate score compared to baseline throughout the study. The recumbency, appetite and 
pain behaviour scores were 1 at all time-points. The median total pain score was 6 (range 6-
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7). There was no significant difference between the total pain scores on each day when 
compared to baseline (Figure 2.5).  
 
Figure 2.5: Line graph showing the median total pain score and the median lameness 
score at each observation point (error bars represent IQR). Probe implantation was 
performed on day 1. The minimum possible total pain score was 6 and the highest possible 
total pain score was 24. The minimum possible lameness score was 1 (no lameness) and the 
maximum possible lameness score was 4 (walks if forced). There were no significant changes 
in either score with time. 
 
The results of the biochemical analyses of the ultrafiltrate and serum samples are shown in 
Table 2.2. The concentrations of TP, albumin, globulin, ALP, AST, GGT, LDH, CK, total 
bilirubin, cholesterol and calcium were all significantly lower in ultrafiltrate compared to 
plasma (P<0.02). The chloride levels in ultrafiltrate were significantly higher than those in 
plasma (P=0.004). There was no significant difference between plasma and ultrafiltrate CO2, 
creatinine, glucose, magnesium, triglycerides, urea, sodium and potassium.  There was no 
significant difference in the biochemical parameters from ultrafiltrate collected on night 1 
(12-24 hours) compared to that collected on night 4 (84-96 hours). Protein was detected in 
only one of the ultrafiltrate samples (horse 1 had a total protein of 1 g/L and globulin of 1g/L 
on night 4) suggestive of damage to the semi-permeable membrane of the UF probe in that 
horse by night 4. There did not appear to be any subjective difference in biochemical analysis 
results between the horses that were lame at the walk (n=2) and horses that showed minimal 
signs of lameness (n=4), however numbers were too small for statistical analyses. 
51 
 
Table 2.2: The results of the biochemical analyses of ultrafiltrate from nights 1 and 4 
and serum samples collected on night 4. Serum analyte concentrations marked with an 
asterisk (*) are significantly different to those in the ultrafiltrate on night 4 (P≤ 0.05). 
Analyte 
Ultrafiltrate night 
1 (median 
[IQR]) 
Ultrafiltrate 
night 4 (median 
[IQR]) 
Plasma night 4 
(median [IQR]) 
Albumin (g/L) 0.05 [0-0.1] 0 [0-0] 31.1 [30.6-31.8]* 
ALP (U/L) 0.25 [0-1.63] 0 [0-0.45] 185 [151-204]* 
AST (U/L) 1 [0.33-4] 2 [0.65-12] 385 [343-411]* 
Carbon Dioxide 
(mmol/L) 22.25 [19.3-26.4] 21.7 [20.5-27.9] 
25.3 [24.4-26.2] 
Calcium (mmol/L) 1.26 [1.11-1.44] 1.42 [1.36-1.72] 2.97 [2.92-3.04]* 
Cholesterol  (mmol/L) 0 [0-0] 0[0-0] 1.6 [1.5-1.7]* 
Creatinine Kinase (U/L) 0 [0-2.63] 0.5 [0-2.5] 298 [281-345]* 
Creatinine  (µmol/L) 78 [74-94.6] 81.5 [70-86] 92 [89-94] 
GGT (U/L) 0.1 [0-0.43] 0 [0-0.1] 58 [40-75]* 
Glucose (mmol/L) 2.1 [0.5-3.15] 1.1 [0.2-2.95] 1.9 [1.8-2.2] 
LDH (U/L) 2.15 [1.25-3.05] 1.3 [1.05-3.0] 479 [385-548]* 
Magnesium (mmol/L) 0.68 [0.62-0.76] 0.75 [0.47-0.78] 0.74 [0.72-0.77] 
Phosphate (mmol/L) 0.7 [0.59-0.84] 0.61 [0.51-0.87] 1.05 [0.85-1.34] 
Total Protein (g/L) 0 [0-0.23] 0 [0-0.45] 73 [71-75]* 
Triglycerides (mmol/L)  1.2 [0.13-2.5] 0 [0-0.53] 0.2 [0.1-0.3] 
Urea (mmol/L) 9.7 [6.6-10.4] 7.9 [6.5-9.1] 8.4 [7.9-8.6] 
Sodium (mmol/L) 137 [131-140] 138 [135-139] 137.0 [136.8-137.1] 
Potassium (mmol/L) 4.4 [4.1-4.7] 4.5 [4.3-4.6] 4.1 [4.0-4.2] 
Chloride (mmol/L) 107 [101-108] 107 [103-109] 99.1 [98.9-99.2]* 
Globulin (g/L) 0 [0-0.15] 0 [0.-0.45] 43 [40-44]* 
Total Bilirubin (µmol/L) 0.15 [0.1-0.28] 0.2 [0.1-0.55] 20.4 [18.5-23.1]* 
 
Histological examination of the tissue sections revealed the probe located in the lamellar 
tissue in all horses, with the tubing exiting through the coronary band and skin. The probe 
was situated between PEL in 3/6 horses and within the sublamellar dermis in the remaining 3 
horses (Figure 2.6). There was evidence of epidermal hyperplasia, inflammation, fibroplasia, 
endothelial reactivity, collagen formation and cellular debris around each probe, consistent 
with a mild foreign body response (Figure 2.7 and 2.8) The inflammatory cell count, 
endothelial reactivity, fibroplasia, collagen bundle formation and cellular debris scores were 
all significantly higher in probe-containing lamellar sections compared to controls (P=0.03). 
Low numbers of macrophages, neutrophils and occasional lymphocytes were present around 
the lamellar portions of the probe in horses 1,3,4 and 5, again consistent with a mild foreign 
body response. Horses 2 and 6 had higher numbers of inflammatory cells (well over 100) 
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consisting primarily of neutrophils and some perivascular lymphocytes which was suggestive 
of either a very low grade bacterial infection or a response to ectopic material such as keratin 
(Figure 2.8 C&D). Notably no microorganisms were observed in any animal.  
 
Figure 2.6: Histological sections around the ultrafiltration probe from horses in the 
study (20x H&E). (A) Distal lamellar section from a horse in the 14 day study group 
showing loops of semipermeable membrane adjacent to the keratinised axis of the primary 
epidermal lamellae (PEL), and at the dermal tips of the PEL. There is marked epidermal 
hyperplasia (scored 3) (B) Mid-lamellar section from a horse in the 14 day study group 
showing 5 loops of semipermeable membrane in the lamellar tissue. This section had an 
epidermal hyperplasia score of 2. The 6th loop was lost during processing. (C) Impermeable 
tubing attached to the probe semipermeable membrane exiting through the skin at the 
coronary band with minimal foreign body response (fibroplasia score=1). (D) Loops of 
semipermeable membrane in the sub-lamellar dermis from a horse in the 5 day group. This 
section had a fibroplasia score of 3 and an inflammatory score of 1. 
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Figure 2.7: Lamellar sections demonstrating some of the histopathologic changes that 
occurred subsequent to probe placement. (A) Flattening of secondary epidermal lamellae 
(SEL) adjacent to the probe placement site (arrowheads), with normal length SEL on the 
opposite side of the PEL (arrows). This section was scored 3 for SEL flattening (H&Ex100). 
(B) Hyperplastic and dysplastic epidermis (bracket) around the ultrafiltration probe (*). A 
blood vessel with reactive endothelium is present (arrowhead). This section was scored 3 for 
epidermal hyperplasia (H&E x 200). (C) Necrosis of the SEL with pyknosis and karyolysis of 
the epidermal basal cells (H&E x 200). (D) Cellular debris where the probe was situated 
(black arrow). Four of the loops have been lost during processing, the void that housed the 
probes remains. This section was scored 3 for cellular debris (H&E x 40). 
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Figure 2.8: Histopathological changes around the ultrafiltration probes. (A and B) 
Collagen bundle formation and fibroplasia around a probe located in the sublamellar dermis 
(Masson’s Trichome x 40 (A) and H&E x 40 (B)). Nascent collagen is present as thin (1-
2µm) bundles in comparison to the prominent, thick, royal-blue pre-exisiting dermal collagen 
bundles (Masson’s Trichrome stain A). These sections were scored 1 for collagen bundle 
formation and 3 for fibroplasia. (C and D) Inflammatory cell infiltrate around the probe in 
horse 6 (H&E x 40 (C) and H&E x 400 (D)). There are a large number neutrophils, 
inflammatory score 3. The probe has been lost during processing. D corresponds to the area 
highlighted by the white box on image C.       
 
2.5 Discussion 
The results of this experiment demonstrate that ultrafiltration probes can be placed in equine 
digital lamellar tissue and used to collect lamellar IF. The technique was well tolerated. The 
lack of any significant changes in the pain scoring evaluation after probe placement supports 
this conclusion. In the two horses that developed mild lameness at the walk, infection around 
the probe was suspected. This was supported by the presence of a large number of 
leukocytes, particularly neutrophils, around the probes histologically, suggesting these 
animals were responding to either a very low grade bacterial infection or ectopic keratin. 
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Assuming this lameness was associated with infection, the study infection rate was 33%. 
Infection may have occurred because of inadequate preparation of the probe placement site, 
insufficient maintenance of sterility during placement, prolonged probe placement time 
associated with performing a novel technique, or inadequate cleanliness of the insertion site 
post-implantation. Further optimisation of the ultrafiltration probe placement technique may 
reduce morbidity. Care should be taken when interpreting pharmaceutical concentrations in 
ultrafiltrate from infected lamellar probes as infection may affect drug concentrations (Cars 
and Ogren 1985; Frazier et al. 2000).    
 
Despite there being > 40 studies using ultrafiltration to measure drugs or metabolites 
concentrations, very few investigate the tissue response to probe placement histologically 
(Huinink 2007). In those that do, the responses encompass varying degrees of foreign body 
reaction, from a small sheath of fibrous tissue around the probe to marked granulomatous 
inflammation dependent on the species, probe material, tissue and duration of implantation  
(Janle-Swain et al. 1987; Clark et al. 2000; Imsilp et al. 2000; Wisniewski et al. 2001).  The 
present study is the first to histologically evaluate tissue response to ultrafiltration probe 
placement in the horse. The scoring system was designed to represent the range of pathology 
present in the samples scored, rather than to act as a comparison with other foreign body 
responses. Therefore, although many of the sections scored highly, the histology in this study 
was consistent with mild to moderate fibrous capsule formation around the probe, and a 
comparatively mild foreign body response, equivalent to or less than that typically seen with 
suture material. 
 
The effect of the mild inflammation on drug recovery is unknown. The vasodilation and 
increased vascular permeability that accompany inflammation can cause an increase in drug 
delivery to the tissue, but viscosity is also increased, slowing diffusion (Barza and Cuchural 
1985). Generally the low level of inflammation compared to infected tissue is a concern in 
antimicrobial pharmacokinetic studies using ultrafiltration (Frazier et al. 2000; Bidgood and 
Papich 2003), as it is preferable to measure drug concentrations in tissue conditions similar to 
the diseased state. Laminitis development involves inflammation (Visser 2009).  Even if there 
is an effect of mild inflammation on drug recovery, it may not alter pharmacokinetics 
compared to during laminitis development. Additional studies comparing drug concentrations 
in ultrafiltrate and lamellar biopsies, particularly during experimental laminitis development 
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may help determine whether inflammation significantly affects ultrafiltrate drug 
concentrations.    
 
The median collection rate of ultrafiltrate in this study (55 µL/h) was similar to, but slightly 
lower than, collection rates previously reported from the subcutaneous tissues of horses using 
3-12 membrane length ultrafiltration probes (68-82 µL/h) (Davis et al. 2005; Davis et al. 
2006). The lower collection rate in the present study may simply reflect the shorter 
membrane length used rather than a true difference between tissues. The rate of fluid 
production in the first 4 days of the present study was sufficient for hourly measurement of 
drug concentrations using UPLC methods (based on an injection volume of 1-20 µL) and two 
hourly measurement of lamellar drug concentrations using HPLC methods (based on an 
injection volume of 50-100 µL). The collection rate decreased significantly with time from 
night 3 onwards. Temporal decreases in ultrafiltrate collection may be attributed to probe 
damage, encapsulation of the probes within fibrous tissue, or biofouling (the adhesion of 
proteins and cells on the outer surface of the UF probe that obstruct filtration) (Clark et al. 
2000; Wisniewski et al. 2001). Due to the highly mobile location of the probes in the present 
study, it is possible that probe damage is responsible for the reduction in ultrafiltrate 
collection. The fibrous capsule formation present histologically may have also played a role.  
Fibrous capsule formation and biofouling can significantly affect the recovery of substances 
by microdialysis (Wisniewski et al. 2001), so could potentially affect drug recovery in 
ultrafiltrate. However, to the authors’ knowledge, this effect has never been demonstrated 
with ultrafiltration. In fact, Janle and Kissinger hypothesised that as ultrafiltration relies on 
bulk flow across the membrane, it is unlikely substance recovery will be affected by fibrous 
capsule formation and reduced filtration rates (Janle and Kissinger 1996). This theory is 
supported by the successful use of ultrafiltration to measure drug concentrations in horses 
despite apparent decreases in the mean rate of ultrafiltrate collection by approximately 50% 
over 36 hours (Parra-Sanchez et al. 2006), and the use of PAN ultrafiltration membranes in 
rat pharmacokinetic studies (Linhares and Kissinger 1993) despite biofouling and fibrous 
capsule formation occurring round PAN membranes in rats (Wisniewski et al. 2001).    
 
As few  studies investigate the histologic changes in tissue surrounding ultrafiltration probes 
(Huinink 2007) probe performance is often interpreted based on the consistent recovery of 
endogenous metabolites e.g. glucose, urea and creatinine (Ash et al. 1992; Janle 1994) and 
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ions (Linhares and Kissinger 1993; Spehar 1998). In the present study there was no 
significant change in the biochemical analytes in the ultrafiltrate over the study period. 
Therefore in the first 4 days after probe placement the decrease in fluid filtration may may 
have minimal effect on drug concentrations. However, the low number of horses in this study 
may not have provided sufficient statistical power to detect subtle differences in the 
biochemical data. Additionally, the recovery of pharmaceuticals may be altered more by 
reduced fluid filtration and local tissue reaction than that of endogenous substances. 
Therefore, the effect of temporal reductions in lamellar ultrafiltrate collection on drug 
recovery should be investigated further.  
 
The results of the biochemical analysis of the ultrafiltrate are consistent with the constituents 
of IF excluding molecules larger than 30 kDa. Albumin, ALP, AST, GGT, LDH, CK, protein, 
globulin and total bilirubin all have molecular weights above the MWCO of the ultrafiltration 
probe (30 kDa). Their concentrations in ultrafiltrate were significantly lower than those in 
plasma (P<0.05). The presence of small amounts of these substances in the ultrafiltrate may 
be an indicator of damage to the probe membrane. However, these results should be 
interpreted with caution as the values were below the limit of detection of the analyser. The 
use of more sensitive analytical methods may provide more accurate information regarding 
the exact levels of these substances in the ultrafiltrate. Ultrafiltrate sodium, potassium and 
calcium ion concentrations corresponded well with their reported concentrations in 
ultrafiltrate from equine subcutaneous tissue (Spehar 1998). The calcium concentration in the 
ultrafiltrate (1.42 [1.36-1.72] mmol/L) was significantly lower than that in plasma (2.97 
[2.92-3.04] mmol/L) (P=0.006). The calcium levels in the IF should be similar to those in the 
plasma (Rose 1989). However, as in plasma, 40-45% of calcium in the IF is protein bound 
and unable to cross the ultrafiltration probe (Toribio 2004). Similar results have been 
obtained from ultrafiltration of equine plasma (Spehar 1998). The chloride levels in the 
ultrafiltrate were significantly higher than in plasma (107 [103-109] mmol/L vs. 99.1 [98.9-
99.2] mmol/L, P=0.004). This is in concordance with previously reported data on the ionic 
composition of plasma and IF (Rose 1989). The lack of a significant difference between 
plasma and ultrafiltrate CO2, creatinine, glucose, magnesium, triglyceride, urea, sodium and 
potassium concentrations is attributable to the small mass of these substances and their 
consequent ability to be drawn across the ultrafiltration probe. 
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 The successful biochemical analysis of the ultrafiltrate and the consistency in the values 
obtained indicates that ultrafiltration has potential as a technique for monitoring the lamellar 
microenvironment. Multiple studies have used ultrafiltration to investigate tissue metabolism 
(Janle-Swain et al. 1987; Linhares and Kissinger 1993; Imsilp et al. 2000; Huang et al. 2006). 
The main disadvantage of ultrafiltration is that the introduction technique is traumatic and the 
size of the UF probe is relatively large compared to those used for microdialysis. Therefore, 
ultrafiltration is associated with more local tissue damage than microdialysis. A second 
impediment to using ultrafiltration to investigate the lamellar microenvironment is the 30 kDa 
molecular weight cut-off (MWCO) of the semi permeable membrane on the ultrafiltration 
probes used in this study. This precludes analysis of cytokines and proteins in the lamellar 
tissue. Small ultrafiltration probes with a 50-400 kDa MWCO have been used successfully to 
sample proteins in mice (Huang et al. 2006; Huang et al. 2006), and rats (Schneiderheinze 
and Hogan 1996). Further work would be necessary to evaluate their applicability for 
sampling the lamellar microenvironment. 
 
One of the advantages of ultrafiltration is that it is considered a recovery technique, i.e. the 
probes can be removed once the study has finished and the animals are left relatively 
unaltered (Linhares and Kissinger 1992). The encapsulation around the lamellar ultrafiltration 
probes in this study may result in difficulty removing the probes and permanent changes in 
the lamellar tissue. As the lamellar tissue is critical for weight bearing these changes could 
result in lameness, precluding use of lamellar ultrafiltration as a recovery technique. 
However, probes have been successfully removed from tissue even in the face of 
encapsulation (Wisniewski et al. 2001). Additionally, horses recover well after implantation 
of lamellar microdialysis probes (Nourian et al. 2010; Nourian et al. 2010). Further work is 
required to assess whether lamellar ultrafiltration can be used as a recovery technique in 
experimental animals. 
 
The results of this study demonstrate it is possible to obtain lamellar IF using ultrafiltration. 
This ultrafiltrate could be used to measure lamellar drug concentrations. The reduction in 
ultrafiltrate collection rate with time plus the histologic evidence of fibrous capsule formation 
and inflammation around the probe, could alter drug concentrations in the IF surrounding the 
probe and thus reduce the accuracy of this technique. Local variations in protein 
concentration may also alter ultrafiltrate drug concentrations as only unbound drug can pass 
59 
 
through the ultrafiltration probe. Therefore, it is necessary to ensure drug recovery remains 
constant with time and to compare drug concentrations in biopsy and lamellar ultrafiltration 
samples, prior to in depth pharmacokinetic studies of drugs with potential for laminitis 
prophylaxis. In spite of these limitations, ultrafiltration remains the only reported technique 
for frequent repeated direct sampling of lamellar IF. Ultrafiltration has been used successfully 
in other tissues in the face of local tissue reactions and inflammation to provide valuable 
pharmacokinetic data (Linhares and Kissinger 1993; Wisniewski et al. 2001).  
 
2.6 Conclusions 
This study demonstrates that lamellar ultrafiltration has potential for collecting IF to measure 
lamellar drug concentrations; a key step in experimentally evaluating the ability of 
pharmaceutical agents to prevent laminitis. Further studies are underway in our laboratory 
evaluating the recovery of drugs in the ultrafiltrate, and comparing drug levels in ultrafiltrate 
with those in lamellar tissue homogenates. 
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Part II discussion 
 
In this section, a placement technique was developed and lamellar ultrafiltration probes were 
inserted into the lamellar tissue of 6 horses. The ultrafiltration probes were well tolerated, 
sufficient volumes of LUF were collected for hourly measurement of pharmaceutical 
concentrations using UPLC-MS, and concentrations of biochemical analytes in LUF were 
stable over a 96 h period. Therefore all three objectives outlined in the introduction were met, 
suggesting ultrafiltration has potential for sampling lamellar interstitial fluid to establish 
lamellar drug concentrations.  However, several issues were identified; namely that the rate 
of LUF collection decreased with time and that there was histologic evidence of a host tissue 
response to the ultrafiltration probes, both of which may result in temporal alterations in 
pharmaceutical recovery. Further validation of the ultrafiltration technique is necessary to 
ensure pharmaceutical recovery does not vary with time, to establish in vitro recovery of the 
pharmaceutical of interest (marimastat) and compare tissue and ultrafiltrate drug 
concentrations.  
 
Overall, part II of this project provided a solid foundation upon which to build the remainder 
of the work. Lamellar ultrafiltration appears to be a suitable technique for sampling the 
lamellar tissue and, with further validation, will play a key role in establishing the optimal 
technique for lamellar drug delivery. Comparison of systemic and regional delivery 
techniques, along with further validation of lamellar ultrafiltration is the next logical step in 
this project. Lamellar ultrafiltration using higher molecular weight cut-off probes may also 
prove useful for sampling other biological molecules in order to investigate laminitis 
pathophysiology, however this was considered beyond the scope of this project. 
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PART III: STUDIES ON SYSTEMIC AND REGIONAL 
LAMELLAR DRUG DELIVERY 
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Part III: Introduction 
 
Having established ultrafiltration for sampling lamellar interstitial fluid, part III goes on to 
address the second and third hypotheses of this study; investigating systemic and regional 
delivery techniques for lamellar delivery of marimastat. Throughout this section, successful 
local drug delivery was defined as target tissue concentrations greater than plasma 
concentrations (Collins 1984). 
 
The second hypothesis was that IOIDP results in higher LUF marimastat concentrations than 
CRI. This was tested in Chapter Three by comparing IOIDP and CRI using identical dosing 
regimens. Two additional objectives were necessary to facilitate the testing of this hypothesis. 
Firstly, to address the concerns raised in Part II and ensure the ultrafiltrate marimastat 
concentrations reflected those in tissue, ultrafiltration was further validated. This included 
ensuring pharmaceutical recovery did not vary with time, establishing the in vitro recovery of 
the pharmaceutical of interest (marimastat) and comparing tissue and ultrafiltrate drug 
concentrations. Secondly, a UPLC-MS method for quantifying marimastat concentrations in 
tissue, plasma and ultrafiltrate was developed and is described in the methodology.  
 
Chapter Three also aimed to obtain in vitro pharmacodynamic data to establish the 
marimastat concentrations required for inhibition of equine lamellar MMP-2 and MMP-9. 
Lamellar tissue obtained from horses 48 h after laminitis induction using the oligofructose 
model was pooled, homogenised and run in zymographic assays with increasing 
concentrations of marimastat (1-1000 ng/mL).  This tissue-based assay was the closest 
possible in vitro simulation of the marimastat concentrations required to inhibit lamellar 
MMPs in vivo, from which target marimastat concentrations could be estimated. 
 
The third hypothesis of this thesis was that RLP would result in higher lamellar marimastat 
concentrations than SIVB. This was tested in Chapter Four by comparing RLP and SIVB 
using the same marimastat dose.  Pharmacokinetic-pharmacodynamic analyses were 
performed using the zymographic data acquired in Chapter 3, to better characterise the 
delivery techniques. Lamellar ultrafiltration was used to measure lamellar marimastat 
concentrations. Biochemical analyte concentrations and the tissue response to the probe were 
investigated to monitor substance recovery.  
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In total, Part Three compares regional and systemic delivery techniques, along with further 
validation of ultrafiltration and the establishment of marimastat concentrations considered 
necessary for MMP inhibition. This enabled a comprehensive analysis of the delivery 
techniques in order to choose the optimal technique to investigate the efficacy of candidate 
anti-laminitis drugs (ALDs). 
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Chapter 3: Intraosseous infusion of the distal phalanx compared 
to systemic intravenous infusion for marimastat delivery to 
equine lamellar tissue 
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3.1 Abstract 
Reasons for performing study: No validated laminitis drug therapy exists, yet 
pharmaceutical agents with potential for laminitis prevention have been identified. Many of 
these, including the MMP inhibitor marimastat, are impractical for systemic administration 
but may be effective if administered locally.  
Objectives: To compare intraosseous infusion of the distal phalanx (IOIDP) with systemic 
intravenous constant rate infusion (CRI), to determine which is more effective for local 
lamellar marimastat delivery.  
Study Design: Experimental pharmacokinetic study  
Methods: Ultrafiltration probes were placed in both forefeet of 5 normal horses to collect 
lamellar interstitial fluid as lamellar ultrafiltrate (LUF). Marimastat solution (3.5 mg/mL) 
containing lidocaine (20 mg/mL) was infused by IOIDP at 0.15 ml/minute for 12h. After a 12 
h wash-out, marimastat (3.5 mg/mL) and lidocaine were infused by CRI at 0.15 ml/minute 
for 12 h. LUF and plasma were collected at intervals. LUF, plasma and lamellar tissue 
marimastat concentrations were quantified using UPLC-MS. Zymography was used to 
establish the inhibitory concentrations of marimastat for equine lamellar MMPs. Data were 
analysed non-parametrically. 
Results:  There was no difference between the steady-state marimastat concentration in 
lamellar ultrafiltrate (LUF[M]) during IOIDP (139[88-497] ng/mL) and CRI (136[93-157] 
ng/mL). During IOIDP, there was no difference between marimastat concentrations in the 
treated foot (139 [88-497] ng/mL), the untreated foot (91 [63-154] ng/mL) and plasma (101 
[93-118] ng/mL).  
Conclusions: LUF[M] after IOIDP and CRI were >IC50 of lamellar MMP-2 and 9, but below 
the concentration considered necessary for in vivo laminitis prevention. Lamellar drug 
delivery during IOIDP was inconsistent and did not achieve higher lamellar marimastat 
concentrations than CRI. 
Potential relevance: Modification or refinement of the IOIDP technique is necessary if it is 
to be consistently effective. Alternative regional delivery techniques for pharmaceuticals with 
laminitis prophylaxis potential should be investigated. 
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3.2 Introduction 
Laminitis is a crippling disease of the equine foot. There are no experimentally validated 
pharmacologic means of treating or preventing laminitis. Activation of matrix 
metalloproteinases (MMPs) and ADAMTS (a disintegrin and metalloproteinase with 
thrombospondin motifs)-4 has been implicated in laminitis pathophysiology (Pollitt et al. 
1998; Visser 2009; Wang et al. 2012).  The broad spectrum MMP inhibitors marimastat and 
batimastat prevent lamellar separation in vitro (Pollitt et al. 1998). They also inhibit 
ADAMTS-4 (Tortorella et al. 2009). Investigation of their in vivo efficacy is warranted, but 
has been prevented by their impracticality for systemic administration due to expense, 
systemic side effects (Levin et al. 2006), and rapid clearance after intravenous administration 
(Pass and Pollitt, unpublished data).  A regional lamellar delivery technique is required for 
experimental evaluation of their anti-laminitis potential. This study investigates whether local 
delivery by intraosseous infusion of the distal phalanx (IOIDP) is superior to systemic 
intravenous constant rate infusion (CRI).  
 
IOIDP has been investigated for short-term delivery of gentamicin to lamellar tissue (Nourian 
et al. 2010). Lamellar gentamicin concentrations were significantly higher than those in 
plasma, suggesting IOIDP had potential for regional lamellar delivery. However, 
administration of insulin by IOIDP over 48 h resulted in foot pain and no evidence of 
effective local delivery (de Laat 2011). The foot pain was hypothesised to be a result of 
pressure overload in the distal phalanx (de Laat 2011) as has been reported in other species 
(Welch et al. 1992). Further investigation is warranted to determine if long-term IOIDP 
results in regional lamellar delivery and whether the technique is tolerated by the subject.   
 
In this study, a modified IOIDP technique is compared with systemic CRI to determine which 
system delivered marimastat more effectively to the lamellar region of the horse’s foot. 
Lamellar ultrafiltrate (LUF) obtained via lamellar ultrafiltration enabled sampling of lamellar 
interstitial fluid. The following hypotheses were tested: (1) IOIDP results in higher LUF 
marimastat concentrations (LUF[M]) than CRI, (2) LUF[M] in the foot receiving IOIDP are 
higher than those in the contra-lateral limb and in plasma (P[M]) and (3) IOIDP with 
20mg/mL lidocaine in the perfusate abolishes signs of foot pain. An additional objective was 
to further validate lamellar ultrafiltration for pharmacokinetic studies. Variations in LUF[M] 
and biochemical analyte (glucose, urea, sodium, potassium and chloride) concentrations over 
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time, along with the difference between LUF[M] and lamellar tissue marimastat concentrations 
(T[M]), were examined. 
 
3.3 Methods 
The project was approved by the University of Queensland Animal Ethics Committee (AEC) 
(approval number: SVS/337/11) that monitors compliance with the Animal Welfare Act 
(2001) and The Code of Practice for the care and use of animals for scientific purposes 
(current edition). All animals were monitored frequently by the investigators. 
 
3.3.1 Animals and monitoring 
Five mature Standardbred horses (4 geldings, 1 mare; aged 6-11 years, 447-502 kg bwt), with 
no lameness nor gross abnormalities of the feet were enrolled in the study. The horses 
received no medications for 1 month prior to the study. During the experiment the horses 
were housed in stalls with ad libitum access to hay and water, and monitored continuously. 
Heart rate, respiratory rate and pain behaviors were recorded at 0, 1, 2, 3, 4, 5, 6, 9 and 12 
hours during both IOIDP and CRI.  
 
3.3.2 In vitro marimastat recovery 
Stock solutions of marimastat (BB-2516, Vernalis) at 0.1, 0.5, 1, 10 and 100 µg/mL were 
prepared in pooled plasma and 0.9% saline; 200 µL of each stock solution was stored for 
analysis. Ultrafiltration probes (BASi) were placed into 5 mL of each stock solution. 
Ultrafiltrate was collected for 2 hours at 37 ⁰C. Experiments were performed in triplicate and 
samples stored at -80 ⁰C prior to analysis by ultra-performance liquid chromatography with 
tandem mass spectroscopy (UPLC-MS).  Recovery was calculated according to the following 
equation: Recovery= (concentration in ultrafiltrate) × (concentration in initial solution)-1 × 
100.  
 
3.3.3 Zymography 
To assess the potency and efficacy of marimastat on MMP enzymes in equine lamellar tissue 
homogenates, an in vitro gel zymography bioassay was used. Gelatin zymography was 
performed as previously described with minor variations to determine the marimastat 
concentration required to inhibit lamellar MMP-2 and -9 (Pollitt, Pass et al. 1998; de Laat, 
Kyaw-Tanner et al. 2011). Briefly; pooled lamellar tissue collected from horses 48 h after 
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administration of 10g/kg oligofructose (archived from a separate study) was homogenised, 
centrifuged and the total protein concentration in the supernatant determined. Samples 
containing 10 µg protein were prepared and run on 7.5% acrylamide mini-gels containing 
0.25% gelatine. Lanes were separately incubated with marimastat at different concentrations 
(range 1 – 1000 ng/ml plus control) in gelatine refolding buffer for 24 hours. Gels were 
stained then analysed by band densitometry (Unscan-it Software, Silk Scientific Inc).  
Densitometry data were expressed as % of activity of control and experiments were repeated 
four times. 
 
3.3.4 In vivo study design and sample collection 
Twenty-four hours prior to IOIDP, ultrafiltration probes were placed in the lamellar region of 
each forelimb. Intravenous catheters were placed in the left and right jugular veins (for blood 
collection and drug administration respectively). An intraosseous cannula was placed in the 
distal phalanx (DP) of one forelimb of each horse (instrumented foot). Sterile marimastat 
solution (3.5 mg/mL marimastat, 20 mg/mL lidocaine (Ilium Lidocaine 20, Troy 
Laboratories) and 1.5 IU/mL heparin sodium) was infused through the intraosseous cannula 
with a target infusion rate of 0.25 ml/minute. Jugular blood and LUF from the instrumented 
foot were collected prior to marimastat administration, then at 1, 2, 3, 4, 5, 6, 9 and 12 h of 
infusion. LUF was collected from the contralateral, uninstrumented foot at 0, 6, 9 and 12 
hours. The volume of marimastat solution infused was recorded. After 12 hours the IOIDP 
cannula was perfused with heparin and lidocaine solution for 1 hour to remove residual 
marimastat then sealed. The horses underwent a 12 h wash-out period (12 times the 
elimination half-life of marimastat after IV administration (Pass and Pollitt, unpublished data) 
prior to CRI.  
 
Baseline LUF samples were collected 1 h prior to CRI. An identical marimastat solution was 
administered by CRI through the right jugular catheter using microinfusion pumps at the 
same rate as the mean IOIDP infusion rate in that horse with sample collection time-points as 
for IOIDP. At the end of the CRI horses were euthanased with pentobarbital sodium 
(Lethabarb, 20 mg/kg bwt i.v.). Lamellar tissue encompassing the UF probe was collected for 
histologic and pharmacokinetic analysis.  
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3.3.5 Ultrafiltration probe placement 
Sterile, custom-made 3-8 ultrafiltration probes (BASi) were placed in the lamellar region of 
both forelimbs under regional anaesthesia as previously described, with the minor variation 
that the probes were placed 1-2 cm lateral to dorsal midline  (Chapter 2) The ultrafiltration 
tubing was cut to a length of 30 cm from the probe prior to sample collection. The location of 
the probe was marked on the surface of the hoof wall to ensure the probe was not damaged 
during IOIDP needle placement. 
 
IOIDP needle placement 
After sedation with 0.03 mg/kg acepromazine (A.C.P. 10) and bilateral perineural anaesthesia 
of the palmar digital nerves at the level of the fetlock and metacarpal nerves at the distal 
aspect of the 2nd and 4th metacarpal bones using mepivicaine (Ilium Vetacaine), the dorsal 
hoof was rasped and aseptically prepared. A midline site 25 mm below the hairline and 1-2 
cm medial to the UF probe was marked on the hoof wall (Appendix 2, Figure II.VII). A 3.2 
mm diameter hole was drilled perpendicular to the hoof wall. The drill bit was cleaned and 
the drill hole flushed with sterile, heparinised saline to remove any hoof wall debris. Drilling 
continued until the dorsal surface of the DP was contacted. The drill bit was adjusted so that 
further drilling extended 4 mm into the DP. The hoof wall was then over-drilled with a 4.8 
mm drill bit.  
 
A sterile 25 mm long nylon dummy needle with a bevelled tip was driven into the DP, 
flushed and then withdrawn to remove any remaining debris. A sterile, custom made, 
intraosseous needle (Figure 3.1) formed from nylon tubing (NY12-07518-500, Industrial 
Specialities Manufacturing) with an external diameter of 3.2 mm and a 1.6 mm hose barb 
elbow connector (N1EUB-1-V-BK, Industrial Specialities Manufacturing) was primed with 
sterile heparinised saline, inserted into the DP and tapped into place until the elbow was flush 
with the hoof surface. A 120 cm plastic extension tube (Pressure Tubing, Edwards Life 
Sciences) preloaded with sterile heparinised saline was connected to the needle and flushed. 
Hoof adhesive (Equilox) was applied to seal and fix the tubing in place. Infusion with 3.5 
mg/mL marimastat solution was initiated immediately using a Springfusor® 30 pump and 30-
2 Flow Control Tubing (Allied Medical). 
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Figure 3.1:  Photograph of IOIDP equipment showing the custom made intraosseous 
infusion needle and 25 mm long flushing needle used to remove debris from the holes drilled 
in hoof and bone.  
 
3.3.6 Sample preparation and analysis 
Marimastat concentrations were quantified in plasma, LUF and tissue homogenates using 
UPLC-MS on a Nexera UPLC coupled with a MS-8030 Triple quadruple mass spectrometer 
(Shimadzu Corporation) operating in positive electrospray ionization mode. All reagents 
were LC-MS grade. A reverse phase C18 column (Kinetex, 1.7 µm  XB-C18, 100A, 50 x 2.1 
mm, Phenomenex) was employed; the injection volume was 1 µl. The mobile phase consisted 
of water (Solvent A) and acetonitrile (Solvent B) in the following program: a gradient run of 
5% B and 95% B for 3 minutes, held for 1 minute and then run at 5% B in an isocratic mode 
for 2 minutes. The flow rate was maintained at 0.4 mL/ min at a temperature of 50 °C. The 
drying gas was at 250 °C, the gas flow at 20 L/min, the nebulising gas flow at 3 L/min, and 
the heating block was at 400 °C. Argon was used as a collision gas, and the capillary voltage 
was 4.5 KV. A positive mode with MRM transmission of 332.20  86.15 was used. The 
dwell time was 100 ms, and the collision energy was set to -20 eV. The limit of quantification 
was 10 ng/mL.  
 
Plasma and LUF samples were extracted using an acid extraction method. 5-sulfosalicyclic 
acid dihydrate (0.1 g/mL) was added in a 1:1 v/v ratio to the sample. The sample was 
vortexed for 30 s, centrifuged for 10 minutes at 15,625 g and the supernatant removed, added 
in a 1:1 v/v ratio to dimethylsulfoxide containing 500 ng/mL of Batimastat (BB-94, Vernalis)  
as an internal standard, vortexed, centrifuged  (10 minutes, 15,625 g) and the supernatant 
removed for analysis. Tissue samples were homogenised in a 1:2 w/w ratio with water. 5-
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sulfosalicyclic acid dihydrate (0.1 g/mL) was added to the homogenate in a 1:1 w/w ratio. 
The samples were vortexed for 30 s and centrifuged for 10 minutes at 15,625 g. The 
supernatant was removed, added in a 1:1 v/v ratio to dimethylsulfoxide containing 500 ng/mL 
internal standard (Batimastat) vortexed, centrifuged (10 minutes, 15,625 g) and the 
supernatant removed for analysis. Calibration and quality control samples were obtained by 
spiking the blank matrix with known amounts of marimastat. The calibration curve was 
analysed using linear regression with a minimum R2 of 0.99. A measure of in vivo recovery 
of marimastat in LUF compared to tissue was calculated using the following equation: in vivo 
recovery= (LUF marimastat concentration 9-12 h into the CRI) × (tissue marimastat 
concentration 12 h into the CRI)-1 × 100.  
 
Biochemical analyte concentrations were measured in LUF collected prior to IOIDP (0-12 h 
after probe implantation), between IOIDP and CRI (24-36 h post implantation) and during the 
last 6h of the CRI (42-48 h post implantation), using a Beckman Coulter AU400 
biochemistry analyser (Beckman Coulter Inc) as previously described (Chapter 2).  
 
3.3.7 Histologic analysis 
A lamellar tissue sample surrounding the ultrafiltration probe was fixed in 10% neutral 
buffered formalin, processed by routine paraffin embedding, sectioned at 4 µm and stained 
with H&E and Masson’s Trichrome for light microscopy as previously described (Pollitt 
1996). The sections were interpreted by a blinded, specialist veterinary pathologist (REA). 
The reaction around the ultrafiltration probe was scored using a previously described semi-
quantitative method presented in Table 2.1 (Chapter 2).  
 
3.3.8 Data analyses 
The relationship between marimastat concentration and pharmacodynamic effect (MMP 
degradation of gelatin, expressed as % of control) was estimated using  PKSolver (China 
Pharmaceutical University), employing an inhibitory sigmoid Emax model in which no 
baseline (E0) was applied as previously described (Shu, Zhou et al. 2011). The maximum 
effect (Emax), the concentration required for 50% inhibition in vitro (IC50) and the shaping 
factor (γ) were calculated for pro-MMP2, pro-MMP-9 and active MMP-2. IC80 and IC90 
values were estimated for each protease. Three pharmacokinetic-pharmacodynamic indices 
were calculated: steady state concentration (Css): IC50, Css:IC80 and Css:IC90. 
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Data were analysed using GraphPad Prism (GraphPad Software Inc). The data were tested for 
normality using D’Agostino-Pearson omnibus normality tests. Data distributions were either 
non-Gaussian, or data numbers were too small to presume a normal distribution, hence non-
parametric tests were used. Paired data were compared by Wilcoxon signed-rank tests, and 
non-paired data by Mann-Whitney tests. Comparisons of repeated measures were analysed 
using Friedman analyses with Dunn’s post-tests. Significance was set at P≤0.05. Unless 
otherwise stated, data are expressed as median [interquartile range]. 
 
Spearman’s rank correlation coefficients (rs) were calculated to examine the association 
between steady-state LUF[M] post IOIDP/CRI with LUF biochemical analyte concentrations 
and total histologic scores. Data were also examined visually. A weak correlation was 
defined as being significant (P<0.05) with an rs <0.4, moderate 0.4–0.7, and strong >0.7 
(Taylor 1990). 
 
3.4 Results 
There was no difference between IOIDP and CRI infusion rates (0.15[0.14- 0.16] mL/minute 
vs. 0.15[0.14-0.16] mL/minute respectively). This equated to a marimastat infusion rate of 
31.5 mg/h. Both infusions were well tolerated with no evidence of pain or lameness. There 
was no change in clinical parameters during either infusion. 
  
The in vitro recovery of marimastat through the ultrafiltration probe was 98[95-100]% in 
0.9% saline and 94[90-99]% in plasma. Ultrafiltration probes were successfully placed in the 
lamellar tissue in both forefeet in all 5 horses. LUF was collected at a median rate of 49[40-
55] µL/h. There was no difference in LUF collection rates during IOIDP (52[39-65] µL/h) 
and CRI (47[40-54] µL/h), nor between the IOIDP instrumented foot (50[39-58] µL/h) and 
the uninstrumented foot (49[40-58] µL/h). The concentrations of biochemical analytes in 
LUF did not vary significantly during the study period (Table 3.1). Once steady state was 
reached, there was no significant difference in LUF[M] during IOIDP or CRI (Figure 3.2A). 
T[M] 12 h into the CRI were significantly higher than LUF[M] obtained 9-12 h into the CRI 
(161[136-276] ng/g vs. 145[118-171] ng/g, respectively), resulting in an in vivo recovery of 
marimastat from tissue of 72 [60-100]%. The within-limb coefficient of variation of 
marimastat concentrations was 5.9-32.9% in tissue samples and 1.5-6.7% in LUF. 
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Table 3.1: The results of the biochemical analyses of ultrafiltrate through the study, 
data are reported as median [IQR]. There were no significant differences in analyte 
concentrations at any of the time points. 
Analyte 0-12 h post probe 
placement 
24-36 h post probe 
placement 
42-48 h post probe 
placement 
Urea (mmol/L) 7.0 [5.7-8.6] 6.1 [5.0-7.6] 5.6 [5.4-6.4] 
Glucose (mmol/L) 2.9 [0.7-4.2] 3.2 [0.7-3.9] 2.7 [0.0-3.2] 
Sodium (mmol/L) 137 [134-140] 131[129-134] 136 [133-138] 
Potassium (mmol/L) 4.2 [4.0-4.4] 3.9 [3.9-4.3] 4.2 [4.1-4.4] 
Chloride (mmol/L) 106 [104-110] 103 [102-104] 107 [104-108] 
 
Figure 3.2: Median (±IQR) marimastat concentrations during intraosseous infusion of 
the distal phalanx (IOIDP) and systemic continuous rate infusion (CRI) with 
marimastat. A) Lamellar ultrafiltrate marimastat concentrations (LUF[M]) during IOIDP 
(red circles) and CRI (blue squares). B) Plasma marimastat concentrations (P[M]) during 
IOIDP (red circles) and CRI (blue squares). C) P[M] (black triangles) and [LUFM] (red 
circles) during IOIDP.  D) P[M] (black triangles) and LUF[M] (blue squares) during CRI. 
There were no significant differences between any of the concentrations at any time-points. 
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Figure 3.3: Box and whisker plot showing steady-state ultrafiltrate marimastat 
concentrations in each horse during IOIDP.  
 
LUF[M] and P[M] reached steady-state 2 hours after initiation of IOIDP and CRI. There were 
no significant differences between LUF[M] or P[M] during IOIDP and CRI, nor between 
LUF[M] and P[M] after either IOIDP or CRI (Table 3.1, Figure 3.2). There were no differences 
between LUF[M] in the instrumented vs. the un-instrumented limbs during IOIDP or CRI. 
However, the LUF[M] in the instrumented limbs during IOIDP were highly variable and 
appeared to fall into 2 groups; 2 horses (horses 2 and 4, high LUF group) had higher steady-
state LUF[M] (512[469-866] ng/mL) and the remainder (low LUF group) had lower steady-
state LUF[M] (108[65-131] ng/mL, Figure 3.3). Neither the P[M] after IOIDP nor the LUF[M] 
after CRI differed subjectively between these groups.  
 
Table 3.2: Estimates of pharmacodynamic parameters for marimastat inhibition of 
equine MMP-2 and MMP-9 in vitro. 
 
 
 Pro-MMP-9 Pro-MMP-2 Active-MMP-2 
Emax  (%) 102.8 [97.2-106.6] 114 [105-119] 105 [103-109] 
γ 0.75 [0.65-1.13] 0.64 [0.62-0.92] 0.9 [0.7-1.3] 
IC50 (ng/mL) 9.2 [7.4-18.8] 2.8 [1.6-3.5] 2.5 [2.0-3.6] 
IC80 (ng/mL) 66 [54-79] 25 [16-38] 20 [20-20] 
IC90 (ng/mL) 177 [131-260] 81 [38-116] 40 [18-56] 
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Table 3.3: Estimates of pharmacokinetic-pharmacodynamic parameters for MMP-2 
and MMP-9 after marimastat administration by intraosseous infusion of the distal 
phalanx (IOIDP) and systemic constant rate infusion (CRI). LUF= lamellar ultrafiltrate, 
Css=steady-state concentration. Data expressed as median [IQR] 
 
 IOIDP LUF IOIDP plasma CRI LUF CRI plasma 
Css (ng/mL) 139 [88-497] 103 [69-114] 136 [93-157] 105 [85-156] 
Css:IC50-MMP9 15 [9.0-55] 14 [9.0-14] 11 [9.1-18] 11 [2.1-7.7] 
Css:IC90-MMP9 0.8 [0.5-2.9] 0.7 [0.5-1.0] 0.6 [0.5-0.7] 0.6 [0.5-0.9] 
Css:IC50-MMP2 50 [29-181] 47 [30-63] 37 [30-45] 37 [30-59] 
Css:IC90-MMP2 1.7 [1.0-6.3] 1.6 [1.0-2.2] 1.3 [1.0-1.6] 1.3 [1.0-2.0] 
Css:IC50-MMP2_active 56 [33-203] 53 [33-71] 41 [33-51] 41 [34-66] 
Css:IC90-MMP2_active 3.5 [2.1-12.7] 3.3 [2.1-4.4] 2.6 [2.1-3.2] 2.5 [2.1-4.1] 
 
Figures 3.4 and 3.5 show the in vitro inhibition of pro-MMP-2, pro-MMP-9 and active-
MMP-2 by marimastat. PK-PD data are detailed in Tables 3.2 and 3.3. Histological 
examination of the tissue sections showed the probe situated between primary epidermal 
lamellae (PEL) in 7/10 limbs and within the sublamellar dermis in the remaining 3 horses. 
There was no significant difference in steady-state LUF[M] during CRI between probes 
located in the sub-lamellar dermis and those located between PEL. The histologic changes 
around the probe were consistent with a mild foreign body response (Figure 3.6). There was 
no significant correlation between total histologic score and steady-state LUF[M] after IOIDP 
or CRI.  
 
Figure 3.4: Zymography of a lamellar homogenate pooled from horses with 
oligofructose-induced laminitis. MMP inhibition was achieved by incubating individual gel 
lanes with increasing concentrations of marimastat. 
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Figure 3.5: Percent inhibition of lamellar MMP gelatin degradation by increasing 
concentrations of marimastat.   
 
 
Figure 3.6: Median (±IQR) histologic scores of lamellar sections surrounding the 
ultrafiltration probe. 
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3.5 Discussion 
IOIDP did not consistently result in higher lamellar marimastat concentrations than 
intravenous CRI, nor were the marimastat concentrations in the treated foot consistently 
higher than those in the untreated foot and plasma.  Hence IOIDP was not considered a 
reliable method for enhanced local lamellar drug delivery and hypotheses 1 and 2 were 
rejected. These results are similar to those of de Laat when investigating local insulin 
delivery by IOIDP (de Laat 2011), and with reports of IO infusion at sites other than the 
distal phalanx, where local delivery is generally not achieved unless a tourniquet is applied 
(Mattson et al. 2005; Errico et al. 2008). However, they differ from two previous 
investigations of IOIDP in horses where local lamellar delivery was successfully achieved 
(Nourian et al. 2010; de Laat et al. 2012). The lack of local lamellar delivery in the present 
study may be attributable to variations in IO cannula placement technique (Nourian et al. 
2010; de Laat et al. 2012) possibly causing the infusion to directly enter the systemic 
circulation. However, insulin delivery by IOIDP, although not assayed at the lamellar level, 
failed to achieve hyperinsulinaemia in veins of the treated foot (de Laat 2011), despite using a 
previously successful placement method (Nourian et al. 2010; de Laat et al. 2012). 
Biodistribution factors attributable to different physico-chemical properties of the 
pharmaceuticals used (Bidgood and Papich 2003), may be responsible for the variation in 
lamellar delivery during IOIDP.  
 
Within this study the extent of lamellar delivery by IOIDP varied.  In two horses local 
lamellar delivery with IOIDP appeared successful; in the remaining 3 horses there was no 
local delivery effect (Figure 3.3). This may be attributable to several factors including 
variations in drug metabolism, IOIDP cannula placement, marimastat recovery and probe 
viability. Probe factors were considered unlikely for the following reasons: (1) There was 
minimal difference between the in vivo probe recovery in the high LUF group (85 [72-99]%) 
compared to the low LUF group (81 [57-108]%). (2) The variations in in vivo probe 
marimastat recovery (56-108%) were insufficient to explain the inter-horse variability during 
IOIDP. (3) The LUF[M]  during CRI and the LUF concentrations of biochemical analytes did 
not vary between groups, nor did there appear to be any correlation between biochemical 
analyte and marimastat concentrations. Therefore, the inter-horse variations in LUF[M] during 
IOIDP probably reflect true IF marimastat concentration variations attributable either to inter-
horse variations in marimastat pharmacokinetics or variations in IOIDP cannula placement, 
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which, whilst undetectable to the authors, may have resulted in different degrees of lamellar 
marimastat delivery. Further investigations, are required to determine whether this variation 
occurs in the same proportions in a larger population, and establish its cause. 
 
Activation of MMP-2, MMP-9, MMP-14, and ADAMTS-4 has been implicated in laminitis 
pathophysiology (Pollitt et al. 1998; Visser 2009; Wang et al. 2012). Zymography established 
basic pharmacodynamic data for marimastat against equine lamellar MMP-2 and -9. 
Marimastat inhibits human MMP-14 and ADAMTS-4 with IC50 values of 0.5 ng/mL and 
26.1 ng/mL respectively (Peterson 2006; Tortorella et al. 2009). Both CRI and IOIDP yielded 
LUF[M] greater than the IC50 of MMP-2, MMP-9, MMP-14 and ADAMTS-4. Direct 
extrapolations from IC50 data should, however, be interpreted with caution: frequently 
concentrations much higher than the IC50 are required for adequate inhibition in vivo (Lees, 
Cunningham et al. 2004; Peterson 2006). The marimastat concentrations required to inhibit 
lamellar MMPs in vivo are unknown. A high level of enzymatic inhibition is generally 
required to produce clinical responses by MMP- inhibitors, therefore, when available, IC90 
concentrations were selected to represent a therapeutic level of MMP inhibition (Lees et al. 
2004; Shu et al. 2011).  There are no published IC90 values for MMP-14 and ADAMTS-4. 
Target trough plasma concentrations six times the IC50 were employed when the anti-
neoplastic activity of marimastat was evaluated (Millar et al. 1998). Based on this, target 
concentrations of at least 3 ng/mL and 156 ng/mL marimastat were set for inhibition of 
MMP-14 and ADAM-TS4 respectively (Peterson 2006; Tortorella et al. 2009). IOIDP and 
CRI yielded steady-state LUF[M] greater than the target concentrations for MMP-2 and MMP-
14 in all horses. However, neither technique consistently achieved target LUF[M] for MMP-9 
and ADAMTS-4. Therefore it is questionable whether, at the rates used in this study, either 
technique would sufficiently inhibit lamellar MMPs in vivo.  
 
IOIDP was performed without complication in all 5 horses. IOIDP in horses has previously 
been associated with signs of pain (pawing and weight shifting) (de Laat 2011). Pain 
associated with IO infusion is also reported in people; lidocaine administration is 
recommended to counteract this (Schalk et al. 2011). The horses in this study received 
lidocaine to block pain associated with IOIDP. As co-administration with lidocaine may have 
altered the pharmacokinetics of marimastat, lidocaine was also infused during CRI. The 
results of this study indicate IOIDP with lidocaine abolished noticeable foot pain when the 
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horses were free to move in the stall; further lameness evaluation would be necessary to 
declare the technique ‘pain free’. Systemic marimastat administration results in a variety of 
side effects in other species including tendonitis like fibromyalgia, arthritis diarrhoea, and 
coughing (Millar et al. 1998, Miller et al. 2002, Peterson 2006). No side-effects of systemic 
marimastat administration were detected in the horses in this study, however, many of the 
side effects in other species occur after long-term use (Millar et al. 1998, Miller et al. 2002, 
Peterson 2006).  
 
This is the first study to use ultrafiltration to collect LUF for pharmacokinetic analyses and 
compare simultaneous tissue and ultrafiltrate concentrations. An additional objective was to 
validate lamellar ultrafiltration for pharmacokinetic studies. LUF was successfully collected 
from every probe placed. Probes were well tolerated and functioned for the duration of the 
study. LUF collection rate did not vary significantly with time, and was sufficient for 
analysis. Based on comparison of T[M] and LUF[M] at the end of the CRI, in vivo marimastat 
recovery was 72%. A <100% in vivo recovery rate is expected as ‘in vivo recovery’ is a 
comparison between unbound drug concentrations in LUF and total drug concentrations in 
tissue, not a direct measure of probe function (Bidgood and Papich 2003). The in vitro 
variability in marimastat recovery was minimal (range 90-102%); whereas inter-horse 
variability in ‘in vivo recovery’ (LUF vs. tissue marimastat concentration) was high (range 
56-108 %). This was attributed to the high within-limb variation in T[M], ascribed to 
inaccuracies during the complicated homogenisation and extraction process, and reflects a 
limitation of using tissue homogenates in pharmacokinetic studies. Key concerns with 
ultrafiltration include whether drug recovery remains constant over time or is affected by 
tissue response to the ultrafiltration probes. The histologic findings in this study support those 
in a previous report, with mild inflammation and fibrous tissue formation around the probes 
(Chapter 2). These changes may alter drug recovery (Wisniewski et al. 2001). In the present 
study, there were no significant differences in LUF[M] during steady state, suggesting 
marimastat recovery was consistent. The lack of significant temporal variations in LUF 
biochemical analyte concentrations and any correlation between biochemical analyte 
concentrations or steady-state LUF[M] and total histologic score suggests  host tissue response 
had minimal effect on recovery.  
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A major limitation of this study was the small number of horses used. Initially, power 
calculations were performed to ensure sample size was sufficient whilst minimising the 
number of horses used in accordance with the welfare principles governing animal research 
(NHMRC 2013). However, the high variability in LUF[M]  after IOIDP was not anticipated. 
During IOIDP, the infusion rate varied very slightly in each horse (range 0.13- 0.17 mL/min), 
presumably due to inter-horse variations in resistance to infusion. However, CRI was 
performed after IOIDP to ensure CRI infusion rates were matched to the IOIDP rate in each 
horse.  
 
In conclusion, both IOIDP and CRI of marimastat at a rate of 31.5 mg/h yielded sufficient 
LUF[M]  to inhibit 50% of MMP-2, MMP-9, MMP-14 and ADAMTS-4 in vitro, and hence 
may have potential for laminitis prophylaxis. However, neither technique resulted in 
consistent local lamellar delivery at concentrations considered sufficient for effective in vivo 
inhibition of MMP-9 and ADAMTS-4. Based on the results of this study, CRI is more 
suitable for lamellar marimastat delivery as it is simpler, yields similar median lamellar 
marimastat concentrations and has potential to deliver high volumes of pharmaceutical 
solution. The CRI dose requires optimisation to ensure target lamellar marimastat 
concentrations are achieved prior to application in experimental studies evaluating the 
efficacy of marimastat as a laminitis prophylactic. However, CRI is a systemic delivery 
technique and even its experimental use may be precluded by cost and systemic adverse 
effects, so further investigation of local delivery mechanisms is warranted. If IOIDP could be 
optimised to consistently yield the higher rate of lamellar delivery achieved in 2/5 horses in 
this study it may be worthy of further development.  Lamellar ultrafiltration played a key role 
in supplying samples of LUF for pharmacokinetic analysis. The successful use of lamellar 
ultrafiltration in this study demonstrated its potential for use in further pharmacokinetic 
studies investigating lamellar drug delivery 
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4.1 Abstract 
Reasons for performing study: Pharmaceutical agents with potential for laminitis 
prevention have been identified. Many of these, including the MMP inhibitor marimastat, are 
impractical for systemic administration.  
Objectives: To compare local delivery of marimastat by regional limb perfusion (RLP) to a 
systemic intravenous bolus dose (SIVB), and establish whether retrograde intravenous 
regional limb perfusion (RLP) is suitable for local lamellar drug delivery.  
Study Design:  Experimental pharmacokinetic study 
Methods: Six healthy adult horses received 0.23 mg/kg of marimastat by RLP followed by a 
0.23 mg/kg by SIVB, with a 24 h washout period between doses. Lamellar ultrafiltration 
probes sampled lamellar interstitial fluid as lamellar ultrafiltrate (LUF). LUF and plasma 
marimastat concentrations (LUF[M]  and P[M] respectively) were measured for 24 h after each 
treatment and regional pharmacokinetic parameters calculated using non-compartmental 
analysis. Ultrafiltrate concentrations of biochemical analytes were measured at three time-
points during the study to monitor probe function. Data were analysed non-parametrically 
with significance set at P<0.05. 
Results: The LUF Cmax following RLP was 232 times that following SIVB. LUF[M]  after 
RLP were higher than those obtained after SIVB for 18 h post-treatment (P<0.03). For 12 h 
following RLP, LUF[M] were higher than P[M] (P=0.03). Median LUF[M] were >IC90 of equine 
lamellar MMP-2 and MMP-9 for 9h after tourniquet removal. 
Conclusions:  RLP is superior to SIVB for lamellar drug delivery of marimastat (higher LUF 
Cmax,, AUC and T>IC90 lamellar MMPs for RLP than SIVB). However frequent (6 hourly) 
dosing remains necessary to achieve therapeutic lamellar concentrations.  
Potential relevance: RLP could be used to investigate whether the MMP inhibitor 
marimastat ameliorates experimentally induced laminitis. Further refinement of the technique 
and dosing interval is necessary before clinical application. 
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4.2 Introduction 
Laminitis is a debilitating disease of horses with no validated pharmacologic means of 
treatment or prophylaxis. Pharmaceutical agents with potential to prevent laminitis have been 
identified, many of which are impractical for systemic delivery due to expense, systemic side 
effects, rapid clearance and/or poor bioavailability. This study investigates whether local 
delivery, by retrograde regional intravenous limb perfusion (RLP), offers advantages over 
systemic intravenous bolus (SIVB) dosing.  
 
Activation of proteolytic enzymes, namely, matrix metalloproteinase (MMP)-2, MMP-9, 
MMP-14, MMP-1, MMP-13 and a disintegrin and metalloproteinase with thrombospondin 
motifs (ADAMTS)-4, have been implicated in the pathophysiology of sepsis-related laminitis 
(Pollitt et al. 1998; Visser and Pollitt 2012; Wang et al. 2012). The broad spectrum MMP 
inhibitors marimastat and batimastat prevent MMP-induced lamellar separation in vitro 
(Pollitt, Pass et al. 1998) and also inhibit ADAMTS-4 (Tortorella et al. 2009). Further 
investigation of their in vivo efficacy is needed but is limited currently by the inherent 
impracticalities of administering MMP inhibitors systemically (Levin et al. 2006; Pass and 
Pollitt, unpublished data). Regional drug delivery could circumvent these limitations, thereby 
enabling in vivo testing of drug efficacy.  
 
Intraosseous infusion of the distal phalanx (IOIDP), investigated for regional lamellar drug 
delivery, did not consistently raise lamellar marimastat concentrations above the IC90 for 
equine lamellar MMP-2 and MMP-9 (Chapter 3). RLP is well-established for regional 
delivery of antimicrobials to distal limb synovial structures, bone, and subcutaneous tissues 
(Parra-Sanchez et al. 2006; Rubio-Martinez et al. 2006; Levine et al. 2010; Beccar-Varela al. 
2011; Kelmer, Bell et al. 2013; Kelmer et al. 2013; Lallemand et al. 2013; Mahne et al. 
2013). In this study, RLP was compared to SIVB to establish which achieved the highest 
lamellar marimastat concentrations. Ultrafiltration probes were used to sample lamellar 
interstitial fluid as lamellar ultrafiltrate (LUF). The following hypotheses were tested: (1) 
RLP results in higher lamellar ultrafiltrate (LUF[M]) marimastat concentrations than SIVB, 
and (2) LUF[M] in the foot receiving RLP are higher than plasma marimastat concentrations 
(P[M]). 
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4.3 Methods 
The project was approved by the University of Queensland Animal Ethics Committee 
(approval number: SVS/337/11) that monitors compliance with the Animal Welfare Act 
(2001) and The Code of Practice for the care and use of animals for scientific purposes 
(current edition). All animals were monitored frequently by the investigators. 
 
4.3.1 Animals and monitoring 
Six mature Standardbred horses (6 geldings; aged 6-15 years, 355-520 kg bwt), with no 
lameness or gross foot abnormalities were enrolled in the study. The horses received no 
medications for 1 month prior to the study. During the experiment the horses were housed in 
stalls and had ad libitum access to hay and water. Heart rate, respiratory rate and temperature 
were recorded at 0, 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24 h after RLP and SIVB.  
 
4.3.2 Study Design 
This was a prospective pharmacokinetic study; each horse received 0.23 mg/kg marimastat 
(Vernalis) delivered by SIVB then RLP. The marimastat dose was based on the maximal 
solubility of marimastat in water (10 mM), the weight of the heaviest horse in the study, and 
the maximum volume (35 mL) estimated safe to infuse into a foot under tourniquet via the 
palmar digital vein at the level of the pastern. The wash-out period between SIVB and RLP 
treatments was 24 h (24 times the 1.0 ±0.35 h plasma elimination half-life of marimastat 
(Pass and Pollitt, unpublished data). LUF was collected for 1 h prior to administration of 
marimastat by RLP to ensure LUF[M] had returned to zero. Plasma and LUF were collected 
and analysed for marimastat concentrations. 
 
4.3.3 Ultrafiltration probe placement 
Twenty-four hours prior to marimastat administration, sterile, custom-made 3-8 ultrafiltration 
probes (BASi) were placed in the lamellar region of a randomly assigned front foot under 
perineural analgesia as previously described (Chapter 2, Appendix 2). The ultrafiltration 
tubing was cut to a length of 30 cm from the probe prior to sample collection. 
 
4.3.4 Systemic Intravenous Bolus 
A 16 G, 13 cm over-the-needle catheter (BD Angiocath, BD) was aseptically placed in the 
left jugular vein using local analgesia. Marimastat was diluted to 10 mM concentration in 
86 
 
0.9% sterile saline using aseptic technique. Marimastat solution was administered through the 
jugular IV catheter over 1 minute at a dose of 0.23 mg/kg. Subsequently the catheter was 
flushed with 5 mL heparinised saline.  Due to an administrative error, the complete 
marimastat dose was not administered by SIVB to one horse and these samples were 
excluded from the study.  
 
4.3.5 Regional Limb Perfusion 
All horses received RLP with 0.23 mg/kg marimastat in the lateral palmar digital vein at the 
level of the pastern in the limb instrumented with an ultrafiltration probe. RLP was performed 
using peri-neural anaesthesia in the standing sedated horse as previously described (Parra-
Sanchez et al. 2006; Kelmer et al. 2013). A 12 cm wide Esmarch tourniquet was placed over 
the metacarpophalangeal joint. Marimastat solution was injected through a 25 G winged 
infusion needle (Surflo Winged Infusion Set, Terumo) into the lateral palmar digital vein over 
1 minute. The needle was flushed with 5 mL of heparinised saline and withdrawn. A pressure 
wrap was applied immediately over the injection site. The tourniquet was kept in place for 45 
minutes following the end of the injection. Tourniquet application and RLP injection were 
performed on each horse by the same investigator (CU). 
 
4.3.6 Sample collection 
Blood and LUF samples were collected for pharmacokinetic analysis prior to SIVB then at 1, 
2, 3, 4, 5, 6, 9 ,12, 18, and 24 h subsequent to SIVB. Blood was also collected at 0.017 h after 
SIVB. Following RLP, blood and LUF were collected upon tourniquet removal, then at 1, 2, 
3, 4, 5, 6, 9, 12, 18 and 24 h after tourniquet removal. LUF samples were collected by 
replacing the plain glass vacutainer tubes with new tubes (Bioanalytical Systems) providing 
continuous suction on the ultrafiltration probes. To ensure a vacuum was present in all tubes 
60mL was withdrawn from the tube using a 25G needle and 60mL luerlock syringe.Whole 
blood samples were collected into heparinised tubes via a 16G IV catheter placed aseptically 
in the right jugular vein. Blood samples were immediately centrifuged (14,310 g, 10 minutes) 
and plasma was separated. LUF samples for biochemical analyses were collected at 0-12 h, 
36-60 h and at 78-84 h after probe placement. All samples were stored at -80 ⁰C prior to 
analysis. At the end of the study horses were euthanased with pentobarbital sodium 
(Lethabarb, Virbac, 20 mg/kg bwt i.v.). Lamellar tissue encompassing the UF probe was 
collected for histology and fixed in 10% neutral buffered formalin prior to processing. 
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4.3.7 Sample preparation and analysis 
Marimastat was analysed in plasma and LUF using UPLC-MS on a Nexera UPLC coupled 
with a LCMS-8030 triple quadruple mass spectrometer (Shimadzu) operating in positive 
electrospray ionization mode using a previously described technique (Chapter 3). All reagents 
were of LC-MS grade. Plasma and LUF samples were extracted using an acid extraction 
method as previously described (Chapter 3). Calibration and quality control samples were 
obtained by spiking the blank matrix (LUF or plasma) with known amounts of marimastat. A 
new calibration curve was prepared for each day’s analysis.  
 
The concentrations of biochemical analytes (urea, glucose, sodium, chloride and potassium) 
were monitored in LUF to provide an indication of probe viability over time. Concentrations 
were measured using a Beckman Coulter AU400 biochemistry analyser (Beckman Coulter) 
as previously described (Chapter 2).  
 
4.3.8 Histologic analysis 
Formalin-fixed lamellar tissue was processed by routine paraffin embedding, sectioned at 4 
µm and stained with H&E and Masson’s Trichrome for light microscopy as previously 
described (Pollitt 1996). The sections were interpreted by a blinded, specialist veterinary 
pathologist (REA). The reaction around the ultrafiltration probe was scored using a 
previously-described semi-quantitative method detailed in Table 2.1 (Chapter 2).  
 
4.3.9 Data analyses 
To facilitate comparison between different administration routes, pharmacokinetic parameters 
were estimated by non-compartmental analysis using PKSolver (China Pharmaceutical 
University). The analysis included all concentrations above the LOQ. The area under the zero 
and first moment curves over 24 h post administration (AUC0-24, and AUMC0-24) were 
calculated using a linear trapezoidal method for consecutively increasing or equal 
concentrations and a log-linear trapezoidal method for decreasing concentrations. The 
terminal elimination slope (λz) was estimated using log-linear regression over at least three 
data points, with visual verification of the regression line (Gabrielsson and Weiner 2012). 
Three pharmacokinetic-pharmacodynamic indices were calculated for MMP-2 and MMP-9: 
AUC0-24:IC90, Cmax:IC90 and T>IC90. Similar to non-steroidal anti-inflammatory drugs, a high 
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level of enzymatic inhibition is generally required to produce clinical responses by MMP 
inhibitors (Lees et al. 2004), therefore IC90 concentrations were selected to represent a 
therapeutic level of MMP inhibition (Shu et al. 2011). IC90 concentrations of 177 ng/mL and 
81 ng/mL were used for MMP-9 and MMP-2 respectively (Chapter 3). T>IC90 was obtained 
using the last sampling time-point at which the marimastat concentrations were > IC90. 
 
Data were analysed using GraphPad Prism (Graphpad Software Inc). The data were tested for 
normality using D’Agostino-Pearson omnibus K2 normality tests. The data were either non-
Gaussian or the numbers were too small to analyse so non-parametric statistical tests were 
used throughout. Clinical parameters measured during RLP and SIVB were compared to their 
respective baselines using repeated measures Friedman analyses with Dunn’s post-tests. RLP 
LUF[M] and P[M] collected at tourniquet removal were compared to SIVB P[M] at 0.017 h, 
subsequently, corresponding time-points were compared directly. Wilcoxon-signed rank tests 
were used for comparison of marimastat concentrations in paired data (plasma vs. LUF) and 
Mann-Whitney tests were used for unpaired data (SIVB vs. RLP) at each time-point. 
Significance was set at P≤0.05. Unless otherwise stated, data are expressed as median 
[interquartile range].).  
 
Spearman’s rank correlation coefficients (rs) were calculated to examine the association 
between LUF Cmax post-RLP, with LUF Cmax post-SIVB, LUF biochemical analyte 
concentrations and total histologic scores. Data were also examined visually. A weak 
correlation was defined as being significant (P<0.05) and rs <0.4, moderate 0.4–0.7, and good 
>0.7 (Taylor 1990). 
 
4.4 Results 
Five of the six horses received the full SIVB dose; the remaining horse was excluded from 
analysis in the SIVB group. All RLP were performed without complication. The median 
marimastat dose was 103 [97-108] mg, administered in a volume of 29.4 [27.7-30.9] mL. 
LUF was collected successfully from all ultrafiltration probes at 49 [40-57] µL/h. There was 
no difference between LUF collection rates during RLP (50 [42-57] µL/h) and SIVB] (48 
[39-53] µL/h). Clinical parameters remained within normal limits at all time-points and did 
not vary significantly following marimastat administration. The horses did not exhibit any 
89 
 
signs of lameness or discomfort during the study. Horse movement was minimal during RLP; 
three horses did not move at all, two shifted weight once and one horse stepped backwards. 
Baseline marimastat concentrations (collected for 1 h prior to RLP and SIVB) were below the 
limit of detection for the analytical method. LUF[M] and P[M] concentrations are shown in 
Figure 4.1. LUF[M] after RLP were higher than LUF[M] after SIVB at every time-point for 18 h 
post-treatment (P<0.03). For 12 h following RLP, LUF[M] were higher than P[M] (P=0.03). 
There were no significant differences between P[M] after SIVB and RLP, nor between LUF[M] 
and P[M] concentrations after SIVB. Pharmacokinetic data describing LUF[M] and P[M] are 
summarised in Table 4.1. AUC0-∞ did not exceed AUC0-24 by more than 10%. Cmax, AUC0-24, 
AUC0-∞, AUMC0-∞ and T1/2 were all higher in LUF after RLP than after SIVB (P<0.004). λz 
was lower in LUF after RLP than after SIVB (P< 0.009). AUC0-24:IC90, Cmax:IC90 and T>IC90 
were higher in LUF after RLP than after SIVB for both MMP-2 and MMP-9 (P<0.04). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Median (±IQR) marimastat concentrations after retrograde intravenous 
limb perfusion (RLP) and systemic intravenous bolus administration (SIVB) of 
marimastat. A) Lamellar ultrafiltrate marimastat concentrations (LUF[M]) during RLP (red 
circles) and SIVB (blue squares). B) Plasma marimastat concentrations (P[M]) during RLP 
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(red circles) and SIVB (blue squares). C) P[M] (black triangles) and LUF[M] (red circles) 
during RLP. D) P[M] (black triangles) and LUF[M] (blue squares) during SIVB. Asterisks (*) 
denote a significant difference between concentrations at a single time-point. 
Table 4.1: Estimates of pharmacokinetic-pharmacodynamic values after marimastat 
administration by regional limb perfusion (RLP) or systemic intravenous bolus (SIVB). 
An asterisk (*) in the RLP lamellar ultrafiltrate column denotes a significant difference 
(P<0.05) between RLP and SIV ultrafiltrate values. 
 
 
The concentrations of glucose, urea, sodium, potassium and chloride in LUF did not vary 
significantly during the study period (Figure 4.2). Histologic examination of lamellar sections 
revealed the probe located within the lamellar region in all horses. Histologic scores were 
consistent with a mild foreign body response (Figure 4.3). There were no significant 
correlations between Cmax after RLP and total histologic score or biochemical analyte 
concentrations.  
Variable RLP lamellar 
ultrafiltrate 
RLP plasma SIV lamellar 
ultrafiltrate 
SIV plasma 
Cmax (ng/mL) 61,200 [16,713-
67,746]* 
647 [281-
1,244] 
264 [195-335] 2,388 [2,199-
4,170] 
Tmax (h) 1.75 [1.5-.1.75] 0.75 [0.75-
0.75] 
1.00 [1.00-
2.00] 
0.017 [0.017-
0.017] 
AUC0-24 (ng.h/mL) 72,532 [27,830-
88,449]* 
712 [397-
1,333] 
399 [359-608] 799 [652-
1,123] 
AUC0-∞ (ng.h/mL) 72,636 [27,942-
89,071]* 
777 [422-
1,358] 
422 [378-656] 821 [678-
1,150] 
AUMC0-∞ (ng.h2/mL) 156,409 [59,038-
233,605]* 
1,791 [705-
4,286] 
722 [640-
1,481] 
372 [364-843] 
T1/2 (h) 4.3 [2.7-7.8]* 1.9 [1.2-3.8] 0.6 [0.6-1.5] 0.9 [0.8-1.5] 
λz (h-1) 0.16[0.09-0.28]* 0.36[0.18-
0.57] 
1.14[0.61-
1.18] 
0.77[0.47-
0.86] 
MRT0-∞  (h) 2.2[2.1-2.4] 2.0[1.8-3.0] 1.7[1.6-2.7] 0.6[0.5-0.7] 
AUC0-24:IC90 MMP9 410[157-500]* 4.0[2.2-7.5] 2.3[2.0-3.4] 4.5[3.7-6.3] 
C max: IC90 MMP9 346 [94-383]* 3.7[1.6-7.0] 1.5[1.1-1.9] 13[12- 24] 
T> IC90 MMP9 9[8.0-9.75]* 0.017[0.013-
0.5] 
1.0[0.5-1.5] 0.017[0.017-
0.017] 
AUC0-24:IC90 MMP2 896[344-1092]* 8.8[4.9-16] 4.9[4.4-7.5] 9.9[8.0-13.9] 
C max: IC90 MMP2 756[206-836]* 8.0[3.5-15] 3.3[2.4-4.1] 29[27-51] 
T> IC90 MMP2 9[8.3-11.3]* 1[0.75-2.25] 2.0[2.0-2.5] 1.0[0.017-1.5] 
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Figure 4.2: Variations in lamellar ultrafiltrate biochemical analyte (glucose (A), urea 
(B), potassium (C), chloride (D) and sodium (E)) concentrations throughout the study. 
There were no significant changes in analyte concentrations over time. 
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Figure 4.3: Median ±IQR histologic scores of lamellar sections surrounding the 
ultrafiltration probes 
 
4.5 Discussion  
LUF[M] were higher after RLP than after SIVB (the LUF Cmax post-RLP was 232 times  the 
SIVB result). After RLP LUF[M] concentrations were higher than P[M[] suggesting RLP acted 
as a genuine regional delivery technique. RLP has previously been validated for regional 
delivery of pharmaceuticals to bone, subcutaneous tissues, and joints (Parra-Sanchez et al. 
2006; Rubio-Martinez et al. 2006; Levine et al. 2010; Beccar-Varela et al. 2011; Kelmer et al. 
2013; Kelmer et al. 2013; Lallemand et al. 2013; Mahne et al. 2013). This is the first study to 
document lamellar drug concentrations following RLP. In the present study, the LUF[M] after 
RLP were high, whilst corresponding P[M] were low. Low P[M] reduces the risk of 
musculoskeletal side effects as reported for MMP inhibitors in other species (Lees et al. 
2004; Levin et al. 2006; Peterson 2006). Thus administering a pharmaceutical by RLP can 
increase concentrations at the target site whilst minimising the risk of dose-related side 
effects (Rubio-Martinez et al. 2005; Parra-Sanchez et al. 2006; Kelmer et al. 2013). 
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The proteolytic enzymes MMP-2, MMP-9, MMP-14 and ADAMTS-4 have been implicated 
in laminitis pathophysiology (Pollitt et al. 1998; Visser and Pollitt 2012; Wang et al. 2012). 
There is limited information for estimating the lamellar marimastat concentrations necessary 
to inhibit these MMPs in vivo. In this study, IC90 values for lamellar MMP-2 and MMP-9 
were used as target concentrations based on recommendations for the in vivo use of the non-
steroidal anti-inflammatory drugs and the MMP-inhibitor apratastat (Lees et al. 2004; Shu et 
al. 2011). Median LUF[M] remained above the IC90 for MMP-2 and MMP-9 for at least 9 
hours after tourniquet removal. Marimastat inhibits human MMP-1, -13 and -14 and 
ADAMTS-4 with IC50 values of 0.05 ng/mL, 0.23 ng/mL, 0.5 ng/mL and 26.1 ng/mL, 
respectively (Peterson 2006; Tortorella et al. 2009). As only the IC50 values of MMP-14 and 
ADAMTS-4 are available, target marimastat concentrations six times the IC50 were employed 
as recommended in marimastat anti-neoplasia studies (Millar et al. 1998). Based on this, 
trough concentrations of at least 0.3 ng/mL, 1.39 ng/mL, 3 ng/mL and 156 ng/mL marimastat 
were set for inhibition of MMP-1, MMP-13, MMP-14 and ADAM-TS4, respectively 
(Tortorella et al. 2009).  Based on the results of the present study, to ensure LUF[M] remained 
above of 156 ng/mL in all horses, RLP would need to be repeated every 6 h. This dosing 
interval is impractical for clinical application, but could be used experimentally to 
demonstrate whether marimastat prevents laminitis. If successful, further work would be 
necessary to quantify the dose-response relationship and establish a suitable dose-regime 
prior to clinical application. 
 
The limitations to clinical application of RLP for lamellar drug delivery include the need to 
dose each limb individually and the need for repetitive dosing over the long time period 
during which the horse is at risk of developing laminitis. Previously reported complications 
of RLP include phlebitis, perivasculitis (Parra-Sanchez et al. 2006), cellulitis, mild limb 
swelling and hematoma formation (Beccar-Varela et al. 2011), occurring at rates of  12-27% 
in horses receiving multiple RLPs (Kelmer et al. 2012; Rubio-Martinez et al. 2012). Although 
no complications were encountered in this study, only a single RLP was performed in each 
horse. There was high inter-horse variability in LUF[M] after RLP (coefficient of variation 
55%). Similar variations have been observed in most studies of RLP in horses (Murphey et 
al. 1999; Butt et al. 2001; Scheuch et al. 2002; Parra-Sanchez et al. 2006; Levine et al. 2009; 
Mahne et al. 2013). These may be attributable to differences in tourniquet type (Levine, 
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Epstein et al. 2009), tourniquet placement (pressure and position), perivascular leakage of 
perfusate and horse movement (Levine et al. 2009; Mahne et al. 2013). The design of this 
study limited these variables; sedation and perineural analgesia were used to minimise horse 
movement and a single operator standardised tourniquet placement on each horse. 
Additionally variability in LUF[M] could be explained by between-probe variations in 
marimastat recovery. However, in vitro inter-probe variations in marimastat recovery are low 
(Chapter 3) and there was no significant correlation between LUF marimastat Cmax post-RLP 
and Cmax post-SIVB, or biochemical analyte concentrations in LUF. Despite the small data 
set, this suggests the variability in LUF[M] was not attributable to probe function. Therefore, 
inter-horse variability in tissue drug concentrations may be an unavoidable consequence of 
RLP in standing sedated horses. 
 
Ultrafiltration was successfully used for collection of LUF. Ultrafiltrate drug concentrations 
are considered to be indicative of the concentrations of free-drug in interstitial fluid (Linhares 
and Kissinger 1992; Bidgood and Papich 2005; Parra-Sanchez et al. 2006). Previously 
marimastat concentrations in LUF were 72% of that in surrounding tissue (Chapter 3), 
therefore it is likely that lamellar tissue marimastat concentrations following RLP are higher 
than the LUF[M] reported in this study. A key concern with ultrafiltration is whether drug 
recovery remains constant with time or is affected by the tissue response to the ultrafiltration 
probes (Barza and Cuchural 1985; Wisniewski et al. 2001). Histologic findings in this study 
support those in previous reports, with mild inflammation and fibrous tissue formation 
around the probes (Chapters 3 & 4). The previously reported consistency of marimastat and 
biochemical analyte concentrations over a 48-96 h period suggests marimastat recovery and 
probe function are stable in the face of these histologic changes (Chapters 3 & 4). The lack of 
any significant temporal variations in LUF glucose, urea and electrolyte concentrations in this 
study provides further evidence that the local inflammation and fibrous tissue had minimal 
effect on marimastat recovery during the time period studied (84 h).  
 
Limitations to this study include the small number of horses which necessitated the use of 
non-parametric analyses, potentially increasing the probability of type II error. In order to 
ensure sufficient LUF was collected at each time-point a minimum sampling interval of 1 
hour was used, which also facilitated the primary objectives of this study (comparison of 
LUF[M] and P[M] after RLP and SIVB).  However, this sampling interval is long compared to 
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the plasma half-life of marimastat and may have reduced the accuracy of the pharmacokinetic 
analyses (Gabrielsson and Weiner 2012). LUF[M] reported in this study were compared 
directly to P[M]. In reality, LUF[M] reflect the average concentration over the sampling period, 
whilst P[M] reflect a single time-point at the end of the sampling period. Therefore P[M] are 
comparatively underestimated. However, LUF[M] after RLP were also higher than those in 
plasma at the preceding time-point (Figure 4.1B).  
 
In conclusion, this study demonstrates that RLP results in high lamellar marimastat 
concentrations, potentially sufficient to inhibit MMP activity in vivo. RLP therefore has 
potential for local lamellar delivery of pharmaceuticals to prevent laminitis. RLP every 6 
hours is required to ensure LUF[M] are for >IC90 for MMP-2 and MMP-9 and >6 x the IC50 for 
MMP-14 and ADAMTS-4. Whilst not ideal for the clinical application this is reasonable for 
experimentally investigating the efficacy of marimastat for laminitis prevention. Further 
studies would then be necessary to optimise dosing and delivery prior to clinical application.   
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Part III discussion 
 
Further validation of ultrafiltration was key to the success of this section. The consistent 
biochemical analyte concentrations in LUF, high in vitro marimastat recovery, lack of 
variation in marimastat concentrations during SIVB and lack of any correlation between 
histologic score, LUF[M], and biochemical analyte concentrations in Chapters Three and Four  
suggested recovery was consistent over the time-period examined and was not affected by 
host tissue response. These observations provided confidence that the LUF[M] obtained in 
these studies closely reflected tissue concentrations.     
 
The next step was to establish the concentrations of marimastat necessary to inhibit lamellar 
MMP-2 and -9, in order to set target concentrations to be met by each of the delivery 
techniques. Zymographic assays using homogenised lamellar tissue from horses with OF-
induced laminitis enabled basic pharmacodynamic analyses. Although, as described in 
Chapters 3 and 8, in vitro inhibitory profiles do not extrapolate directly to in vivo situations, 
the assay used in Chapter 3 (a homogenate based assay using diseased tissue) most closely 
approximated the in vivo situation. Using the IC90 values as a target in vivo concentration, or 
six times the IC50 when IC90 values are unavailable, is a well-documented and accepted 
extrapolation (Nemunaitis, Poole et al. 1998; Lees, Cunningham et al. 2004; Shu, Zhou et al. 
2011), hence this framework was applied throughout this work. 
 
Neither of the systemic delivery methods (SIVB and CRI) yielded sustained lamellar 
marimastat concentrations considered sufficient to inhibit lamellar MMPs in vivo. 
Pharmacokinetic parameters for marimastat after SIVB were similar to those previously 
reported (Pass and Pollitt, unpublished data), with rapid clearance and a short (0.9 h) plasma 
half-life. Although, technically, the quantities of marimastat administered systemically could 
be increased to a level at which target lamellar concentrations are achieved, this is an 
inefficient method of lamellar drug delivery and is likely to be precluded by cost. In contrast, 
RLP with the same marimastat dose as SIVB, resulted in a higher AUC than SIVB (72,532 
ng.h/mL vs. 399 ng.h/mL) consistent with efficient lamellar drug delivery.  
 
In contrast to a previous report (Nourian, Mills et al. 2010), IOIDP did not consistently result 
in successful local lamellar delivery, therefore the second hypothesis of this thesis was 
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rejected. Close evaluation of the data revealed that in two of the five horses some local 
delivery effect was achieved, with steady-state concentrations sufficient to inhibit at least 
90% of lamellar MMP-2 and MMP-9 (512 [469-866] ng/mL, Chapter 3). An explanation for 
the apparent success in two horses, but concurrent failure in three others was not established, 
hence further investigations are required to establish its cause and determine whether this 
variability extends into a larger population. The over-arching aim of this research was to 
establish a delivery method applicable to the experimental setting for evaluating the efficacy 
of candidate ALDs. In this setting, it is essential that the delivery technique reliably achieves 
target lamellar drug concentrations; at this stage the variability in efficacy of IOIDP 
eliminated it from further consideration.  
 
RLP also demonstrated inter-horse variability, however, LUF[M] after RLP were greater than 
target concentrations considered necessary for in vivo inhibition in all horses for at least six 
hours and maximum LUF[M] were over 300 times target concentrations. Therefore RLP every 
six hours should reliably achieve marimastat concentrations considered necessary for in vivo 
inhibition of lamellar MMPs and the third hypothesis of this thesis (that RLP with marimastat 
results in higher lamellar marimastat concentrations than SIVB) was accepted. Even if IOIDP 
was optimised so steady state LUF[M]  were consistently equivalent to those in the two 
successful horses (512 ng/mL), for six hours of delivery this would require a greater 
marimastat dose (189 mg vs 103 mg) and result in a lower LUF AUC than RLP (3264 
ng.h/mL vs 72,089 ng.h/mL respectively). Therefore RLP appeared to be the more efficient 
technique for lamellar marimastat delivery. Based on this, RLP paired with lamellar 
ultrafiltration to confirm marimastat concentrations, was deemed the most suitable 
framework for application in experimental trials investigating the efficacy of marimastat in 
preventing laminitis. 
 
This section focused on the regional delivery techniques of IOIDP and RLP. Other regional 
delivery techniques, such as intra-arterial perfusion (with or without tourniquet), topical 
application and local injection into the tissue are available (Collins 1984) and may be 
amenable to adaption for lamellar drug delivery. In planning this work, IOIDP and RLP were 
considered most practical and most likely to succeed. Therefore, due to the apparent success 
of RLP along with time and financial constraints further techniques were not investigated. 
 
98 
 
An important consideration with pharmacologic investigations is that the pharmacokinetics of 
different drugs will vary depending on their physico-chemical properties. Therefore, although 
it is probable that RLP would result in high lamellar concentration of other potential ALDs, 
preliminary studies establishing their pharmacokinetics and recovery via ultrafiltration would 
be necessary to optimise dosing regimens prior to evaluation of their efficacy in experimental 
laminitis models. 
 
Overall, the results of Part III indicated that RLP, with concurrent ultrafiltration, was a 
suitable framework to investigate the efficacy of potential laminitis prophylactics. Based on 
the pharmacokinetic data obtained in this section, RLP needed to be repeated every six hours 
to ensure lamellar marimastat concentrations were above those considered necessary to 
inhibit lamellar MMPs. The next step was to investigate the practicality of applying this 
framework, including the 6 hourly dosing interval, to an experimental model of laminitis for 
evaluation of candidate ALDs. 
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PART IV: EVALUATING THE APPLICABILITY OF REGIONAL 
DELIVERY DURING EXPERIMENTALLY INDUCED LAMINITIS 
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Part IV introduction 
 
In part III RLP with concurrent ultrafiltration was identified as the optimal regional delivery 
technique. Part IV tests the fourth hypothesis in this thesis; that RLP and ultrafiltration could 
be applied to the oligofructose model of laminitis to evaluate of the efficacy of potential anti-
laminitis drugs (ALDs). In doing this the ability of marimastat to prevent oligofructose-
induced laminitis was investigated. In order to accept this hypothesis the following objectives 
were set: 
1) To perform repeated RLP throughout the experimental period in order to achieve 
target marimastat concentrations 
2) To collect sufficient LUF for analysis of marimastat concentrations by UPLC 
3) To achieve marimastat concentrations greater than the those considered necessary for 
in vivo inhibition of lamellar MMPs 
4) To evaluate the severity of laminitis pathology histologically 
 
In addressing these objectives, this section completed the final stage of the project and 
determined whether RLP and ultrafiltration were a suitable investigative model for evaluation 
of candidate ALDs. 
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Chapter 5: Regional delivery of marimastat during oligofructose-
induced laminitis development has minimal effect on lesion 
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5.1 Abstract 
Reasons for performing study: Proteolytic enzyme activation has been implicated in 
laminitis pathophysiology. The MMP inhibitor marimastat prevents in vitro lamellar 
separation caused by MMP-activation yet its in vivo efficacy remains unknown.  
Objectives: To determine whether regional limb perfusion (RLP) with marimastat prevents 
oligofructose-induced laminitis, and establish the suitability of RLP and lamellar 
ultrafiltration as a model for assessing pharmaceutical laminitis treatments.  
Study Design: Randomised, controlled, blinded experimental trial. 
Methods: Twelve horses underwent experimental laminitis induction using the oligofructose 
model. Six treatment horses received 140 mg marimastat six-hourly via RLP whilst six 
control horses received saline. Plasma and lamellar ultrafiltrate (LUF) were collected and 
analysed for marimastat concentrations. Sections of dorsal lamellae (proximal, middle and 
distal from each foot) were harvested 48 h after oligofructose administration, stained with 
H&E and PAS, randomized and coded for blinded histological analysis. The severity of 
laminitis pathology was scored (0 [normal] to 4 [severe]). 
Results: LUF marimastat concentrations in treated limbs were > IC90 MMP-2, MMP-9 and > 
six times the IC50 MMP14 and ADAMTS-4 at all time-points. All horses developed 
histologic evidence of laminitis. There was no difference in median histologic scores between 
treatment and control horses, nor between feet receiving marimastat by RLP compared to feet 
receiving placebo by RLP. However, significantly fewer (5%) of sections from marimastat-
treated horses received a histologic score of 4, compared to control horses (42% of sections 
scored a 4, P=0.009).  
Conclusions: RLP with concurrent ultrafiltration successfully delivered marimastat and 
confirmed target marimastat concentrations. Marimastat did not prevent laminitis pathology 
in the oligofructose model, but may have reduced its severity.  
Potential relevance: The results suggest that proteases within the inhibitory spectrum of 
marimastat are not the key factor initiating laminitis pathology. The investigative model used 
may be suitable for evaluating other locally acting pharmaceuticals for laminitis. 
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5.2 Introduction 
Laminitis has puzzled researchers and crippled horses for decades yet there are no 
experimentally validated pharmacologic means of successfully preventing the disease. 
Laminitis pathology is irreversible so prophylaxis is paramount. Several key steps in laminitis 
pathophysiology have been elucidated, resulting in identification of drugs that may prevent 
laminitis (anti-laminitis drugs (ALDs)). Potential therapeutic targets involved in sepsis-
related laminitis include inflammation (Belknap, Giguere et al. 2007; Leise, Faleiros et al. 
2011; Visser and Pollitt 2011; Leise, Watts et al. 2012; Tadros, Frank et al. 2012), proteolytic 
enzyme activation (Pollitt, Pass et al. 1998; Visser and Pollitt 2012; Wang, Pawlak et al. 
2012) and destabilization of the laminar epidermal:dermal junction by Wnt-pathway 
dysregulation (Wang, Pawlak et al. 2013). Activation of a disintegrin and metalloproteinase 
with thrombospondin motifs (ADAMTS)-4 and matrix metalloproteinase (MMP)-1, MMP-2, 
MMP-9, MMP-13 and MMP-14, have been implicated in laminitis pathophysiology (Pollitt 
et al. 1998; Visser and Pollitt 2012; Wang et al. 2012, Wang et al. 2014). The broad spectrum 
MMP inhibitor marimastat inhibits these enzymes and may prevent laminitis development 
(Pollitt et al. 1998; Tortorella et al. 2009).  
 
Marimastat is a synthetic, low molecular weight, peptidomimetic inhibitor that binds to the 
Zn2+ ion at the active site of MMPs (Millar et al. 1998; Barlaam et al. 1999). It has been used 
in multiple oncologic clinical trials (Rosenbaum et al. 2005; Levin et al. 2006), has anti-
inflammatory properties (Bruce and Thomas 2005; Nenan et al. 2007) and protects against 
ischaemia reperfusion injury (Novak et al. 2010). Marimastat’s anti-inflammatory properties 
may also reduce inflammation involved in the pathogenesis of laminitis, adding to its 
potential as an ALD. 
 
Marimastat is impractical for systemic administration in horses due to expense, systemic side 
effects (Peterson 2006), lack of oral bioavailability and rapid clearance after intravenous 
administration (Chapter 4, Barlaam et al. 1999, Levin et al. 2006). In normal horses, regional 
retrograde intravenous limb perfusion (RLP) with marimastat yields lamellar marimastat 
concentrations considered sufficient to inhibit MMP activity in vivo (Chapter 4). The 
combination of RLP and lamellar ultrafiltration provide an investigative model for delivering 
marimastat to lamellar tissue and confirming target concentrations, but this has yet to be 
applied during laminitis induction. The objectives of this study were to evaluate whether 
104 
 
marimastat prevents oligofructose-induced laminitis, and to establish the suitability of RLP 
with concurrent lamellar ultrafiltration as a model for assessing candidate ALDs. 
 
5.3 Methods 
The project was approved by the University of Queensland Animal Ethics Committee 
(approval number: SVS/418/12) that monitors compliance with the Animal Welfare Act 
(2001) and the Code of Practice for the care and use of animals for scientific purposes 
(current edition). All animals were monitored continuously by the investigators. 
 
5.3.1 Animals, laminitis induction and monitoring procedures 
Twelve mature Standardbred horses (10 geldings, 2 mares; aged 4-12 years, 383-538 kg bwt), 
with no lameness and no gross nor radiographic foot abnormalities were housed and fed in 
stables for 4 weeks prior to the experiment. The horses received no medications for 1 month 
prior to the study. Laminitis induction was by alimentary overload with OF, as previously 
described (van Eps and Pollitt 2006). Oligofructose administration was considered time zero. 
Immediately after nasogastric administration of the bolus dose (10 g/kg bwt of OF, up to a 
maximum dose of 4.2 kg), each horse was confined to stocks for the remainder of the 
experiment. Heart rate, respiratory rate and temperature were recorded every two hours. 
Human  pedometer devices (Yamax digiwalker sw700, Yamasa Tokei Keiki Co.) were taped 
onto the antebrachium of both forelimbs to provide data on frequency of weight shifting as 
previously described (van Eps et al. 2012). The total pedometer readings were recorded 
bihourly, and the pedometers were then reset. 
 
Upon first recognition of weight shifting associated with foot pain (Obel grade I lameness), 8 
mg/kg phenylbutazone (Phenylarthrite, Ausrichter) was administered IV and subsequently 
administered every 12 hours for the remainder of the study. If further pain relief was 
required, supplementary perineural anaesthesia of the palmar digital nerves was performed 
using 5 mL 2% mepivicaine (Ilium Vetacaine, Troy Laboratories) per site. 
 
At 48 h after administration of oligofructose (or earlier if comfort was not maintained using 
the above analgesic protocol), each horse was euthanased with pentobarbital sodium 
(Lethabarb, Virbac Animal Health, 20 mg/kg bwt i.v.). Lamellar tissue (including proximal, 
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middle and distal sections) was collected for histologic, zymographic and pharmacokinetic 
analyses. 
 
5.3.2 Ultrafiltration probe placement 
Six hours prior to oligofructose (OF) administration, ultrafiltration probes were placed in 
both front feet of marimastat treated horses and the limb receiving placebo RLP in control 
horses to sample lamellar interstitial fluid as lamellar ultrafiltrate (LUF). Sterile, custom-
made 3-8 ultrafiltration probes (BASi) were placed in the lamellar region under perineural 
analgesia as previously described (Chapter 2, Appendix 2). After probe placement the 
ultrafiltration tubing was cut to a length of 30 cm from the probe and then connected to a 3 
mL glass vacutainer for continuous collection throughout the study. 
 
5.3.3 Regional limb perfusion 
Twenty-gauge, 2.8 cm catheters (Terumo) were placed in the lateral palmar digital vein at the 
level of the pastern in one randomly assigned limb on all horses under perineural analgesia (3 
mL 2% mepivacaine injected around the lateral palmar digital nerve at the level of the 
metacarpophalangeal joint). A 75 cm extension set was connected to the catheter and taped to 
the metacarpus. Catheters were flushed bihourly with heparinised saline. 
 
Horses were randomly assigned to marimastat-treated and control groups and were kept in 
pairs during the experiments (one marimastat-treated, one control horse). Treatment horses 
received RLP with 40 mL of 10 mM sterile marimastat solution (total dose 140 mg) every six 
hours. This dosing regime was based on the maximal solubility of marimastat in water (10 
mM), the maximum volume (40 mL) estimated safe to infuse via RLP at the level of the 
pastern, and the minimum time after RLP that LUF marimastat concentrations (LUF[M]) 
exceed the level considered necessary to inhibit lamellar proteases in vivo (Chapter 4). 
Control horses received 40 mL 0.9% sterile saline. RLP was performed using peri-neural 
anaesthesia in the standing sedated horse as previously described (Chapter 4) (Parra-Sanchez, 
Lugo et al. 2006; Kelmer, Bell et al. 2013). The tourniquet was kept in place for 45 minutes 
following the injection.  
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5.3.4 Sample collection 
In limbs receiving marimastat by RLP (RLP-M limbs), LUF was collected at 2, 4 and 6 h 
after each RLP. In the contralateral limb of marimastat dosed horses (non-RLP-M limbs) and 
limbs receiving RLP with placebo in control horses (RLP-C limbs), LUF was collected for 6 
h after each RLP. LUF samples were collected by replacing the plain glass vacutainer tubes 
which provided continuous suction on the ultrafiltration probes. Whole blood samples were 
collected into heparinised tubes every 2 h in treatment and control horses via a 16 G IV 
catheter (AngioCath, BD) placed aseptically in the right jugular vein. Blood samples were 
immediately centrifuged (14,310 g, 10 minutes) and plasma was separated. All samples were 
stored at -80 ⁰C prior to analysis.   
 
5.3.5 Sample preparation and analysis 
Marimastat was detected in plasma, lamellar tissue and LUF using UPLC-MS on a Nexera 
UPLC coupled with a LCMS-8030 triple quadruple mass spectrometer (Shimadzu) as 
described previously (Chapter 3). All reagents were of LC-MS grade. All LUF samples were 
analysed. Only plasma samples collected between 0-12 h post-OF administration were 
analysed. An acid extraction method was used as previously described (Chapter 3). 
Calibration and quality control samples were obtained by spiking the blank matrix (LUF, 
tissue or plasma) with known amounts of marimastat prior to extraction. A new calibration 
curve was prepared for each day’s analysis.  
 
To monitor probe function, the concentrations of biochemical analytes (urea, glucose, 
sodium, chloride and potassium) were measured in LUF and plasma using a Beckman 
Coulter AU400 biochemistry analyser (Beckman Coulter) as previously described (Chapter 
3). Biochemical analytes were measured in LUF collected prior to OF administration 
(baseline) and 36-48 h after OF administration, and in plasma collected immediately prior to 
OF administration (baseline) and at 42 h after OF administration.   
 
Formalin-fixed lamellar tissue was processed by routine paraffin embedding, sectioned at 4 
µm, stained with H&E and PAS, randomized and coded for histological analysis performed 
by 2 blinded observers (AWVE & CCP). The severity of laminitis pathology was scored for 
each section using a system based on the 0-4 scale described by Pollitt(Pollitt 1996) and van 
Eps(van Eps, Pollitt et al. 2013). 
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5.3.6 Data analyses 
The average LUF[M]  (LUF[M]av) was calculated for each perfusion in RLP-M limbs. LUF[M]av 
in non-RLP-M limbs was considered to be the marimastat concentration in the single LUF 
sample collected following each perfusion. Marimastat inhibits equine lamellar MMP-2 and 
MMP-9 with IC90s of 177 ng/mL and 81 ng/mL respectively (Chapter 3). These values were 
used to calculate the following pharmacokinetic-pharmacodynamic indices for MMP-2 and 
MMP-9: time LUF[M]av > IC90,  LUF[M]av in RLP-M limbs:IC90,  maximum LUF[M]  in RLP-M 
limbs: IC90 and average LUF[M]av in non-RLP-M limbs: IC90. Marimastat inhibits human 
MMP-14 and ADAMTS-4 with IC50 values of 0.5 ng/mL and 26.1 ng/mL, respectively 
(Peterson 2006; Tortorella et al. 2009). These values were used to calculate the following 
pharmacokinetic-pharmacodynamic indices for MMP-14 and ADAMTS-4; time LUF[M] > six 
times IC50,   LUF[M]av in RLP-M limbs: six times IC50,  maximum LUF[M]  in RLP-M limbs: 
six times IC50 and average LUF[M]av in non-RLP-M limbs: six times IC50.   
 
Data were analysed using GraphPad Prism (GraphPad Software Inc.). The data were tested 
for normality using D’Agostino-Pearson omnibus K2 normality tests. Data distributions were 
either non-Gaussian, or data numbers were too small to presume a normal distribution, hence 
non-parametric tests were used. Paired data were compared by Wilcoxon signed-rank tests, 
and non-paired data by Mann-Whitney tests. Comparisons of repeated measures were 
analysed using Friedman analyses with Dunn’s post-tests. A Fisher’s exact test was used to 
establish whether the number of histologic sections scored 4 (complete separation) was 
greater in control versus marimastat-treated horses. Significance was set at P≤0.05. Unless 
otherwise stated, data are expressed as median [interquartile range]. Spearman’s rank 
correlation coefficients (rs) were calculated to examine the association between LUF[M] and 
histologic score, LUF collection rate and  biochemical analyte concentrations.  Data were 
also examined visually. A weak correlation was defined as being significant (P<0.05) with an 
rs <0.4, moderate 0.4–0.7, and strong >0.7 (Taylor 1990). Inter-evaluator agreement for the 
histological grades was assessed using a weighted Kappa test. The Kappa statistic was 
interpreted based on the scale developed by Landis and Koch (Landis and Koch 1977). 
 
5.4 Results 
All horses developed diarrhoea between 7 and 14 h and lameness (Obel grade 3-4) by the end 
of the study. Two control horses developed clinical signs consistent with hypovolaemic 
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shock. Neither responded to intravenous fluid therapy, hence these horses were euthanased at 
24 and 32 h. Consequently, their data were excluded from comparisons between marimastat-
treated and control horses. The remaining horses began weight-shifting and received 
phenylbutazone between 18 and 22 h. The median time of euthanasia was 45[41.5-48] h. 
There was no significant difference in study duration between treatment and control horses. 
There were no significant differences in heart rate, respiratory rate or temperature between 
treatment and control horses (Figure 5.1). There were no significant differences in pedometer 
counts between any of the limbs studied (Figure 5.2). 
 
 
 
 
 
 
 
 
 
Figure 5.1: Temporal variations in clinical parameters (heart rate (A), respiratory rate 
(B) and temperature (C)) throughout the study. There were no significant differences 
between treatment (red circles) and control (blue triangles) horses. Significant differences 
compared to baseline are demarcated with an asterisk (P<0.002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Temporal variations in pedometer count frequency in: A) RLP-M (red 
circles) and RLP-C limbs (blue triangles) and B) non-RLP-M (red circles) and non-RLP-C 
(blue triangles) limbs. There were neither significant temporal differences in pedometer 
count frequency nor differences between limbs at each time-point. 
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The histologic scores between RLP-M and RLP-C, between RLP-M and non-RLP-M, and 
between RLP-C and  limbs not receiving RLP in control horses (non-RLP-C limbs) did not 
vary significantly in the different section levels nor when considering the median histologic 
score in each foot (Table 5.1 and Figure 5.3). The median histologic scores in each foot and 
the histologic scores of mid-lamellar sections in non-RLP-M limbs were lower than those in 
non-RLP-C limbs (P=0.03). There were no significant differences between the median 
histologic score in horses treated with marimastat (2.9 [2.4-3]) compared to the median 
histologic scores in control horses (3.4 [2.8-4.0]) (Figure 5.4). However, significantly fewer 
(5%) sections from marimastat horses received a histologic score of 4, compared to control 
horses (42% of sections scored a 4, P=0.009). There was no significant correlation between 
LUF[M] and histologic score. The weighted kappa statistic for the blinded evaluators was 0.63 
(substantial agreement).  
 
Table 5.1: Median histologic scores at each section level in the limbs receiving 
marimastat by RLP (RLP-M), the non-RLP limbs in marimastat treated horses (non-
RLP-M), the limbs receiving saline by RLP in control horses (RLP-C) and the non-RLP 
limbs in control horses (non-RLP-C). There was a significant difference between middle 
sections in non-RLP-M and non-RLP-C limbs (P=0.03).  
Section Level RLP-M  RLP-C Non-RLP-M Non-RLP-C 
Proximal 3.0[2.9-3.3] 3.5[3.0-4.0] 3.0[2.9-3.3] 4.0[3.25-4.0] 
Middle 3.0[2.4-3.0] 3.25[2.5-4.0] 2.5[2.0-3.0]* 3.5[3.0-4.0]* 
Distal 2.5[2.4-3.0] 2.3[0.9-2.9] 2.0[1.1-3.0] 2.5[2.2-3.6] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Median histologic scores in limbs receiving marimastat by RLP (RLP-M), 
non-RLP limbs in marimastat treated horses (non-RLP-M), limbs receiving saline by 
RLP in control horses (RLP-C) and non-RLP limbs in control horses (non-RLP-C). 
Median histologic scores were lower in non-RLP-M feet compared to non-RLP-C feet 
(P=0.03). 
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Figure 5.4: Median histologic scores in each horse.  
 
RLPs were performed at six-hourly intervals on all horses, with a median of seven perfusions 
per horse. One digital vein catheter failed during the experiment; subsequent perfusions in 
this horse were performed using a 25 G winged infusion needle. Baseline marimastat 
concentrations and LUF and plasma marimastat concentrations (P[M]) in control horses were 
below the limit of detection of the analytical method. Median LUF[M] at each time-point are 
shown in Figure 5.5A. Total median LUF[M] in RLP-M limbs (20.1 [8.5-46.7] µg/mL) were 
higher than those in non-RLP-M limbs (0.125 [0.079-0.215] µg/mL, P=0.03). LUF[M] in 
RLP-M limbs were higher than P[M] at each time-point analysed (Figure 5.5B, P<0.05). 
Tissue marimastat concentrations (T[M]) were higher in RLP-M limbs than non-RLP-M limbs 
(0.375 [0.296-1.309] ng/g vs. 0.213 [0.183-0.275] ng/g, respectively, P=0.03). There was no 
significant difference between T[M] and LUF[M] in non-RLP-M limbs, however LUF[M] were 
57[44-80]% of the corresponding T[M]. The within-horse coefficient of variation in maximum 
LUF[M] (collected 0-2 h after each RLP), was 35 [23-45]%. The inter-horse coefficient of 
variation in maximum LUF[M] was 95 [70-99]%. Pharmacokinetic-pharmacodynamic indices 
are summarised in Table 5.2. One horse reacted to the tourniquet during the first RLP 
performed, necessitating early tourniquet removal. As a result this horse had unusually low 
LUF[M] during this perfusion (1.9 µg/mL 0-2 h post RLP dropping to 0.164 µg/mL at 4-6 h 
post RIVI). Otherwise, all horses had LUF[M] greater than both the IC90 of MMP-9 and MMP-
2 and six times the IC50 of ADAMTS-4 and MMP-1, MMP-13 and MMP-14 at all time-
points throughout the study. There did not appear to be a large variation in (increase or 
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decrease) in LUF marimastat concentrations throughout the course of the study as a result of 
the underlying disease process (Figure 5.5) 
 
Table 5.2: Pharmacokinetic-pharmacodynamic indices estimated in this study ( RLP-M; 
limbs receiving marimastat by RLP, non-RLP-M limbs in marimastat treated horses not 
undergoing RLP, LUF[M]; lamellar ultrafiltrate marimastat concentration).Data are 
expressed as median [±IQR]  
 Maximum LUF[M]  
RLP-M limb 
Average LUF[M] 
RLP-M limb 
Average LUF[M] 
non-RLP-M limb 
Ratio to IC90 MMP-9 398 [290-632] 168 [145-208] 1.0 [0.7-1.7] 
Ratio to IC90 MMP-2 981 [665-1381] 368 [316-454] 2.2 [1.5-3.7] 
Ratio to 6 x IC50 MMP-14 26,474 [17,942-
37,299] 
9,931 [8,535-
12,252] 
60 [41-99] 
Ratio to 6 x IC50 ADAMTS-4 509 [345-717] 191 [164-236] 1.2[0.8-1.9] 
Percentage of time > IC90 MMP-9 (%) - 100 [99-100] 26 [11-52] 
Percentage of time > IC90 MMP-2 (%) - 100 [100-100] 100 [47-100] 
Percentage of time >6 x IC50 MMP-14 
(%) 
- 100 [100-100] 100 [100-100] 
Percentage of time > 6 x IC50 
ADAMTS-4 (%) 
- 100 [100-100] 27 [19-71] 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: (A) Median lamellar ultrafiltrate marimastat concentrations (LUF[M]) in 
RLP-M (red circles) and non-RLP-M limbs (blue triangles). The hashed black line 
denotes the marimastat concentration considered necessary for inhibition of MMP-9, MMP-
2, MMP-14 and ADAMTS-4 in vivo. (B) Median LUF[M] and plasma marimastat 
concentrations (P[M]) in the first 12 h of the study. LUF[M] were higher than P[M] at all time-
points analysed (P<0.05).  
 
LUF was collected from all probes at a rate of 47 [33-57] µL/h. There was no significant 
difference between LUF collection rate in RLP-M limbs compared to non-RLP-M and RLP-
C limbs. There were no significant correlations between LUF collection rate and LUF[M]. 
Plasma and LUF urea and potassium concentrations were higher 36-48 h after OF 
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administration when compared to baseline (Figure 5.6, P<0.03). LUF sodium concentrations 
at 36-42 h were lower than baseline (P=0.002), although there was no significant change in 
plasma sodium concentrations. Plasma glucose concentrations were higher at 36-42 h 
compared to baseline (P=0.03), but there was no significant change in LUF glucose 
concentrations. There were no significant changes in either LUF or plasma chloride 
concentrations. LUF chloride concentrations were higher than plasma chloride concentrations 
at both time-points (P<0.05), but there were no significant differences between the LUF and 
plasma concentrations of other biochemical analytes. There were no significant correlations 
between biochemical analyte concentrations and LUF[M].  
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Figure 5.6: Lamellar ultrafiltrate (LUF) and plasma urea (A), sodium (B), potassium 
(C), glucose (D) and chloride (E) concentrations during the study. Significant differences 
between LUF analytes at baseline and at 36-48 h are denoted by ^, significant differences 
between plasma analytes at baseline and at 36-48 h are denoted by *. 
 
5.5 Discussion  
Lamellar marimastat concentrations, measured using ultrafiltration, were greater than those 
considered necessary to inhibit lamellar MMPs. The combination of RLP and lamellar 
ultrafiltration is a successful model for evaluating the efficacy of pharmaceutical therapies 
during laminitis induction. In the face of adequate marimastat concentrations, all horses 
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developed lameness consistent with laminitis. All horses developed histologic changes 
consistent with laminitis resulting in a median histologic score in RLP-M limbs of 3.0. In 
comparison, digital hypothermia initiated at the onset of lameness results in a dramatic 
reduction in the severity of the laminitis pathology (median histologic score of 0.75 in treated 
limbs compared to 2.8 in controls, (van Eps et al. 2013)). Despite the lack of a significant 
difference in median histologic scores in marimastat-treated vs. control horses, there did 
appear to be a mild reduction in laminitis severity in marimastat treated-horses, with 
significantly fewer sections exhibiting complete separation of lamellar epidermis from dermis 
(score 4). Therefore marimastat may be of some benefit in combination with drugs that target 
other laminitis pathways. Further investigation using a larger number of horses would be 
necessary to confirm this relationship and establish whether the observed subtle differences in 
median histologic scores were due to chance. 
 
Demonstrating in vivo MMP-inhibition is challenging (Peterson 2006), hence the exact 
marimastat concentrations required to inhibit lamellar MMPs in vivo are unknown. LUF[M] in 
RLP-M limbs were above the target values considered necessary to inhibit MMP-1,MMP-9, 
MMP-2, MMP-13, MMP-14 and ADAMTS-4 in vivo (Chapter 3). The target values in this 
study were based on the concentrations of marimastat required to inhibit lamellar MMPs in 
vitro along with recommendations from clinical and pre-clinical trials of marimastat and 
enzymatic inhibitors in other species (Chapter 3, Millar et al. 1998; Lees et al. 2004; Shu et 
al. 2011). It is possible the marimastat concentrations required for inhibition of lamellar 
MMPs were underestimated. However, the LUF[M] achieved in RLP-M limbs in this study 
not only exceeded the target concentrations, but did so to such an extent (median LUF[M] 
>150 times IC90) that a failure of in vivo inhibition seems unlikely. 
 
Assuming lamellar MMPs were successfully inhibited, the negligible effect of marimastat in 
preventing laminitis pathology suggests the spectrum of proteolytic enzymes inhibited by 
marimastat is not critical to laminitis development and progression within the experimental 
time-period (48 h). This is consistent with the findings of Visser (Visser 2009), whose 
investigations showed little activation of MMP-2, -7, -10, -11 and -14 at the initiation of 
basement membrane pathology. However, the mild reduction in laminitis pathology in 
marimastat-treated horses during the current study suggests proteolytic enzyme activation 
may exacerbate the laminitis lesion. Inflammation has also been implicated in laminitis 
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pathophysiology (Belknap et al. 2007; Visser 2009; Leise et al. 2011). Marimastat has anti-
inflammatory properties based on its ability to inhibit MMP-9, MMP-12 and tumour-necrosis 
factor alpha converting enzyme (TACE) (Barlaam et al. 1999; Nenan et al. 2007). Frequently, 
however, this inhibitory activity does not translate into reduced cytokine or adhesion 
molecule expression nor any clinical effect (Corbel et al. 2001; Tsuji et al. 2002; Birrell et al. 
2006). Therefore, even though LUF[M] in RLP-M limbs were considered sufficient to inhibit 
TACE (Barlaam et al. 1999), further investigations are necessary to establish whether this 
translated into lower levels of lamellar inflammatory cytokines and establish whether 
laminitis developed in the face of reduced inflammation.  
 
This is the first study to investigate the ability of a locally delivered pharmaceutical to 
prevent laminitis. The investigative model used (RLP with concurrent measurement of LUF 
drug concentrations) successfully delivered and quantified marimastat concentrations in 
lamellar tissue and may have application in experimental studies investigating the efficacy of 
other candidate ALDs. Histologic analysis of lamellar sections provides a quantitative 
measure of effect. Pharmacokinetic-pharmacodynamic modelling was precluded in this study 
by a lack of effect, but could be performed using this model once a successful laminitis 
prophylactic is identified to establish a dose-effect relationship. Eighty-five of the 86 RLPs 
were completed successfully. In the one unsuccessful perfusion, the horse appeared to have 
pain in the RLP limb. This was attributed to inadequate perineural anaesthesia and highlights 
the importance of ensuring effective analgesia prior to tourniquet placement. There was 
moderate within-horse and high inter-horse variation in maximum LUF[M] post-RLP. Similar 
variations in inter-horse tissue drug concentrations have been observed previously after RLP 
(Chapter Four, Murphey et al. 1999; Butt et al. 2001; Scheuch et al. 2002; Parra-Sanchez et 
al. 2006; Levine et al. 2009; Mahne et al. 2013), but within-horse variation has not been 
examined. The greater inter-horse compared to within-horse variation in LUF[M] suggests 
that, in addition to the usual factors of tourniquet placement, perfusate leakage and  
movement; inter-horse factors, such as variations in anatomy, also play a role in variations in 
tissue concentrations post-RLP.  
 
The concentrations of biochemical analytes in LUF were measured to evaluate probe 
function. The lack of correlation between LUF[M] and biochemical analyte concentrations 
suggests variations in LUF[M] were real and not a result of varying degrees of substance 
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recovery in different probes. In previous studies using normal horses, consistent biochemical 
analyte concentrations over time indicated consistent substance recovery for up to 96 h 
(Chapters Two, Three and Four).  In the present study the LUF sodium, urea and potassium 
concentrations varied with time. These variations reflected those occurring in plasma and 
hence were attributed to systemic biochemical changes rather than true variations in 
ultrafiltration substance recovery. Changes in LUF glucose concentrations did not reflect 
those in plasma; further investigations are required to determine whether these changes were 
a result of altered recovery in LUF or real alterations in lamellar glucose concentrations 
associated with laminitis pathophysiology. LUF[M] were 57% of corresponding T[M] at 
euthanasia. As LUF[M]  reflects only the unbound marimastat concentrations in interstitial 
fluid, whereas T[M] reflect intra- and extracellular total marimastat concentrations, this is not 
unexpected and does not necessarily indicate poor probe function; but does suggest that 
LUF[M] are underestimations of T[M]. 
 
In conclusion, this study demonstrated that marimastat, at concentrations considered 
inhibitory for key proteases, had minimal preventive effect on OF induced laminitis 
development. RLP with concurrent lamellar ultrafiltration was a practical and successful 
technique for administering a locally active pharmaceutical in order to evaluate its ability to 
prevent experimental laminitis and could be used as an experimental model to evaluate other 
candidate ALDs. 
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Part IV discussion 
 
RLP successfully delivered marimastat to lamellar tissue, with lamellar marimastat 
concentrations well in excess of those considered necessary for in vivo MMP inhibition. 
Lamellar interstitial fluid was collected by ultrafiltration and used to confirm that target 
lamellar marimastat concentrations were achieved. RLP was performed every six hours 
without major complications. Therefore, the fourth hypothesis of the thesis was accepted and 
the investigative model of RLP with lamellar ultrafiltration was deemed suitable for 
evaluating the efficacy of candidate ALDs. This framework may be useful for the testing 
other potential laminitis prophylactics such as chemokine receptor antagonists, STAT3 
inhibitors and Wnt-pathway agonsits (Faleiros et al., 2009; Leise et al., 2012; Wang et al., 
2013).  
 
Despite achieving lamellar marimastat concentrations considered inhibitory for the 
proteinases known to be associated with laminitis, marimastat failed to prevent clinical and 
histologic laminitis development. As discussed in Chapter five, this has interesting 
implications for laminitis pathophysiology. Further studies, investigating the degree of 
enzymatic and inflammatory mediator inhibition in marimastat treated limbs would provide 
valuable information on laminitis pathophysiology, but were beyond the scope of this work.  
 
As discussed in Chapter 2, one of the caveats of performing pharmacokinetic studies in 
normal animals is that tissue drug concentrations may be altered by inflammation and 
changes in vascular permeability occurring during the diseased state (Barza and Cuchural 
1985). In this study, LUF marimastat concentrations did not appear to vary from one 
perfusion to the next (Figure 5.5) in spite of the development of laminitis and accompanying 
inflammation and changes in vascular permeability, suggesting these had minimal effect on 
lamellar marimastat distribution.   
Unfortunately, as no in vivo effect was demonstrated, development of further 
pharmacokinetic-pharmacodynamic models to describe the dose response relationship was 
precluded. In a scenario where a successful ALD was trialled, the combination of RLP with 
lamellar ultrafiltration, along with a ranked assessment of in vivo efficacy (e.g. histologic 
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scores), would allow quantification of a dose-tissue, concentration-response relationship 
enabling precise optimisation of doses for clinical application. 
 
Once a successful ALD is identified, the delivery technique used for clinical application can 
be optimized, based on the pharmacokinetics of that drug. Detailed evaluation of the subtle 
clinical complications associated with RLP was not performed in Chapter Five as this was not 
a study objective. However, it is probable that in a clinical scenario six-hourly RLP would 
result in complications which may preclude continued dosing and result in treatment failure. 
Therefore investigation of alternative delivery techniques may be necessary for successful 
clinical application.  
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PART V: NANOPARTICLE FORMULATIONS FOR TARGETED 
LAMELLAR DRUG DELIVERY 
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Part V Introduction 
 
As indicated in Part IV it is quite probable that lamellar delivery techniques will need 
refining once a successful prophylactic is identified. The final hypothesis of this thesis was 
that a nanoparticle formulation would provide a clinically applicable means of achieving 
sustained marimastat concentrations in lamellar tissue. In Chapter Six, liposomes are used as 
an example of a passively targeted nanoparticle to determine whether they accumulate in 
lamellar tissue during laminitis development. Chapter Seven explores the loading of 
marimastat onto and development of nanoparticles specifically designed for active targeting 
of and sustained release to maximise lamellar drug delivery.    
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6.1 Abstract 
Liposomes are phospholipid nanoparticles used for targeted drug delivery. This study aimed 
to determine whether intravenous liposomes accumulate in lamellar tissue during laminitis 
development, to assess their potential for targeted lamellar drug delivery.  
    
PEG-liposomes were prepared according to the film hydration method and labelled using 
99mTc-hexamethyl-propylene-amine-oxime. Six horses received 10 g/kg oligofructose via 
nasogastric tube to induce laminitis. Four control horses received water via nasogastric tube. 
All horses received 300 µmol 99mTc-PEG-liposomes (5.5GBq) plus 5.5 µmol/kg PEG-
liposomes by slow intravenous infusion. Scintigraphic imaging was performed at 0, 6 and 12 
hours post-infusion. Radiopharmaceutical uptake was measured in regions of interest over the 
hoof, fetlock and metacarpus. At the study end-point horses were euthanized, tissue samples 
collected and tissue liposome levels were calculated as the percentage of the injected dose of 
99mTc-PEG-liposomes per kilogram of tissue. Data were analysed non-parametrically. 
   
All horses receiving oligofructose developed clinical and histologic signs of laminitis. 
Radiopharmaceutical uptake in the hoof increased with time in laminitis horses (P=0.04), but 
decreased with time in control horses (P=0.01). Liposome levels in lamellar tissue from 
laminitis horses was 3.2-fold higher than controls (P=0.02). Liposome levels were also higher 
in laminitis vs. control skin, muscle, jejunum, colon, and kidney (P<0.05). 
 
PEG-liposomes accumulate in lamellar tissue during oligofructose-induced laminitis 
development and demonstrate potential for targeted lamellar drug delivery in acute laminitis. 
This study provides further evidence that lamellar inflammation occurs during laminitis 
development. Liposome accumulation also occurred in the skin, muscle, jejunum, colon and 
kidneys, suggesting systemic inflammation in this model. 
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6.2 Introduction 
Acute laminitis is a crippling disease of the equine foot. Laminitis pathology is irreversible so 
prophylaxis is paramount. There are three broad aetiologic categories of laminitis 
(endocrinopathic, sepsis-related and supporting limb laminitis). Similar to sepsis-related 
organ failure in man, sepsis-related laminitis often results in the demise of the patient after 
successful treatment of the primary condition. Distal limb cryotherapy prevents sepsis-related 
laminitis (Van Eps and Pollitt 2004; van Eps et al. 2013); but it is labour-intensive and 
practically challenging.  
 
Potential therapeutic targets involved in the pathophysiology of sepsis-related laminitis have 
been identified.  These include inflammation (Belknap et al. 2007; Leise et al. 2011; Visser 
and Pollitt 2011; Leise et al. 2012; Tadros et al. 2012), proteolytic enzyme activation (Pollitt 
et al. 1998; Visser and Pollitt 2012; Wang et al. 2012) and Wnt-pathway dysregulation 
(Wang et al. 2013). Pharmaceuticals directed to address these targets are available and 
include non-steroidal anti-inflammatory drugs, corticosteroids, STAT3 inhibitors (Leise et al. 
2012), protease inhibitors (Pollitt et al. 1998; De Savi et al. 2011) and Wnt-pathway agonists 
(Wang et al. 2013). Evaluation of these substances for laminitis prophylaxis has been 
hindered by their unsuitability for systemic delivery due to cost, rapid clearance, low 
bioavailability, inability to achieve therapeutic tissue concentrations, unwanted systemic side 
effects and/ or degradation in the circulation (Levin et al. 2006; Nourian et al. 2010). Recent 
work has investigated methods of regional lamellar delivery (Nourian et al. 2010; Chapters 
Three and Four). Despite initial promising results (Nourian et al. 2010), intraosseous infusion 
of the distal phalanx does not consistently yield therapeutic lamellar drug concentrations 
(Chapter Three). Regional limb perfusion requires frequent dosing (of each limb separately) 
to maintain therapeutic concentrations (Chapter Four), so is not suitable for widespread 
clinical application. A means of lamellar drug delivery that provides sustained, therapeutic 
lamellar drug concentrations and has potential for clinical application is required. 
 
Nanoparticles are ordered structures used for targeted drug delivery.  They improve the 
therapeutic index and safety profile of the substances they carry (Cordeiro et al. 2000; 
Metselaar et al. 2003; Hofheinz et al. 2005; Rose et al. 2005). Nanoparticles also provide a 
means of sustained delivery over a period of days or even weeks (Sahoo and Labhasetwar 
2003; Bakker-Woudenberg et al. 2005; Fahmy et al. 2005). As a consequence, nanoparticle 
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formulations may require a reduced dose compared to free drug, thus reducing the cost of 
using expensive pharmaceuticals (Underwood and van Eps 2012).  
 
Liposomes are phospholipid nanoparticles that form highly flexible delivery systems with the 
ability to carry both hydrophilic and hydrophobic pharmaceuticals. Their safety and 
biodistribution has been established in normal horses (Underwood et al. 2012). Small 
polyethylene-glycol (PEG) coated liposomes are most suitable for targeted drug delivery after 
intravenous administration. After injection, a relatively small number of PEG-liposomes are 
endocytosed by macrophages. Those evading endocytosis remain in circulation for prolonged 
periods of time (Arulsudar et al. 2004). Together with their small size, these long-circulating 
characteristics confer the ability to extravasate at sites of increased vascular permeability and 
facilitate accumulation in the tissue around those sites (Laverman et al. 2001). This has been 
termed the enhanced permeability and retention (EPR) effect and is the underlying principle 
behind many passively targeted nanoparticle drug delivery systems.   
 
Increased vascular permeability occurs at sites of inflammation, and inflammation occurs 
during laminitis development (Belknap et al. 2007; Visser 2009; Faleiros et al. 2011; Tadros 
et al. 2012). Therefore, liposomes may accumulate in lamellar tissue during laminitis 
development and provide a means of targeted lamellar drug delivery. The objectives of this 
study were 1) to establish whether liposomes accumulate in the lamellar tissue during 
laminitis development in the oligofructose (OF) model of laminitis (a sepsis model), and 2) to 
establish the biodistribution of liposomes during sepsis in the OF model. In completing these 
objectives this is the first study to investigate the potential of nanoparticle delivery systems 
for lamellar drug delivery and also the first study to investigate the biodistribution of 
liposomes in an animal sepsis model. 
 
6.3 Materials and Methods 
The project was approved by the University of Queensland Animal Ethics Committee 
(approval number: SVS/117/11) that monitors compliance with the Animal Welfare Act 
(2001) and The Code of Practice for the care and use of animals for scientific purposes 
(current edition).   
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6.3.1 Animals and laminitis induction 
Ten mature Standardbred geldings (aged 4-11 years, 395-583 kg bwt), with no lameness and 
no gross nor radiographic abnormalities of the feet were enrolled in the study. The horses 
were housed and fed in stables for 4 weeks prior to the experiment as previously described 
(van Eps and Pollitt 2006). During the experiment the horses were housed in climate-
controlled, lead lined stalls and had ad libitum access to hay and water. Six horses (laminitis 
group) received alimentary overload with OF (bolus dose of 10 g/kg OF via nasogastric tube, 
up to a maximum dose of 4.2 kg) to induce laminitis as previously described (van Eps and 
Pollitt 2006). Four control horses (control group) received equivalent volumes of plain water 
by nasogastric tube. The horses were monitored 2 hourly throughout the study. Their heart 
rates, respiratory rates and temperatures were recorded every 6 hours. Upon onset of Obel 
grade 2 lameness, defined as lameness detectable at the walk (Obel 1948), a single dose of 
phenylbutazone (Phenylarthrite, Ausrichter Pty Ltd) was administered intravenously at 8 
mg/kg 
.   
 6.3.2 Liposome preparation 
Dipalmitoyl phosphatidylcholine (DPPC) and PEG-(2000)-distearoyl 
phosphatidylethanolamine (PEG-(2000)-DSPE) were obtained from Lipoid GmbH, 
cholesterol and glutathione (GS-H) were obtained from Sigma. All chemicals were of reagent 
grade. A chloroform/methanol mixture (10:1 volumetric ratio) containing DPPC, PEG-
(2000)-DSPE and cholesterol was prepared at a molar ratio of 1.85:0.15:1. A lipid film was 
formed by rotary evaporation followed by nitrogen flushing to remove residual organic 
solvent. The lipid film was dispersed at 50°C in 100 mmol/L GS-H in HEPES buffer (10 
mmol/l HEPES, 135 mmol/L NaCl, pH 7.5) at a total lipid concentration of 100 mmol/L. 
Empty liposomes were dispersed in HEPES buffer only. The liposomes were sequentially 
sized by extrusion using a high pressure extruder (Lipex) with polycarbonate filters of 200, 
100, 80 and 50 nm pore size (Whatman International Ltd). Unentrapped GS-H was removed 
by dialysis against HEPES buffer using Slide-A-Lyzer dialysis cassettes with a molecular 
cut-off of 10 kDa (Pierce). Finally, the liposomes were passed through a 0.2 mm sterile disc 
filter. The mean particle size was determined by dynamic light-scattering with an ALV CGS-
3 system (Malvern instruments Ltd). The liposomes had a mean size of 85 nm with a 
polydispersity index of 0.139. Phospholipid content was determined with a phosphate assay 
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(Fiske 1925; Rouser, Fkeischer et al. 1970). The final liposome preparations contained an 
average of 33.3 mg total lipid/mL. 
 
6.3.3 Radiolabelling of liposomes 
Preformed G-SH-PEG-liposomes were labelled by transporting 99mTc as a lipophilic 99mTc-
hexamethylpropylene-amine-oxime (HMPAO) complex through the lipid bilayer as described 
previously ((Underwood, AW et al. 2011). The 99mTc-HMPAO was irreversibly trapped in 
the internal aqueous phase due to reduction by the encapsulated G-SH (Oyen, Boerman et al. 
1996). For each dose, 8.5 GBq of 99mTc was incubated with 1 mg HMPAO (Ceretec, GE 
Healthcare). A dose calibrator (Atom Lab 400, Biodex) was used to measure the activity of 
liposomal and non-bound 99mTc-HMPAO to enable calculation of labelling efficiency.  
 
 6.3.4 Liposome administration and monitoring procedures.  
All horses received 300 µmol (phospholipid) 99mTc-PEG-liposomes and 5.5 µmol 
phospholipid/kg bwt unlabelled PEG-liposomes in 1 L 0.9% NaCl via an intravenous catheter 
into the left jugular vein. The dose was based on a previously reported liposome dosing 
regimen for equine scintigraphic studies (Underwood et al. 2011). Unlabelled liposomes were 
administered to increase the total phospholipid dose to a level above that at which rapid 
clearance is seen (Laverman, Brouwers et al. 2000). In the laminitis group 2 horses received 
liposomes immediately after OF administration (LAM-0), 2 horses received liposomes 12 h 
after OF administration (LAM-12) and 2 horses received liposomes 18 h after liposome 
administration (LAM-18).  The liposomes were infused slowly to avoid complement 
mediated hypersensitivity reactions (Szebeni 2005). Heart rate, respiratory rate and rectal 
temperature were monitored every 10 min for 60 min from the start of the infusion. 
 
6.3.5 Imaging Studies 
Scintigraphic examinations were performed in all horses at 1, 6 and 12 h after the start of the 
liposome infusion (p.i.) using a large field-of-view scintillation camera with a high resolution 
collimator (Technicare Omega 500 gamma camera, GE Healthcare) in a climate controlled 
lead-lined room. Scans were also performed at 18 and 24 h p.i. in the LAM-0 group. Post-
acquisition nuclear medicine software was used for image display and analysis (NuQuest 
v3.0 imaging software, MedX). Three minute static images of the dorsal and lateral aspects of 
both forefeet were acquired at each time point with the hooves positioned a set distance from 
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the camera. Images were stored in a 256 x 256 matrix. Images were analysed retrospectively 
by a blinded observer (CU), all measurements were performed in triplicate. The count density 
was established in regions of interest (ROI) over the hoof, fetlock, and metacarpus in each 
image. The count density per second (CD/s) was calculated, and corrected for both the decay 
and the total initial dose in each horse. The ratio of the count densities in the hoof and 
metacarpus (hoof: metcarpus) and the fetlock and metacarpus (fetlock: metacarpus) in each 
horse were calculated. Hoof wall surface temperature (HWST) was recorded before each 
examination using a hand-held infra-red scanner (Exergen Corporation). 
 
6.3.6 Liposome Biodistribution  
Blood samples were collected directly from the right jugular vein immediately following 
liposome infusion and at 6 and 12 h p.i. Blood radioactivity was measured on a shielded well 
scintillation gamma counter (Ludlum Instruments) and corrected for volume and decay to 
estimate the clearance of 99mTc-PEG-liposomes from the blood.  
 
At the end of the study (immediately following the 12 h scintigraphic examination in the 
LAM-12 and LAM-18 groups and the 24 h scintigraphic examination in the LAM-0 group) 
the horses were examined for lameness at the walk. Lameness was scored according to the 
Obel grading system (Obel 1948). The horses were euthanased with pentobarbital sodium (20 
mg/kg bwt i.v.).  Samples of lung, liver, spleen, kidney, jejunum, colon, forelimb lamellar 
tissue, muscle, skin and adipose tissue were dissected immediately following euthanasia. 
Samples were weighed and the activity of the sample (equivalent to the amount of 99mTc-
liposomes present in the sample (Phillips, Rudolph et al. 1992)) was measured using a 
shielded well scintillation gamma counter (Ludlum instruments). To correct for physical 
decay, an aliquot of the original injected dose was counted simultaneously. The results were 
expressed as percentage injected dose/kg of tissue (%ID/kg).  
 
6.3.7 Histological evaluation 
Dorsal lamellar sections from the forelimbs were fixed using 10% neutral buffered formalin, 
processed by routine paraffin embedding, sectioned at 4 µm and stained with H&E and PAS 
for light microscopy as previously described (Pollitt 1996). Histological analysis was 
performed by a blinded observer (AVE). The severity of laminitis pathology was scored for 
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each section using a system based on the 0-3 scale previously described by Pollitt (Pollitt 
1996). 
6.3.8 Data analyses 
Data were analysed using a statistical software package (Graphpad Prism 6). The data 
were tested for normality using D’Agostino-Pearson omnibus normality tests. Data 
distributions were either non-Gaussian, or group numbers were too small to presume a 
normal distribution, hence non-parametric tests were used. Non-paired data were compared 
by Mann U Whitney tests. Comparisons of repeated measured were analyused using 
Friedman alnayses with Dunn’s post-tests. For the analysis of scintigraphic data only data 
from the final 12 h of the LAM-0 group were used. Significance was set at P≤0.05. Unless 
otherwise stated, data are expressed as median [interquartile range]. 
 
6.4 Results 
All horses that received OF (the laminitis group) developed fever, diarrhoea and lameness 
(Obel grade 2-3). Median histological scores were significantly greater in the laminitis group 
(1.5[1-2]) compared to the control group (0[0-0.38], P=0.01).  
 
Radiolabelling efficiency was 82[63-90]% and the median activity of the 99mTc-liposomes 
immediately prior to infusion was 5.5[4.5-6.6] GBq. There was no difference in the median 
radioactivity of the 99mTc-liposomes administered to laminitis versus control horses (5.0[4.2-
6.8] GBq vs. 6.1[4.8-6.4] GBq respectively). Each horse received the full liposome dose and 
the median infusion time was 38[35-49] min. No adverse reactions were detected and there 
were no significant changes in heart rate, respiratory rate or temperature during the infusions 
(Appendix 3).  
 
Based on the radioactivity in sequential blood samples (corrected for decay), the 99mTc-
liposomes exhibited slow elimination from the circulation with a median half-life of 22.9[8.4-
32.4] h. There was no difference in the median half-life between the laminitis and control 
groups. There was a decrease in the blood radioactivity (corrected for decay) with time in the 
laminitis group (P<0.001, Figure 6.1). At 12 h p.i. the blood radioactivities in laminitis horses 
were lower than those in control horses (P=0.01, Figure 6.1).    
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Figure 6.1: Decay corrected radioactivity in sequential blood samples following 99mTc-
liposome infusion in laminitis (     ) and control (        ) horses. At 12 h p.i. the blood 
radioactivity in the laminitis group was lower than that in the control group (   , P=0.01), 
and lower than the activity immediately p.i. in the laminitis group (      , P=0.001). Data are 
expressed as median ± interquartile range. 
 
The scintigraphic images demonstrated subjective diffuse increased radiopharmaceutical 
uptake in the hoof and distal limb of laminitis horses compared to controls; evident at 6 h, 
and more marked at 12 h p.i. (Figure 6.2).  In the laminitis group the CD/s increased with 
time in the dorsal hoof and fetlock ROIs (P<0.01, Figure 6.3A and B). Conversely in control 
horses the CD/s in the dorsal hoof, fetlock and metacarpal ROIs decreased with time, and the 
CD/s in the lateral hoof ROI also decreased with time p.i (P<0.05, Figure 6.3 A-C). The CD/s 
in the lateral hoof ROIs were higher in laminitis horses compared to controls at 6 and 12 
hours p.i. (P=0.02, Figure 6.3D). The lateral hoof:metacarpal and fetlock:metacarpal CD/s 
ratios were higher in laminitis horses compared to controls at 12 h (1.9[1.8-2.0] vs. 1.5[1.4-
1.6] and 1.5[1.4-1.8] vs. 1.1[1.0-1.1] respectively, P=0.03). There was no change in HWST 
with time, nor any difference in HWST between laminitis and control horses at any time-
point. 
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Figure 6.2: Dorsal scintigraphic images from one of the control horses (A-C) and one of 
the laminitis horses (D-F) in the study. Images A&D were obtained at 1 h p.i., B&E at 6h 
p.i. and C&F at 12 h p.i. Images are corrected for acquisition time, decay and initial dose.  
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Figure 6.3: Variations in the median count density/s (CD/s) (± inter-quartile range), in 
scintigraphic ROIs, in laminitis (      ) and control (      ) horses over time. All data are 
corrected for decay and initial dose.  There was an increase in the CD/s in dorsal hoof (A) 
and dorsal fetlock (B) ROIs of laminitis horses (  ) and a decrease in the CD/s in the dorsal 
hoof (A) and fetlock (B) ROIs of control horses (   ), P<0.01. There was also a decrease in 
the CD/s of the dorsal metacarpal ROI (C) of control horses (  , P<0.01). The CD/s in the 
lateral hoof ROI (D) of control horses decreased with time, (P< 0.05, ) and was 
significantly lower than that in laminitis horses at 6 and 12 h p.i. (D,   , P=0.02). Data are 
expressed as median ± interquartile range. 
 
 The liposome levels in lamellar tissue of laminitis horses were higher than those in controls 
(0.21[0.14-0.3] %ID/kg vs. 0.065[0.06-0.11] %ID/kg respectively, P=0.019, Figure 6.4). 
Lamellar liposome levels were highest when the liposomes were administered at 18h p.i; with 
a 4.8 fold increase compared to control horses (Figure 6.5), however the numbers were too 
small for statistical analyses. There were increased liposome levels in the skin, muscle, 
jejunum, colon and kidney of laminitis horses compared to controls (P<0.05, Figure 6.4). 
There was a trend towards increased liposome levels in the liver of laminitis horses compared 
to controls, and towards decreased liposome levels in the blood of laminitis horses compared 
to controls (P=0.06, Figure 6.4).  
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Figure 6.4: The median liposome levels (expressed as %ID/kg) in various tissues in 
laminitis vs. control horses (    LAM-0      LAM-12,    LAM-18 and       control groups). 
The %ID/kg was higher in lamellae (A), skin (B), muscle (C), jejunum (D), colon (E) and 
kidney (F) of laminitis horses (P<0.05). There were trends towards an increased %ID/kg in 
the liver (G) and a decreased %ID/kg in the blood (H) of laminitis horses (P=0.06), an 
asterisk (*) denotes a statistically significant difference from control tissues. 
* * 
* * 
* * 
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Figure 6.5: Lamellar liposome levels appeared to increase when liposomes were 
administered at later time-points post-OF administration. Data are expressed as median 
± interquartile range. 
 
6.5 Discussion 
This study demonstrates that 99mTc-liposomes accumulate in the lamellar tissue during the 
development of sepsis-related laminitis in the OF experimental model. This conclusion is 
supported by both the scintigraphic imaging studies and the tissue biodistribution data. 
Previous studies have reported evidence of lamellar inflammation during laminitis 
development (Black et al. 2006; Belknap et al. 2007; Leise et al. 2011; Visser and Pollitt 
2011; Tadros et al. 2012).  The accumulation of liposomes in lamellar tissue provides further 
evidence that lamellar inflammation and increased vascular permeability occur during 
laminitis development in the OF model. 
 
The primary objective of this study was to evaluate whether liposomes accumulate in, and 
have potential for, targeted lamellar drug delivery. The increased lamellar liposome levels in 
laminitis horses at 12 h p.i indicates liposomal drug delivery systems have potential to yield 
sustained lamellar drug concentrations. Recent studies performed in our laboratory 
investigated lamellar marimastat concentrations after intravenous administration of 0.23 
mg/kg bwt (104 mg/450 kg horse, Chapter Four). If the same dose was administered in 
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liposomes at 18h post-OF, based on the lamellar liposome levels in the LAM18 group (0.31 
%ID/kg), the lamellar marimastat concentration would be 332 ng/g tissue at 12 h post 
injection. This tissue concentration exceeds both the concentrations achieved 12 h after RLP 
and the concentration necessary for inhibition of 90% of lamellar MMP-2 and MMP-9 
(Chapter Three). Additionally liposomes would probably continue to accumulate in the 
following 12h resulting in further increases in lamellar drug concentrations (Oyen et al. 1996; 
Boerman et al. 1997; Erdogan et al. 2000). There were no adverse reactions to liposome 
administration, and no changes in heart rate respiratory rate or temperature; adding to the 
evidence from previous studies (Underwood et al. 2012; Burton 2013) that slow intravenous 
liposome administration is safe in horses. Therefore, based on this preliminary study 
liposomes appear to have potential for lamellar drug delivery.  
 
The subjective increase in lamellar liposome levels between LAM-0, LAM-12 and LAM-18 
groups respectively suggests there is a temporal increase in lamellar inflammation post-OF 
administration, consistent with previous reports (Visser 2009). Liposomes were administered 
immediately following, then at 12 and 18 h after OF administration to achieve high 
circulating liposome levels coinciding with the onset of lamellar inflammation (Visser 2009).  
The highest uptake was achieved when liposomes were administered at 18h post-OF.  By 18 
h the horses were exhibiting Obel grade 1-2 lameness; this may be too late for delivery of 
ALDs. However, prophylactic digital cryotherapy is effective when initiated at Obel grade 2 
lameness (18.5h post-OF administration) (van Eps, Pollitt et al. 2013), so it is possible that a 
pharmaceutical means of laminitis prophylaxis would still be effective at this stage. Further 
work is needed to evaluate the optimal time-point for administration of liposomal-
formulations of drugs for ALDs. 
 
The 3.2 fold increase in the liposome levels in the lamellar tissue of laminitis horses 
compared to controls is somewhat lower than  the 24-fold increase reported in infected 
muscle in an equine focal infection model (Underwood 2011). This result initially seems 
somewhat discouraging; however, there are three key points to consider: Firstly, liposome 
accumulation depends on the intensity of the inflammatory response (Oyen et al. 1996). Focal 
infection models involve established inflammation, whereas in the present study liposomes 
were administered before or during the early stages of inflammation. Secondly, the 
biodistribution data in the focal infection study was obtained at 24h p.i. whereas most of 
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thedata in this study were collected at 12h p.i. (LAM-12 and LAM-18). Liposomes 
accumulate gradually with time (Oyen et al. 1996; Boerman et al. 1997). In a mouse focal 
infection model the abscess:control muscle ratio increased from 2.2 at 6 h p.i., to 11.7 at 24 h 
p.i.(Erdogan et al. 2000). Therefore, it is probable if sampled at a later time-point there would 
be greater lamellar accumulation of liposomes. Thirdly, as lamellar inflammation and 
laminitis pathology is focused at the dermo-epidermal interface (Pollitt 1996; Faleiros et al. 
2011), greater liposome accumulation may be present at this target site than in the lamellar 
tissue as a whole (Metselaar et al. 2003). 
 
Acute laminitis shares many characteristics with sepsis-related organ failure and the systemic 
inflammatory response syndrome (SIRS) in humans (Belknap and Black 2012; Tadros et al. 
2012). The accumulation in skin, muscle, jejunum colon and kidney, plus the trend towards 
increased hepatic liposome levels is supportive of a systemic inflammatory response resulting 
in inflammation and increased vascular permeability in these organs. To the authors’ 
knowledge this is the first study to investigate liposomal biodistribution in an animal sepsis 
model. The accumulation of liposomes in multiple organs in this study indicates liposomes 
may have potential for targeted drug delivery to prevent sepsis related organ failure in other 
species. It is, however, interesting that there was a more profound increase in liposome 
accumulation (compared with control) in the lamellar tissue compared with all the other 
studied tissues.  This indicates the inflammatory response and increase in vascular 
permeability in lamellar tissue is unique.  Increased interleukin (IL)-1β, IL-6 IL-8, IL10 and 
tumour necrosis factor (TNF)-α gene expression has been reported previously in liver and 
lung of horses with OF-induced laminitis (Tadros et al. 2012). Interestingly, in the present 
study, there was no evidence of liposome accumulation in the lung. Normal horses 
demonstrate high pulmonary liposome uptake (Underwood et al. 2012), most probably due to 
endocytosis of liposomes by the increased numbers of pulmonary intravascular macrophages 
(PIMs) present in the horse (Longworth et al. 1994). During sepsis, PIMs are activated and 
endocytose lipopolysaccharide and bacteria (Tsokos 2003; Parbhakar et al. 2005).  Therefore, 
it is probable that during the development of OF-induced laminitis PIMs have already been 
activated and are unavailable to endocytose liposomes. This reduction in liposomal 
endocytosis may counter-balance the liposomes extravasating into the pulmonary 
parenchyma due to inflammation-associated increases in vascular permeability. Interestingly, 
the median lung uptake in the LAM-18 group appeared lower than that in the LAM-0 group 
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(1.2 [0.95-1.45] %ID/kg vs. 1.87 [1.59-2.15] %ID/kg respectively), potentially indicative of 
reduced liposomal endocytosis uptake at 18 h due to saturation of PIMs in the systemic 
inflammatory response prior to liposome administration. However, the numbers were too 
small for statistical analyses so further studies are necessary to evaluate this hypothesis. 
 
Limitations of this study include the small numbers of horses, particularly the low numbers in 
each of the LAM groups, and the limited study duration of only 12 h p.i.  Further 
investigations of liposomal delivery systems for sustained lamellar drug delivery are 
warranted. These studies should focus on determining free and liposome-encapsulated drug 
concentrations at multiple time-points over a prolonged period (>24 h). When considering the 
scintigraphic data, it is important to note that the RPU in the hoof ROI includes all sources of 
radioactivity within the hoof, including blood in the vascular system, along with a mild 
shielding effect of the hoof wall. Changes in perfusion occur during laminitis development 
and may have affected scintigraphic data (Van Eps and Pollitt 2004). Although, artefactual 
alterations in the scintigraphic data due to changes in perfusion cannot be definitively ruled 
out, the lack of significant changes in HWST (an indicator of digital vascular perfusion), and 
the reduction in blood activity with time suggest the increase in CD/s in the hoof ROIs of 
laminitis horses was attributable to liposome accumulation rather than increased perfusion. 
The tissue biodistribution data more accurately represent liposome levels in specific tissues. 
However, these levels could still have been altered by residual blood in the tissue and 
changes in lamellar perfusion. Perfusion of the disarticulated limbs with saline may have 
further aided to remove any residual blood from the lamellar tissue. This was attempted in 
one forelimb of the initial two horses, however, it was not practical and did not appear to alter 
the %ID/kg lamellar tissue (0.09 [0.08-0.1]% in the perfused limbs vs. 0.07 [0.07-0.08] % in 
the non-perfused limbs). Therefore, it was considered unlikely that changes in perfusion had 
a significant effect on lamellar biodistribution data; further investigation would be needed to 
definitively rule this out. 
 
6.6 Conclusions 
Intravenous 99mTc-PEG liposome administration to horses with OF-induced laminitis resulted 
in liposome accumulation in the lamellar tissue. The degree of liposome accumulation 
indicates liposomes have potential for targeted drug delivery to lamellar tissue. With further 
experimental validation liposomal drug delivery systems have the potential to be the first 
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clinically applicable method for delivering sustained therapeutic concentrations of 
pharmaceuticals with lamellar targets, including drugs with potential for laminitis 
prophylaxis, analgesics and anti-inflammatories. Liposomes also accumulate in other tissues 
undergoing inflammation hence may have potential as a drug delivery system in sepsis 
related organ failure in other species. 
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Chapter 7: In vitro development of a targeted nanoformulation of 
marimastat 
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7.1 Abstract 
Nanoparticles can increase the therapeutic index of the drugs they carry by targeting a 
specific site and incorporating means of sustained delivery. In order to optimize lamellar drug 
delivery, a nanoparticle system specifically formulated to actively target lamellar tissue and/ 
or provide sustained lamellar drug release is desirable. The initial step in this process is to 
engineer a suitable nanoformulation that can be loaded with the pharmaceutical of interest. 
The aim of this study was to investigate two types of nanoformulation for marimastat drug 
loading; nanoemulsions and mesoporous silica nanoparticles (MSNs).  
 
Water-in-oil-in-water (W/O/W) and solid-in-oil-in-water (S/O/W) nanoemulsions were 
investigated for their ability to encapsulate marimastat. Miglyol 812 was used as the oil-phase 
and nanoemulsions were stabilized with a peptide surfactant, AM1. Subsequent to 
formulation droplet size was measured using dynamic light scattering (DLS). The marimastat 
concentrations in each phase were measured using HPLC after the oil and aqueous phases 
were separated. MSNs were synthesized, and their structure and porosity were confirmed 
using transmission electron microscopy and nitrogen adsorption-desorption isotherms, 
respectively, prior to loading with marimastat. Loading efficiency and marimastat release 
kinetics from MSNs were investigated.  
 
Both nanoemulsion formulations yielded stable monodisperse nanoemulsiuons with a mean 
droplet sizes of <200 nm. However, marimastat was not trapped within the oil phase. For the 
MSN formulation, only a small amount of marimastat (1.9 % by weight) was loaded into the 
MSNs. This was released rapidly within 6 h. 
 
In summary, marimastat was not encapsulated in the nanoemulsions nor loaded into the 
MSNs at levels sufficient for targeted drug delivery. Further studies using either alternative 
nanoformulations, investigating alternative methods to form stable double emulsions, or 
alternative loading approaches onto MSNs are necessary. However, as marimastat did not 
prevent laminitis, and nanoformulations are, to some extent, pharmaceutical specific, an 
alternative potential pharmaceutical for laminitis prophylaxis is required prior to extensive 
nanoformulation development.   
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7.2 Introduction 
Nanoparticles are ordered structures with diameters smaller than 1000 nm (Brigger et al. 
2002). They can be loaded with pharmaceuticals to improve the therapeutic index of the 
drugs they carry through four key mechanisms: (1) enabling the use of drugs that would 
otherwise be insoluble or unstable, (2) targeting the pharmaceutical to its site of action 
resulting in an increased concentration at that site, (3) lowering the drug concentrations in 
healthy tissues thereby reducing systemic toxicity, (4) providing a mechanism of sustained 
release over a period of days or even weeks (Sahoo and Labhasetwar 2003; Bakker-
Woudenberg, Schiffelers et al. 2005; Fahmy, Samstein et al. 2005). An ideal nanoformulation 
is simple and inexpensive to manufacture, biodegradable and easily modified to target a 
certain tissue or delivery mechanism. The pharmaceutical of interest should be loaded 
efficiently onto the nanoformulation, and drug release from the formulation should be slow, 
unless triggered by a specific mechanism, in order to achieve a means of sustained drug 
delivery. The over-arching aims of this study were to (1) develop nanoformulations suitable 
for active targeting of marimastat to the lamellar tissue and (2) to develop a nanoformulation 
optimized for sustained release of marimastat in lamellar tissue.    
 
Nanoparticles can target drugs to their site of action using passive or active mechanisms. 
PEG-liposomes, an example of a passively targeted nanoparticle, accumulate in lamellar 
tissue during laminitis development (Chapter Six). A major disadvantage of passive targeting, 
however, is the reliance on an underlying physiologic processes (in this case inflammation), 
to enable nanoparticle accumulation. This causes the timing of nanoparticle administration to 
be crucial, and requires pathology be initiated prior to nanoparticle administration; neither of 
which are ideal for clinical application. Active targeting, achieved by attachment of a 
targeting moiety which causes the nanoparticle to adhere to a particular receptor/ cell type, 
increases the nanoparticle concentration and therapeutic effect at the site of interest (Goutayer 
et al. 2010; Huynh et al. 2010). For lamellar delivery, nanoparticles could be targeted for 
uptake and transcytosis across the vascular endothelium as previously reported (Lu et al. 
2005; Lu et al. 2006; Kratzer et al. 2007; Hombach and Bernkop-Schnurch 2009; Huang et al. 
2010) after delivery by retrograde intravenous infusion to the foot. The advantage of targeting 
a transcytotic pathway in the vascular endothelium is that the particles can be coated with 
macromolecules normally transported by transcytosis, e.g. albumin, lactoferrin, 
apolipoprotein E, rather than using expensive antibodies (Lu et al. 2007; Weiss et al. 2008). 
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Although liposomes can be actively targeted, their production is technically challenging, 
labour-intensive and expensive. Nanoemulsions are meta-stable dispersions of nano-sized 
droplets of one liquid in a different immiscible liquid (Fryd and Mason 2012). Basic (water-
in-oil or oil-in-water) nanoemulsions are simple and inexpensive to prepare and can be easily 
modified for active targeting. Most commonly, drugs are loaded into the dispersed phase 
where the droplet size is typically 20-200 nm. Nanoemulsions can be prepared from many 
different aqueous solutions, surfactants and oil constituents. According to the properties of 
their constituents, they exist in a wide range of compositions and thus perform a wide variety 
of tasks. As nanoemulsions are easily produced and readily tailorable, addition of a surface 
coating to target nanoemulsions to certain cell types e.g. vascular endothelial cells, is easily 
achieved. Therefore a nanoemulsion was investigated for active targeting of marimastat to the 
lamellar tissue. 
 
To form a successful drug delivery system, the nanoemulsion must first be loaded with 
sufficient pharmaceutical. The first objective of this study was to load marimastat into a 
nanoformulation amenable to easy surface modification for active targeting. As marimastat is 
a weakly hydrophilic drug (soluble to 10 mM in water, 20 mM in ethanol and 100 mM in 
dimethylsulfoxide (DMSO)), use of a double emulsion system is necessary (S/O/W or 
W/O/W). Double emulsion formulation is somewhat challenging (Fryd and Mason 2012). 
This study investigated whether marimastat could be loaded into either a W/O/W 
nanoemulsion based on the combination of two previously described formulation techniques 
(Chuan, Zeng et al. 2012) (Zhao and Middelberg 2009), or a S/O/W nanoemulsion combining 
the formulation techniques of Chuan (Chuan et al. 2012) and Piao (Piao et al. 2006; Piao et 
al. 2007). Miglyol 812, which is generally regarded as a safe pharmaceutical product (Traul 
et al. 2000) was used as the oil phase for both emulsion formulations. AM1 peptide surfactant 
was used to stabilise the external O/W interface. AM1 has high interfacial activity and rapid 
interfacial adsorption (Middelberg et al. 2000). These factors result in rapid formulation of 
stable nanoemulsions with narrow size distributions that do not need a wash step following 
emulsion formulation. AM1 is also highly tuneable and can be molecularly tailored to target 
the nanoemulsion to certain cell types (Chuan et al. 2012).  
 
142 
 
The second objective of this study was to develop a slow-release nanoformulation loaded 
with marimastat for administration directly into the lamellar tissue. Mesoporous silica 
nanoparticles (MSNs) are easy to prepare and engineer to a desired shape, size and porosity. 
They are biocompatible, have large surface to volume ratios, large load capacity (>35% wt) 
and high surface tailorability (Lai et al. 2003; Trewyn, Giri et al. 2007; Liong et al. 2008; 
Mamaeva et al. 2013). MSNs can be functionalised for sustained or stimuli responsive drug 
release by either covalent linking of the drug to the silica framework through cleavable bonds 
(Mamaeva et al. 2013), or the addition of cap systems that cover the pores and hence prevent 
loaded drug molecules from leaving the pore (Lai et al. 2003). These cap systems can be 
removed under various triggers such as pH (Zhao et al. 2010), enzymatic and chemical 
reactions (Schlossbauer et al. 2009; Luo et al. 2011), light (Ferris et al. 2009), and molecular 
interactions (Coll et al. 2011). Therefore, MSNs were chosen for initial development of a 
sustained-release nanoparticle. The initial aim was to load MSNs with marimastat and 
establish the release kinetics. Subsequently, the mSiO2NPs-loaded with marimastat would be 
functionalised for sustained release with the aim of injecting them directly into the lamellar 
tissue via small drill holes through the hoof wall.   
 
7.3 Materials and Methods     
7.3.1 Materials 
AM1 peptide (molar mass 2473, 95% purity) was custom synthesised by GenScript 
Corporation (Piscataway, NJ, USA). Peptide concentration was determined by quantitative 
amino-acid analysis (Australian Proteome Analysis Facility, Sydney, Australia) on 
lyophilized samples. Miglyol 812 was a gift from Sasol (Rosebank, Johannesburg, South 
Africa).  Bovine serum albumin (BSA) was purchased from Sigma–Aldrich (Castle Hill, 
Australia). Marimastat was a gift from Vernalis plc. (formerly British Biotech, Oxford, UK). 
Iron oxide nanocrystals (20 nm, 510 mg/ml in toluene), cetyltrimethyl ammonium bromide 
(CTAB), tetraethyl orthosilicate Si(OC2H5)4 (TEOS, >99%), sodium hydroxide, 3-
aminopropyltriethoxysilane (APTES) and ethylacetate were purchased from Sigma-Aldrich 
Australia. Water was obtained from a MilliQ system (Millipore, North Ryde, Australia) 
equipped with a 0.22 μm filter. All other reagents were analytical grade. 
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7.3.2 Water-oil-water nanoemulsion preparation 
To prepare the water-in-oil phase of the emulsion 200 µL ethanol containing 8.5 mg/mL 
marimastat or 200 µL DMSO containing 30 mg/mL marimastat, was mixed with 8 µL water 
containing 3.5 mg/mL marimastat then added to 200 µL Miglyol 812 and vortexed 
vigorously for 60s. Lyophilized AM1 was dissolved in HEPES (25 mM, pH 7.0) to prepare 
an AM1 solution at 400 µM. Zinc chloride was added at 800 µM. 5 % v/v 
Miglyol/ethanol/water/marimastat solution was added to the AM1/ zinc chloride mixture and 
homogenized using a Branson Sonifier 450 ultrasonicator for two 60 s bursts at 30 W. To 
coat the emulsion with BSA, marimastat-loaded emulsion was added to 80mg/mL BSA in a 
1:1 v/v ration, followed by 60 s of vigorous vortexing. Aqueous marimastat solutions were 
prepared at the same dilution as in the emulsions (0.125 and 0.393 mg/mL) and processed as 
per the emulsion to act as control samples. 
 
7.3.3 Solid-in-oil-in water nanoemulsion preparation 
A mixture of 375 µL of 3.5 mg/mL aqueous marimastat solution and 625 µL cyclohexane or 
625 µL MiGlyol plus 2-6% v/v surfactant was homogenized using a Branson Sonifier 450 
ultrasonicator for two 40 s bursts at 15 W to form a water-in-oil emulsion. Two low 
hydrophilic-lipophilic balance (HLB) surfactants; Span 80 with a HLB of 4.3 and a mix of 
83% w/w Span 80 and 17% w/w Tween 80 to equate to a surfactant with a HLB of 6, were 
investigated at concentrations of 2, 4 and 6%. The resulting emulsion was rapidly frozen on 
dry ice, and lyophilized using a freeze-drying machine for 24 h. 1 mL of Miglyol 812 was 
added to the resulting viscous paste and homogenized for two 60 s bursts at 30 W to form a 
solid-in-oil emulsion. Lyophilized AM1 was dissolved in HEPES (25 mM, pH 7.0) to prepare 
an AM1 solution at 400 µM. Zinc chloride was added at 800 µM. Either 2% or 5% v/v solid-
in-oil emulsion was added to the AM1/ zinc chloride solution and homogenized using a 
Branson Sonifier 450 ultrasonicator for two 60 s bursts at 30 W. To coat the emulsion with 
BSA, marimastat-loaded emulsion was added to 80mg/mL BSA in a 1:1 v/v ration, followed 
by 60 s of vigorous vortexing. A control emulsion was made using the constituents of the 
S/O/W nanoemulsion without sonication (emulsion control), and a control aqueous 
marimastat solution was prepared at the same concentration as the S/O/W emulsion (aqueous 
control). 
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7.3.4 Particle size measurement 
Emulsions were diluted 100-fold into water prior to analysis to avoid multiple scattering 
effects. Particle size measurements were performed using a Malvern Zetasizer Nano ZS 
(Malvern, Worcestershire, UK), equipped with a He–Ne laser (633 nm). Data analysis was 
with DLS software (Malvern, version 4.2), using a non-negatively constrained least squares 
fitting algorithm. Dispersant refractive index and viscosity were assumed to be 1.33 and 1.02 
cP, respectively. 
 
7.3.5 Assessment of marimastat encapsulation in nanoemulsions 
In order to assess whether marimastat was trapped in the oil phase separation of the aqueous 
and oil phases was necessary. Two techniques were used for this: (1) Centrifugation method: 
900 µL of emulsion was centrifuged at 22,000 g, 26 ⁰C for 5 minutes. The bottom aqueous 
layer was extracted to measure the marimastat concentration in the aqueous portion, and 50 
µL of the upper oily layer was removed to represent the marimastat concentration in the oil 
phase. These concentrations were compared to the marimastat concentration in the control 
solution(s). (2) Dialysis method: 250 µL of the nanoemulsion was placed in a plastic 
container sealed with 10 kDa molecular weight cut off dialysis membrane (dialysis chamber). 
This was placed in 1 mL of water for 24 hours during which time any free marimastat in the 
aqueous phase of the nanoemulsion was able to diffuse into the water, but marimastat 
retained in the oil phase was trapped in the dialysis chamber.  Aliquots were collected from 
the water outside the chamber (dialysate), the emulsion in the dialysis chamber and the initial 
emulsion for measurement of marimastat concentrations using HPLC. The release of 
marimastat from aqueous and emulsion control samples was investigated using the same 
method.  
 
7.3.6 Measurement of marimastat concentrations on HPLC 
Marimastat concentrations were measured by HPLC using a Shimadzu system equipped with 
a Phenomenex Jupiter C-18 column (150 x 4.6 mm). The mobile phase consisted of Solvent 
A (99.9% v/v water with 0.1% v/v trifluoroacetic acid) and Solvent B (90% v/v acetonitrile, 
0.1% v/v trifluoroacetic acid) in the following program: initially 95% A and 5% B in a linear 
gradient over 12 minutes to 5% B; linear gradient to 95 % A for 4 minutes, followed by a 
final isocratic run for equilibration for 4 minutes (total run 20 minutes). The flow rate was 
maintained at 1 mL min-1 at ambient temperature. A calibration curve was constructed using 
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standards (1- 3,000 µg/mL) prepared by dissolving weighed amounts of marimastat in water. 
Samples involving the oil phase of the emulsions were diluted 1:3 v/v with isopropanol prior 
to analysis. 
 
7.3.7 Synthesis of Fe3O4-mSiO2NPs 
Mesoporous silica nanoparticles with a magnetite nanocrystal core (Fe3O4-SiO2NPs) were 
synthesised based on a previously described method (Kim, Kim et al. 2008). Briefly,  0.25 ml 
of Fe3O4 nanocrystals in toluene were poured into 2.5 ml of 0.055 M aqueous CTAB 
solution, and sonicated (four 30 s bursts at 20 W) to make an oil-in-water emulsion. This was 
heated to 60°C for 20 min with stirring to evaporate the toluene, resulting in a transparent 
black Fe3O4/CTAB solution. The Fe3O4/CTAB solution was added to a mixture of 22.25 ml 
of water and 0.15 ml of 2 M NaOH solution. The resulting solution was heated to 70°C under 
stirring. Then 0.25 ml of TEOS, 25 µL APTES and 1.5 ml of ethylacetate were added in 
sequence with stirring. The solution was stirred at 70 ⁰C for 3 h. The synthesized 
nanoparticles were washed 3 times with ethanol to remove unreacted species by 
centrifugation and then redispersed in 20 ml of ethanol. To extract the CTAB, 50 µl of HCl 
was added to the dispersion at 60°C and the solution was stirred and refluxed using a 
condenser for 3h at 60⁰C. After washing three times with water, the nanoparticles were 
lyophilised to give Fe3O4-mSiO2 nanoparticles. 
 
7.3.8 Characterisation of Fe3O4-mSiO2NPs 
Nanoparticles were characterised using a JEOL-1010 transmission electron microscope 
(TEM) with an accelerated voltage of 100 kV. Nitrogen adsorption-desorption isotherms 
were measured at -196°C using a Micromeritics Tristar II 3020 system to confirm the porous 
structure of the MSNs.  
 
7.3.9 Drug loading of Fe3O4-mSiO2NPs 
Marimastat was dissolved in DMSO to a concentration of 30 mg/ml. 40 mg Fe3O4-mSiO2 
nanocomposite was dispersed in 2 ml of marimastat solution and sonicated for 2 x 60s bursts 
at 20W. The mixture was stirred at room temperature for 48 h. Then the suspension was 
centrifuged to collect the marimastat loaded mSiO2NPs, and lyophilised. The supernatant was 
retained to measure the amount of marimastat loaded onto the nanoparticles. 
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7.3.10 In vitro drug release from mSiO2NPs 
10 mg of marimastat-loaded mSiO2NPs were added to 5 ml of water and stirred at 37°C in a 
water bath.  At regular intervals (0, 2, 4, 6, 20 and 24 h) 200 µL aliquots were taken and 
replaced with 200 µL fresh solution. The aliquot was centrifuged to obtain a clear supernatant 
and analysed by RP-HPLC for marimastat concentrations. 
 
7.3.11 Data analysis 
Unless otherwise stated all data are expressed as mean ± standard deviation. No statistical 
interpretations were employed. 
 
7.4 Results 
7.4.1 Formulation of water-oil-water (W/O/W) nanoemulsion 
The mean size (Z-averaged diameter) of oil droplets in the W/O/W nanoemulsion that used 
ethanol to formulate the internal aqueous phase and an oil concentration of 2% was 140 ±3 
nm. The mean size of oil droplets in the W/O/W nanoemulsion that used DMSO to formulate 
the internal aqueous phase was 140 ± 3 nm. When the concentration of the oil phase was 
increased to 5% the droplet size increased to 195 ±3 nm for the ethanol formulation and 161 
±3 nm for the DMSO formulation. With all formulations the emulsion droplets were highly 
monodisperse (polydispersity index <0.2). As using a 5% oil phase produced a monodisperse 
emulsion and had potential to increase the concentration of marimastat in the emulsion, 5% 
v/v of oil phase was used for further investigations.  
 
7.4.2 Marimastat loading onto W/O/W nanoemulsions 
In both the emulsion formulated with ethanol and that formulated with DMSO the marimastat 
concentration in the oil phase did not appear to be different to that in the external aqueous 
phase or the control sample (Table 7.1), indicating the rapid diffusion of marimastat from the 
oil phase to the external aqueous phase during the emulsion preparation process as a result of 
the intrinsic high partition coefficient between the external aqueous phase to the oil phase. As 
the volume ratio of oil phase to the external aqueous phase is only 5%, the total amount of 
marimastat which was encapsulated in the oil phase is negligible. 
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Table 7.1 The concentration of marimastat in the external aqueous and oil phases of the 
W/O/W emulsion and the aqueous control solution after separation using the 
centrifugation method. Similar marimastat concentrations are present in each phase 
consistent with a lack of marimastat entrapment in the internal aqueous (W/O) phase. 
  
Emulsion 
formulation 
Marimastat 
concentration in 
external aqueous phase 
(µg/mL) 
Marimastat 
concentration in the oil 
phase (µg/mL) 
Marimastat concentration 
in aqueous control 
solution (µg/mL) 
Ethanol 112 ± 10.1 120 ± 12.5 116 ± 2.1 
DMSO 201 ± 43 205 ± 48 190 ± 23 
 
7.4.3 Formulation of the solid-oil-water (S/W/O) nanoemulsion 
For preparing the S/O phase of the emulsion, only the formation using cyclohexane and 2% 
HLB 4.3 surfactant (Span 80) yielded a stable monodisperse emulsion (Z-average diameter 
138±4 nm, PDI <0.2). Therefore only this formulation was used for further investigation. 
When the oil and aqueous phases were separated using the centrifugation method, marimastat 
was present at a concentration of 26.2 ±6.8 µg/mL in the aqueous phase and 21.1 ±11.5 
µg/mL in the oil phase, consistent with minimal entrapment of marimastat in the oil phase. 
The diffusion method was also used to evaluate whether marimastat was trapped in the oil 
phase. There appeared to be no difference in the concentration of marimastat in the diffusion 
chamber and the diffusate between the S/O/W emulsion, the control emulsion, and control 
aqueous marimastat solution, again consistent with failure to entrap marimastat within the oil 
phase (Figure 7.1 A and B) 
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Figure 7.1: Marimastat distribution in the S/W/O emulsion (A) Variation in the 
percentage of the total initial amount of marimastat remaining in the diffusion chamber 
(i.e. entrapped within the oil phase) with time using S/W/O emulsion (red squares), the 
control emulsion mixture (black circles) and the aqueous control solution (blue triangles). 
(B) Variation in the amount of marimastat (expressed as percentage of total initial 
amount of marimastat) in the diffusate with time from S/W/O marimastat emulsion (red 
squares), control emulsion mixture (black circles) and aqueous control solution (blue 
triangles). 
 
7.4.4 Synthesis of Fe3O4-mSiO2NPs 
Monodispersed mesoporous Fe3O4-mSiO2 nanoparticles (Figure 7.2) were synthesized as 
described in the methods section. The mean diameter of the Fe3O4-mSiO2NPs was 85±10 nm. 
The porous structure of the nanocomposite was confirmed by N2 adsorption-desorption 
isotherms, with capillary condensation at 0.2– 0.4 P/P0 as is typical of Fe3O4-mSiO2NPs 
(Zhao et al. in press). Marimastat was loaded into the Fe3O4-mSiO2NPs at 19 µg 
marimastat/mg Fe3O4-mSiO2NP (1.9 % weight) by a diffusion method. Marimastat was 
released rapidly from the Fe3O4-mSiO2NPs reaching saturation at about 6h (Figure 7.3).  
 
A. B
.
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Figure 7.2. TEM images of MSNs showing uniformly-sized Fe3O4-mSiO2 nanoparticles of 
approximately spherical shape with a mean diameter of 85 ±10 nm, formed in this work. 
Dark Fe3O4 nanocrystals are present at the centre of the nanoparticles and the particles 
display a typical 2-D hexagonal mesoporous structure. 
 
 
Figure 7.3. Release profile of marimastat from Fe3O4-mSiO2NPs, showing instantaneous 
release of 40% of marimastat and almost 100% of marimastat released within 6 h.  
 
7.5 Discussion 
This work aimed to develop a nanoparticle system for targeted lamellar delivery of 
marimastat, and had two objectives: (1) to formulate a nanoemulsion containing marimastat 
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which, via surface modification could be directed for transcytosis across lamellar digital 
endothelial cells and (2) to load marimastat into mesoporous Fe3O4-mSiO2 nanoparticles that 
could then be functionalised for sustained drug release.  
 
Neither of the emulsion formulations retained marimastat within the oil phase. W/O/W 
microemulsions have been successfully formulated using microfluidic mass-transfer control, 
through co-solvent (ethanol) shifting from a dispersed ethanol/oil/water phase into the 
continuous carrier phase (water), and utilised to entrap hydrophilic substances (Zhao and 
Middelberg 2009). The initial emulsion formulation method in this work aimed to employ the 
same mechanism on a nano-scale, using AM1 as a peptide surfactant between dispersed oil 
droplets and the continuous aqueous phase. Marimastat was not successfully entrapped within 
the oil phase. This may be attributable to a lack of surfactant between the internal aqueous 
phase, with subsequent inadequate steric hindrance to retain the aqueous marimastat solution 
inside the oil phase during the vigorous sonication process necessary for nanoemulsion 
formulation or secondly, because the marimastat is less soluble in oil than in water, it 
partitions into the aqueous phase irrespective of how stable the emulsion is. One limitation of 
this work is that the successful formulation of a W/O/W nanoemulsion was not confirmed; 
hence it is quite possible that the method resulted in formation of a simple O/W emulsion. 
Cryogenic TEM studies would be beneficial in further studies to confirm formation of a 
double emulsion (Hanson et al. 2008).  
 
In an attempt to entrap marimastat within the oil phase a 2-step formulation process was 
employed utilising a low HLB surfactant to form a S/O nanoemulsion, as described by Piao et 
al. (Piao et al. 2006; Piao et al. 2008). This S/O emulsion was employed as the dispersed 
phase in a Miglyol-AM1 O/W nanoemulsion as formulated previously (Chuan et al. 2012). 
Although a stable monodisperse nanoemulsion was produced, again, marimastat did not 
appear to be encapsulated in the oil phase. Encapsulation was evaluated using both 
centrifugation and diffusion methods. The limitation of the centrifugation method is that it 
may result in aggregation of the dispersed oil phase and subsequent release of marimastat. 
However, an important caveat of the diffusion method is that it measures both unencapsulated 
marimastat and that released from the marimastat over the time period studied, therefore 
simultaneous evaluation of control samples is critical.  There was minimal evidence of 
marimastat encapsulation using either method. This supports the conclusion that marimastat 
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was not successfully entrapped within the oil phase. Further investigations focused on 
obtaining a reliable method for stable double nanoemulsion formation are warranted. 
Development of stable double (W/O/W or S/O/W) nanoemulsions is particularly challenging 
(Fryd and Mason 2012). Membrane emulsification (Liu et al. 2011), two step homogenisation 
processes (Qi et al. 2011) and microfluidic devices (Zhao and Middelberg 2009) have been 
successfully used to formulate double micro-emulsions. However, as exemplified by this 
current work, reducing the particle size to the nanoscale whilst maintaining droplet stability is 
a major challenge. As a result, there are very few reports of nanoscale double emulsions 
(Hanson et al. 2008; Tang et al. 2012; Sigward et al. 2013).  Microemulsions are too large to 
be targeted for endocytosis by vascular endothelial cells ((Nguyen et al. 2009), hence are 
unlikely to be suitable for targeted lamellar delivery by this mechanism. The next steps in 
developing a nanoformulation targeted for uptake by equine digital vascular endothelial cells 
involves either developing a methodology for simple in-expensive formulation of a double 
nanoemulsion, or investigation of alternative nanoparticle formulations that have already 
been targeted for uptake by vascular endothelial cells such as polymeric nanoparticles 
formulations (Andrieux and Couvreur 2009; Chang et al. 2009), solid lipid nanoparticles 
(Blasi et al. 2007)and hydrogel nanospheres (Nguyen et al. 2009). 
 
Marimastat loading into Fe3O4-mSiO2 NPs was negligible, at only 1.9% by weight. This is 
much lower than previously reported for other pharmaceuticals, e.g. ibuprofen, which is 
loaded at 33% by weight (Zhao et al. 2013). Furthermore, the instantaneous release of 40% of 
the marimastat suggests that true loading was only 1.1 % by weight (11.1 µg/ mg Fe3O4-
mSiO2 nanoparticles). This degree of loading from a 20 mg/mL marimastat solution results in 
a loading efficiency of only 0.28%. Hence there is significant wastage of expensive 
pharmaceutical using the described loading method, making the technique impractical. Drug 
loading onto MSNs is achieved by 2 main methods: physical adsorption from solution as 
described in this study, or by covalent linking of the drug to the MSNs (Rosenholm et al. 
2011). As marimastat is poorly water soluble it was loaded from DMSO, a non-aqueous 
solvent. In this scenario, the driving force for adsorption is hydrogen-bonding and/or polar 
interactions. Solvent properties may have a great influence on the adsorption process as they 
can compete for adsorption sites on the silica (Hata et al. 1999). In the current study, it is 
probable that there was either not enough attraction between the silica and marimastat to 
attract and retain marimastat within the MSNs, or that the DMSO was competing for 
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adsorption sites on the silica. Therefore, further investigation with alternative solvents may 
improve marimastat loading. Introduction of surface groups onto the MSN with either have 
strong affinity for marimastat or that will covalently bind marimastat may also enhance 
loading.  An additional caveat to the use of marimastat loaded MSNs is that 93% of 
marimastat was released from the nanoparticles within 6h. In comparison, only 
approximately 65 % of ibuprofen was released from MSNs in 6 h (Zhao et al. 2013). Further 
functionalization of the nanoparticles, such as capping the pores to ensure that 
pharmaceutical is either slowly released or only released at a target site would be necessary 
for MSNs to be used for sustained delivery (Ferris et al. 2009; Coll et al. 2011; Luo et al. 
2011).  
 
7.6 Conclusion 
Difficulties were identified with both nanoformulations that resulted in their being unsuitable 
for further development for targeted lamellar drug delivery. The limitations with the 
nanoemulsion formulation most probably revolved around successful production of a double 
nanoemulsion, whereas the limitations with MSNs were centred on inadequate loading of the 
specific pharmaceutical (marimastat). Further development of both formulations would be 
required to enable successful loading of marimastat. Based on this work, it is apparent that 
nanoparticle formulations are, in many cases, highly drug specific. Therefore, further 
development of a nanoparticle formulation for targeted lamellar delivery requires 
identification of a pharmaceutical with demonstrated in vitro and preferably in vivo efficacy 
in preventing laminitis. MMP inhibitors such as marimastat are the only pharmaceutical 
demonstrated to prevent laminitis in an in vitro model (Pollitt et al. 1998). As reported in 
Chapter Five, the lack of efficacy of marimastat in preventing in vivo laminitis precludes 
further development of nanoformulations specifically tailored for lamellar marimastat 
delivery. At this stage, additional pharmaceuticals that prevent laminitis in vitro and in vivo 
have not been identified, and further work on nanoformulation development is likely to be of 
limited benefit until that point.  
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Part V discussion 
 
The accumulation of liposomes in lamellar tissue, described in Chapter Six suggests 
passively targeted nanoparticles, such as PEG-liposomes, have potential for lamellar delivery. 
Multiple pharmaceuticals, including dexamethasone, a potent anti-inflammatory with 
inhibitory activity against ADAMTS-4 have been successfully encapsulated into liposomes 
(Hofkens et al. 2011). Hence it may be possible to trial a previously validated liposomal 
formulation such as dexamethasone liposomes against laminitis. As liposomes have been 
loaded with both hydrophilic and hydrophobic substances, it is probable that once a laminitis 
prophylactic is identified, it could be loaded onto liposomes. However, loading efficiencies 
can be low resulting in wastage of pharmaceutical. Although the results of Chapter Six were 
promising, further work including encapsulation of a successful laminitis prophylactic is 
necessary prior to accepting hypothesis five of this thesis (that a nanoparticle formulation will 
provide a more clinically applicable means of achieving sustained pharmaceutical 
concentrations in the target lamellar tissue). 
 
Chapter Seven describes development of a nanoemulsion optimised specifically for lamellar 
drug delivery. Due to difficulties loadingmarimastat onto the nanoparticle formulations 
trialled, further development was prevented. Whilst successful formulation of double 
nanoemulsions is considered a challenging area in nanotechnology, loading of marimastat 
onto MSNs should have been straightforward. Therefore the results of Chapter Seven 
demonstrate how dependent nanoparticle loading is on the physicochemical properties of the 
pharmaceutical involved. Continued development of a nanoparticle formulation to target the 
lamellar tissue may result in development of a nanoformulation that cannot be loaded with 
the successful ALD once identified. Therefore, further development of nanoformulations, 
were deemed inappropriate at this stage. Once a successful laminitis prophylactic is 
identified, the nanoformulation approaches outlined in this study may have great potential for 
developing a clinically applicable means of delivery. 
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PART VI: CONCLUSION 
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Chapter 8: General Discussion 
 
8.1 Introduction 
This thesis evaluates local, systemic and nanoparticle drug delivery mechanisms to establish 
a method of delivery that yields sustained, therapeutic lamellar concentrations for 
experimental and potential clinical use. Marimastat was used as a model pharmaceutical in 
these investigations based on evidence suggesting proteolytic enzyme activation plays a key 
role in laminitis pathophysiology (Pollitt et al. 1998; Visser and Pollitt 2012; Wang et al. 
2012). This work systematically investigates a variety of lamellar delivery techniques, 
culminating in application of the most successful delivery technique trialing the efficacy of 
marimastat in preventing OF laminitis. Finally nanoparticle delivery systems were 
investigated as a more clinically applicable means of lamellar drug delivery. 
 
8.2 Lamellar ultrafiltration for sampling lamellar interstitial fluid 
A means to repeatedly sample lamellar drug concentrations was essential to compare the 
efficacy of the different delivery systems and ensure therapeutic/ inhibitory tissue 
concentrations were achieved. Measurement of drug concentrations in lamellar tissue 
presents a unique challenge; and, prior to this project, was limited to serial lamellar biopsies 
(Visser 2009) and tissue microdialysis (Nourian et al. 2010). Both of these latter techniques 
have significant limitations, therefore the initial work in this thesis focused on the 
development of lamellar ultrafiltration for repeated, direct sampling of lamellar interstitial 
fluid as lamellar ultrafiltrate (LUF). 
 
In a preliminary study, a placement technique was developed and lamellar ultrafiltration 
probes were inserted into the lamellar tissue of 6 horses (Chapter Two). The ultrafiltration 
probes were well tolerated, sufficient volumes of LUF were collected for hourly 
measurement of pharmaceutical concentrations using UPLC-MS, and concentrations of 
biochemical analytes in LUF were stable over a 96 h period of collection. These results 
suggested the technique had potential for sampling lamellar interstitial fluid to establish 
lamellar drug concentrations.  However, several issues were identified; namely that the rate 
of LUF collection decreased with time and that there was histologic evidence of a host tissue 
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response to the ultrafiltration probes, both of which may have resulted in temporal alterations 
in pharmaceutical recovery.  
 
In order to address these issues, a secondary objective of Chapter Three was to further 
validate lamellar ultrafiltration. In vitro marimastat recovery was high (98%) with minimal 
variation between probes. Neither lamellar ultrafiltrate marimastat concentrations (LUF[M]) 
during steady-state intravenous constant rate infusion (CRI)  nor biochemical analyte 
concentrations varied with time indicating consistent recovery during the time-periods 
studied (12 h and 48 h respectively). There was no correlation between LUF[M] and 
biochemical analyte concentrations or histologic score indicating substance recovery was 
consistent between probes and not affected by host tissue responses. Within limb variations in 
LUF[M] at a single time-point were minimal (2.6%), whereas within-limb variations in tissue 
marimastat concentrations (T[M]) at a single time-point were high (26%). The high within-
limb variation in T[M] is probably due to unavoidable inaccuracies that occur  during  the 
complex extraction and homogenization process. In addition to being more practical for 
collection of multiple samples, fluid collected by ultrafiltration requires very simple, if any, 
extraction prior to analysis hence minimisesthe aforementioned variables. The low numbers 
in each of the individual studies in Chapters Two through Five could have resulted in type II 
error, so biochemical analytes and histologic data from each of the studies were pooled 
(n=21, using the analytical methods employed in Chapter Three). There remained no 
temporal difference in biochemical analyte concentrations and no association between analyte 
concentrations and total histologic score (P>0.05), further ratifying the conclusion that there 
are no significant changes in recovery, and no significant effect of host tissue response on 
recovery in the time period studied (up to 96 h).  
 
Throughout this study a total of 40 ultrafiltration probes were placed in lamellar tissue. Only 
one of the 40 probes placed did not collect LUF. The only horses to show signs of infection 
were those in the initial study (Chapter Two). This may have been related to the long time 
required for probe placement in these horses (45 minutes) and initial problems associated 
with performing an unfamiliar technique. In subsequent studies, probe placement time was 
reduced to 5 minutes per probe, and no further clinical nor histologic signs of infection were 
encountered.  
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Based on these findings lamellar ultrafiltration was deemed suitable for collection of LUF for 
pharmacokinetic analyses, with the caveat that in vitro and in vivo recovery should be 
established for each pharmaceutical investigated. Throughout this study the concentrations of 
biochemical analytes were measured as a quality control measure. Further investigations, 
comparing iv vitro  probe recovery, prior to and after implantation as described by Wisniewki 
et al. (Wisniewski et al. 2001), would provide further validation of the technique, however, it 
is questionable whether, as would be required for that purpose, the delicate ultrafiltration 
probes could be removed intact from lamellar tissue.  
  
8.3 Comparison of regional and systemic delivery techniques. 
The next step was to investigate the most effective method to deliver marimastat to the 
lamellar region in normal horses. Two regional delivery techniques were investigated: 
intraosseous infusion of the distal phalanx (IOIDP) and regional limb perfusion (RLP), as 
discussed in Chapters Three and Four respectively. Each technique was compared with 
systemic administration using an identical dosing regimen (CRI and systemic intravenous 
bolus (SIVB)), to verify achievement of a local delivery effect.  Successful local drug 
delivery was defined as target tissue concentrations greater than plasma concentrations 
(Collins 1984). 
 
SIVB administration of marimastat confirmed previous findings (Pass and Pollitt, 
unpublished data) demonstrating rapid clearance and a short (0.9 h) plasma half-life. LUF[M] 
decreased below the target concentration considered necessary for in vivo inhibition of 
lamellar MMPs (177ng/mL) within 1 h. Systemic intravenous CRI with marimastat  did result 
in sustained LUF[M], however they were <177 ng/mL. Therefore, using the dosing regimens 
investigated neither CRI nor SIVB were deemed suitable for lamellar marimastat delivery. It 
is possible that higher marimastat doses administered systemically would augment LUF[M]. 
Further studies would be necessary for dose optimisation; however, even experimental 
investigations using CRI or SIVB with higher doses of marimastat are likely to be precluded 
by cost.  
 
In contrast to a previous report (Nourian et al. 2010), IOIDP did not consistently result in 
successful local lamellar delivery. Close evaluation of the data revealed that in two of the five 
horses some local delivery effect was achieved, with steady-state concentrations sufficient to 
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inhibit at least 90% of lamellar MMP-2 and MMP-9 (Chapter Three). An explanation for the 
apparent success in two horses, but concurrent failure in three others was not established, 
hence further investigations are required to establish its cause and determine whether this 
variability extends into a larger population. If the reason behind successful local deliverycan 
be established and applied to develop a new method IOIDP may be a useful technique for 
local lamellar delivery.  RLP, on the other hand, resulted in high LUF[M], sufficient to inhibit 
90% of lamellar MMPs for at least 6 h in all horses. Although complications associated with 
repeated tourniquet placement and the need to anesthetise the distal limb for each RLP, 
would probably preclude clinical application, this dose regimen is suitable for experimental 
investigation of the efficacy of pharmaceuticals in preventing laminitis.  Therefore, RLP was 
identified as the most suitable technique for administration of marimastat during 
experimentally induced laminitis. 
 
8.4 Application of RLP to evaluate the efficacy of marimastat in preventing 
oligofructose induced laminitis 
The primary objective of Part IV was to apply the optimal delivery technique established in 
Part III (RLP) to investigate the efficacy of a pharmaceutical in preventing experimental 
laminitis. In Chapter 5 RLP with 140mg of marimastat every 6 h resulted in LUF[M] 
consistently above the concentration considered necessary to inhibit lamellar MMPs in vivo, 
hence from this aspect the technique was deemed successful.  A key concern was whether 
frequent repeated RLP could be performed without complications that result in lack of 
venous access. Therefore, to minimize trauma associated with repeated venepuncture, RLPs 
were performed using digital venous catheters rather than direct injection (Kelmer et al. 2009; 
Kelmer et al. 2012). Eleven of the 12 catheters functioned for the duration of the study, 
enabling easy administration of pharmaceutical. Eighty-five of eighty-six RLPs were 
completed, with perineural analgesia, sedation, tourniquet placement and lack of movement 
all being considered essential for successful perfusion. Based on the results of Chapters Four 
and Five the high variability in LUF[M] subsequent to RLP is an unavoidable sequela of  RLP. 
Providing LUF drug concentrations sufficiently exceed the target therapeutic concentration 
(as in Chapter Five) this should not preclude its experimental use. However it does require 
the dosing interval be adjusted to ensure therapeutic concentrations are met in all horses (6 h) 
rather than using the median time over which concentrations are considered above therapeutic 
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level (9 h).  In addition tissue drug concentrations should be measured to quantify the inter-
horse variation.  
 
Lamellar ultrafiltration was successfully employed to sample lamellar interstitial fluid, to 
establish lamellar drug concentrations and confirm adequate delivery. This is a key factor in 
efficacy trials; in the absence of a clinical effect (as in Chapter Five) it enables confirmation 
of inhibitory/ target concentrations. In the presence of a clinical effect it can be used to 
establish a dose response relationship. As ultrafiltration is a minimally invasive technique, 
and only disrupts a small area, this does not preclude histologic evaluation of the remainder 
of the lamellar tissue to establish disease severity.  
 
In summary, results obtained in Chapter Five demonstrated that RLP with concurrent 
measurement of LUF[M] was a suitable investigative strategy for delivery and quantification 
of marimastat concentrations in lamellar tissue during experimental laminitis development. It 
may therefore be used in experimental studies investigating the efficacy of other drugs with 
candidate anti-laminitis drugs (ALDs). The focus of this work was to develop a model that 
could be applied to experimentally evaluate pharmaceuticals for their ability to prevent 
laminitis. Once a pharmaceutical that prevents experimental laminitis is identified, further 
investigations may be necessary to optimise and establish the suitability of RLP for clinical 
application. Alternative delivery techniques that are more practical for clinical application 
may need consideration. 
 
8.5 Establishing target therapeutic concentrations 
The determination of appropriate in vivo target tissue concentrations for marimastat was an 
important factor in this research. For many pharmaceuticals, dose and tissue concentrations 
necessary to achieve an effect have been established by in vivo pharmacodynamic modeling 
(Collins 1984). Despite intensive research, these data are lacking for marimastat, partially 
because, in oncologic trials, conventional efficacy measures fail due to marimastat’s 
cytostatic rather than cytotoxic activity (Peterson 2006) and secondly because there is no  in 
vivo assay to directly measure the amount of  MMP inhibited. The in vitro inhibitory profile 
of marimastat has been thoroughly classified using enzyme based methods, with IC50s for 
most MMPs in the nanomolar range (Wojtowicz-Praga et al. 1997; Peterson 2006). However, 
these do not directly extrapolate to the in vivo situation; tissue/cell based assays and in vivo 
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efficacy generally requires much higher concentrations for adequate enzymatic inhibition 
(Barlaam et al. 1999; Lees et al. 2004; Peterson 2006; Tortorella et al. 2009).  Maintaining 
plasma concentrations above the in vitro IC80 or IC90 has been recommended for adequate in 
vivo enzymatic inhibition (Lees et al. 2004; Shu et al. 2011). In Chapter Three the IC90 of 
marimastat against lamellar MMP-2 and MMP-9 was established using a tissue- based 
zymographic assay. As expected, the IC50 values obtained using this assay were 
approximately 6 times higher than those obtained using enzyme based assays (Wojtowicz-
Praga et al. 1997; Peterson 2006). For proteolytic enzymes whose inhibitory activity could 
not be assessed by gelatin based zymography, selecting an appropriate target concentration 
was challenging. A meta-analysis using a reduction in the rate of  rise of  serum tumour 
biomarker levels as a measure of marimastat efficacy indicated free-drug concentrations of 
six times the IC50 were necessary for a biological effect (Nemunaitis et al. 1998). This 
recommendation was subsequently adopted for phase I and II trials (Millar et al. 1998; Miller 
et al. 2002).  Therefore, when the IC90 was unavailable, six times the IC50 was employed as 
the target LUF[M] concentration in this project.  
 
LUF[M] levels achieved in Chapter 5 easily exceeded target marimastat concentrations, and 
were adequate for zymographic inhibition of more than 90% of MMP-2 and 9 in lamellar 
homogenates from horses 48 h after oligofructose administration. Hence it seems probable 
that lamellar proteases within the spectrum of marimastat, were inhibited. The unfolding of 
MMPs during zymographic processing results in loss of marimastat from the enzyme’s active 
site, invalidating the use of zymography for establishing the extent of in vivo inhibition.  
Therefore, in the absence of any clinical effect, and with no applicable biomarker or assay to 
confirm in vivo inhibition, it is impossible to definitively state that lamellar proteases were 
inhibited in vivo during the oligofructose trial in Chapter Five. Further investigations, 
considered beyond the remit of this thesis, would be required to develop suitable assays to 
establish the degree of in vivo enzymatic inhibition occurring.  
 
8.6 Marimastat does not prevent oligofructose induced laminitis. 
In demonstrating that broad-spectrum MMP inhibition with marimastat does not prevent 
laminitis, this work resolved a query that been at the forefront of laminitis research for over a 
decade, but has gone unanswered due to lack of a suitable delivery mechanism. The results of 
Chapter Five clearly demonstrate that at the doses used, marimastat did not prevent 
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experimental laminitis. Even if higher doses did result in some preventive effect, due to cost 
and delivery limitations it is unlikely marimastat would suitable for clinical application. It 
was considered probable that LUF[M] were sufficient to inhibit lamellar proteases within 
marimastat’s spectrum, in particular MMP-2, MMP-9, MMP-14 and ADAMTS-4, thus 
calling into question the importance of their activation in laminitis pathophysiology. 
However, as mentioned above, this cannot be definitively confirmed without demonstrating 
that in vivo inhibition was achieved.  As marimastat has purported anti-inflammatory effects 
the results of this study may have implications for the importance of inflammation in 
laminitis pathology. However, the mechanisms by which these anti-inflammatory effects are 
enacted are complex. Further studies investigating whether marimastat treatment reduced the 
inflammatory-mediators associated with laminitis development would be required to quantify 
its anti-inflammatory effects.   
 
8.7 Nanoparticle delivery systems for targeted lamellar delivery 
The final aim in the thesis was to investigate nanoparticle delivery systems as a more refined, 
clinically applicable method for lamellar drug delivery. The accumulation of PEG-liposomes 
in lamellar tissue during laminitis development, as demonstrated in Chapter Six, suggests that 
passively targeted nanoparticles have potential for lamellar drug delivery. Further 
investigations delivering a pharmaceutical within liposomes and assessing its release into 
tissue would be necessary to establish whether therapeutic lamellar concentrations are 
reached and if so, for how long. Although small numbers precluded statistical analyses, the 
trend towards increased liposome accumulation when liposomes were administered 12 and 
18h after OF administration, demonstrates how timing of nanoparticle administration can be 
crucial when using passively targeted nanoparticles such as liposomes. Greater control over 
nanoparticle delivery can be achieved using active targeting. In Chapter Seven, two 
nanoformulations were investigated with the aim of developing a nanoparticle system that 
actively targeted marimastat to lamellar tissue. Neither the nanoemulsion nor the silica 
nanoparticle formulation was successfully loaded with marimastat, demonstrating that in 
many cases, nanoparticle formulations are highly drug specific. Therefore, further nano-
particle development appears pointless until a pharmaceutical that successfully prevents 
laminitis is identified. 
 
8.9 Conclusions  
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RLP was the optimal technique for lamellar marimastat delivery. Along with lamellar 
ultrafiltration to confirm drug concentrations this formed an investigative model for 
evaluating the efficacy of potential laminitis prophylactics. The suitability of the model was 
demonstrated in Chapter 5 against laminitis induced with OF. Although marimastat did not 
prevent OF-induced laminitis, the successful application of the model during laminitis 
induction demonstrated its usefulness for investigating alternative pharmaceuticals, with the 
caveat that quantification of in vitro recovery and lamellar pharmacokinetics in normal horses 
would be necessary for each pharmaceutical investigated.  Nanoparticle delivery systems 
were investigated as a more clinically applicable means of lamellar drug delivery. Passively 
targeted nanoparticles (liposomes) accumulated in lamellar tissue during laminitis 
development, indicating potential for lamellar drug delivery. However, further refinement of 
a nanoparticle delivery system is required with pharmaceuticals that successfully prevent 
laminitis.  
 
The novel research described in this thesis advances laminitis science by presenting a new 
investigative model for drug delivery tested against experimentally induced laminitis using 
the MMP inhibitor marimastat. Further work should utilise this model to investigate 
alternative pharmaceuticals with potential to prevent laminitis, then optimise delivery 
techniques for clinical application. When laminitis pathogenesis can be effectively arrested 
by the efficacious delivery of a safe, potent anti-laminitis pharmaceutical genuine progress 
will have been made.   
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E-mail address: c.underwood1@uq.edu.au (C. UndNanomedicine is a rapidly expanding ﬁeld with a promising future that is already permeating veterinary
science. This review summarises the current applications for nanoparticles in human medicine and
explores their potential applicability for veterinary use. The principles underlying the use of nanoparti-
cles in drug delivery, imaging and as vaccine adjuvants are explored along with the unique issues sur-
rounding nanoparticle toxicity and regulatory approval. A brief overview of the properties of different
nanoparticle systems including, liposomes, micelles, emulsions and inorganic nanoparticles, is provided,
along with a description of their current and potential future applications in veterinary medicine.
 2012 Elsevier Ltd. All rights reserved.Introduction
Nanotechnology is revolutionizing human medicine, particu-
larly in the ﬁelds of imaging and drug delivery. For over 30 years,
nanoparticles, deﬁned as ordered structures with diameters smal-
ler than 1000 nm (Brigger et al., 2002), have been engineered to de-
velop novel diagnostic methods and targeted therapies (Fig. 1). In
the medical ﬁeld, nanoparticle research has focused primarily on
targeted delivery of therapeutic agents, vaccine development and
novel diagnostic methods. In some of these areas, nanoparticles
have delivered effective and scientiﬁcally validated solutions, lead-
ing to their incorporation into marketable products that are al-
ready extending to veterinary species. However, ‘over-
speculation’ on the potential of futuristic nano-inventions that
are in the early stages of development can cloud the realistic pro-
gress that is being made.
This review will focus on the basic principles behind the use of
nanoparticles for drug delivery, diagnostics and vaccine formula-
tion. Common forms of nanoparticle are discussed, along with their
clinical applications and limitations, providing the reader with a
realistic synopsis of the practical applications of nanoparticles to
veterinary medicine at present and in the near future.ll rights reserved.
IM, intramuscular; SLN, solid
nance imaging; PET, positron
EG, polyethylene glycol; EPR,
nd Drug Administration.
erwood).Nanoparticles as precise drug delivery systems
The use and efﬁcacy of many currently available pharmacolog-
ical agents are limited by low bioavailability and unwanted side ef-
fects. Approximately 95% of all potential therapeutic agents have
poor bioavailability and pharmacokinetics (Brayden, 2003). Nano-
particle drug delivery systems can be engineered to overcome
these issues and thus improve the therapeutic index and safety
proﬁle of the substances they carry. In multiple studies, nanoparti-
cles have already demonstrated remarkable efﬁcacy for targeting
delivery of anti-neoplastic agents (Hofheinz et al., 2005), antimi-
crobials (Cordeiro et al., 2000), analgesics (Rose et al., 2005) and
anti-inﬂammatory agents (Metselaar et al., 2003). There are over
200 nanoparticle drug delivery systems in development, with at
least 30 nanoparticle based therapeutic products approved for clin-
ical use in humans and a similar number in clinical trials (Wagner
et al., 2006; Bawa, 2008). Many of these preparations are prohibi-
tively expensive for veterinary use, but, several nanoparticle for-
mulations are already available on the veterinary market, and as
nanoparticle production facilities are scaled up for commercialisa-
tion, these preparations will increasingly become more affordable
for veterinary application.
Nanoparticles improve the therapeutic index of the pharmaceu-
tical agents they carry through four key mechanisms. Firstly, they
enable the use of drugs that would otherwise be insoluble or
unstable. Secondly, they increase the concentration of pharmaceu-
tical at its intended site of action, resulting in increased efﬁcacy.
Thirdly, because of preferential accumulation at target sites, they
lower systemic toxicity and drug concentration in healthy tissues.
Fourthly, nanoparticles have reduced clearance compared to the
Fig. 1. A schematic diagram depicting the relative size of a typical nanoparticle compared to an erythrocyte, an E. coli bacterium and a molecule of ﬁbrinogen. Whilst
nanoparticles are deﬁned as being less than 1000 nm in diameter, most nanoparticles used in medical applications are between 50 and 200 nm in diameter.
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lease over a period of days or even weeks (Sahoo and Labhasetwar,
2003; Bakker-Woudenberg et al., 2005; Fahmy et al., 2005).
As a consequence of these mechanisms, nanoparticle formula-
tions require a reduced dose compared to free drug. This is partic-
ularly pertinent to veterinary medicine as it may (1) allow the use
of expensive human pharmaceuticals whose application has previ-
ously been precluded by the cost of dosing and (2) reduce the lev-
els in carcasses leading to lower environmental impact and lower
residues in food.
To form a successful drug delivery system, the nanoparticle
must be loaded with a sufﬁcient amount of pharmaceutical, carry
this to the target tissue and then release the pharmaceutical at
the target site. Nanoparticles can be loaded with drugs via encap-
sulation within the particle or via surface attachment (Lu et al.,
2007). The method of drug loading depends upon the type of nano-
particle as well as the drug type and the target. By loading a drug
into the nanoparticle, the drug essentially takes on the external
properties of the nanoparticle until the particle is destroyed or
the drug is released at its target.
Targeting of nanoparticles to speciﬁc sites is achieved passively
(based on the innate properties of the nanoparticle) and/or actively
(the coupling of a targeting moiety to a nanoparticle). The arche-
typical mechanism of passive targeting occurs via the ‘enhanced
permeability and retention (EPR) effect’, which is demonstrated al-
most ubiquitously by nanoparticles due to their small size (Maeda,
2010). This effect relies on the ability of intravenous (IV) nanopar-
ticles to extravasate at sites of increased vascular permeability, but
otherwise be retained in the circulation. This results in accumula-
tion of nanoparticles at sites of increased vascular permeability
(e.g. tumours, infections and areas of inﬂammation), hence target-
ing of the agents they carry to these sites (Ishihara et al., 2010).
Opsonisation and subsequent uptake of nanoparticles by the
reticuloendothelial system reduces the number remaining in circu-
lation and able to extravasate (Laverman et al., 2000). To overcome
this, nanoparticles can be coated with hydrophilic substances, the
most commonly used being polyethylene glycol (PEG), whichreduces opsonisation and prolongs circulation time (Arulsudar
et al., 2004).
In addition to a PEG coating, nanoparticle characteristics, such
as size, surface charge, hydrophobicity and architecture can be
engineered to passively target certain tissues or cell types (Adise-
shaiah et al., 2010). In fact, omission of a hydrophilic coating re-
sults in rapid uptake of nanoparticles by cells of the mononuclear
phagocyte system, rendering them ideal for targeting intracellular
parasitic, bacterial, fungal and viral infections (Schiffelers et al.,
2001). Passive targeting does not require the addition of a targeting
moiety and so is often less expensive than active targeting and is
potentially more useful for application to veterinary medicine.
In addition to passive targeting, active targeting may be neces-
sary to increase the interaction between nanoparticles and target
tissues. This is achieved via attachment of a targeting moiety to
the nanoparticles, causing them to adhere to a particular recep-
tor/cell type so increasing their concentration at the site of interest
(Goutayer et al., 2010).
Ligand-mediated binding is particularly valuable for therapeu-
tics that are not easily taken up by cells, and require facilitated fu-
sion, endocytosis or another uptake processes to access
intracellular active sites. Signiﬁcant progress has been made by ac-
tively targeting nanoparticles to inﬂammatory markers, adhesion
molecules and abnormal cell surface receptors enabling delivery
of high levels of pharmaceutical to vascular diseases (e.g. athero-
sclerosis) and to tumours (Guccione et al., 2004; Winter et al.,
2010).
The use and development of antibodies and antibody fragments
to target nanoparticles to a particular tissue or cell type can be
expensive; however, targeting nanoparticles to speciﬁc tissues
simply by altering their charge, or coating them in a substance that
is naturally taken up by that tissue is a more cost-effective ap-
proach in developing targeted nanoparticles for veterinary use.
This method has been successfully used to enhance nanoparticle
adherence to and uptake across the blood–brain barrier for
treatment of neurological diseases (Lu et al., 2006; Weiss et al.,
2008).
14 C. Underwood, A.W. van Eps / The Veterinary Journal 193 (2012) 12–23Once at the target site the next essential step is drug release. A
myriad of mechanisms for drug release/nanoparticle uptake may
occur based on the properties and surface characteristics of the
nanoparticle in question (Georgieva et al., 2010). Possible mecha-
nisms of drug release include (1) liberation due to nanoparticle dis-
integration, or enzymatic breakdown; (2) diffusion from the intact
nanoparticle; (3) release from the surface of the nanoparticle; (4)
fusion of the nanoparticle with the cell surface membrane and sub-
sequent release of contents into the cell; (5) endocytosis of the
nanoparticle with subsequent release of contents into the endo-
plasmic reticulum, and (6) triggered release initiated by applica-
tion of an external factor, such as a magnetic ﬁeld, a change in
temperature or pH (Couvreur, 1993; Liu et al., 2007). Often a com-
bination of these processes coexists, and particles can be engi-
neered to have optimal and controllable release kinetics that
target them to speciﬁc intracellular pathways.
Nanoparticles have found widespread use in drug delivery, with
indications including cancer, infection and analgesia. In addition to
IV administration, nanoparticle delivery systems improve the
pharmacokinetics of ocular, inhalational, intra-articular, peri-
neural, epidural, oral and topical pharmaceuticals, primarily via
increasing drug penetration to the target tissue, increasing the con-
centration of drug and its retention time in that tissue (Shek et al.,
1994; Aly, 2008; Gershkovich et al., 2008; Cevc and Vierl, 2009; Cai
et al., 2010). Although there are still large areas of nanotechnology
not yet explored for veterinary application, a number of studies
have evaluated nanoparticle formulations speciﬁcally for veteri-
nary use (Table 1) and more work will be undertaken as develop-
ment costs fall. In addition to those listed in Table 1 many
nanoparticle based therapeutics have been studied in veterinary
species in pre-clinical studies of pharmaceuticals targeted for the
human market. Some of these pharmaceuticals also have potential
for veterinary application particularly anti-cancer drugs for com-
panion animal use.Nanoparticles in diagnostics
Recently, extensive research has been performed to develop
nanoparticle systems for in vivo diagnostic imaging and labora-
tory-based diagnostics. The aim is to enable sub-clinical disease
identiﬁcation via the use of reﬁned nanoparticle systems in both
sensitive high-resolution imaging modalities that can detect small
aggregates of atypical cells within an entire organism, and in di-
rect, rapid and sensitive diagnostic assays for early detection of
biomarkers and pathogens.
Harnessing similar delivery principles as those for nanoparticle
drug delivery systems, nanoparticle platforms can be loaded with
imaging agents to detect pathological tissues and speciﬁc cell
types. Imaging can be macroscopic or at a molecular level where
nanoparticles are used to visualise, characterise and measure cellu-
lar processes in living organisms. Some nanoparticles, such as
quantum dots, gold nanoparticles and perﬂuorocarbon nanoparti-
cles, have innate imaging properties, whereas others (such as lipo-
somes) can be loaded with imaging contrast agent to enable
detection of pathological tissues (Matteucci and Thrall, 2000; Ben-
tolila et al., 2009). These nanoparticles rely on passive delivery
mechanisms or are conjugated to various ligands (e.g. monoclonal
antibodies, peptides, polysaccharides or aptamers) to direct them
to a certain cell type or pathway.
Initial work focused on the macroscopic use of nanoparticles
with conventional imaging modalities, such as radiography, mag-
netic resonance imaging (MRI), nuclear scintigraphy, positron
emission tomography (PET) and computerised tomography (CT),
for the diagnosis of tumours and inﬂammatory foci. Due to the in-
creased permeability at these sites, nanoparticles extravasate anddemonstrate the EPR leading to an increased signal from the imag-
ing contrast agent they carry at that site.
Some nanoparticle formulations, such as radiolabelled lipo-
somes, have progressed to clinical trials in human medicine. How-
ever, concerns over toxicity and safety, in particular the
complement mediated hypersensitivity reactions that occur in 5–
45% of human patients during liposome administration, have re-
stricted their use for diagnostic purposes (Szebeni et al., 2007). In
the veterinary species, where lesion localisation may be more chal-
lenging and fewer alternative agents/imaging modalities exist,
nanoparticle imaging may prove to be very useful. For examples,
of radiolabelled liposomes have the potential to locate tumours
or septic foci in large animals where size prohibits the use of con-
ventional imaging (Fig. 2).
Whilst this ﬁeld of research does lag behind other nanotechnol-
ogy applications in its readiness and applicability for clinical use,
investigation of nanoparticle systems in diagnostic imaging has
gained considerable momentum and labelled nanoparticles are
an extremely valuable tool from a research standpoint. Ligand di-
rected nanoparticles, such as ﬂuorescent quantum dots can iden-
tify diseased tissues and molecular processes via intravital
microscopy providing unprecedented information on disease path-
ophysiology (Bentolila et al., 2009). On a larger scale, nanoparticle
based imaging techniques have been used extensively in animal
disease models to evaluate the biodistribution of potential nano-
particle-drug delivery systems. Much of the information available
regarding nanoparticle clearance, degree of uptake by the MPS
and tissue localisation is based on the results of studies with imag-
ing agents conjugated to the potential nanoparticle delivery
system.
Novel diagnostic assays have been successfully formed by link-
ing functionalised nanoparticles to biological molecules such as
antibodies, peptides, proteins and nucleic acids (Driskell et al.,
2005; Luchini et al., 2010). Coupled with spectroscopy, ﬂow cytom-
etry and histological methods these provide a powerful novel plat-
form for mapping the molecular proﬁles associated with disease
and infection and a highly sensitive, ampliﬁcation-free method of
pathogen detection (Halfpenny and Wright, 2010). The ultimate
aim for this technology is to develop a simple, sensitive panel for
biomarker proteins that enables early detection of diseases such
as cancer.
Whilst further work is necessary before this complex system
becomes a clinical reality, there are a multitude of nanoparticle
based detection systems successfully validated for the detection
of viral, parasitic and bacterial pathogens in the veterinary ﬁeld
(Kumanan et al., 2009; Yuan et al., 2009). In addition to disease
diagnosis, nanoparticles conjugated to monoclonal antibodies of
veterinary drug have been integrated into immunoassays to pro-
vide a fast, sensitive and simple analytical method for determining
drug levels in foodstuffs (Shen et al., 2007; Zhang et al., 2008).
These techniques have great potential for the detection of drug res-
idues and early identiﬁcation of diseased animals.Vaccine delivery
Vaccines, designed to stimulate a long lasting and protective
antibody response to a pathogen, are comprised primarily of anti-
gen and adjuvant. Traditionally, inactivated microorganisms pro-
vided the antigen, but recently there has been a shift towards the
use of safer synthetic peptides and recombinant proteins (Nordly
et al., 2009). Alone, these new vaccine candidates are often poorly
immunogenic and sensitive to degradation, and they require an
optimised adjuvant that improves immunogenicity (Nordly et al.,
2009). Conventional adjuvants are not tuneable, but with the
advent of nanotechnology a plethora of novel antigen carrying
Table 1
An overview of some of the nanoparticle systems evaluated for drug and vaccine delivery for veterinary use. All studies listed have been performed in the species for which the
nanoparticle is intended. d Clinical trial/evaluated in animals with clinical disease, 4 pharmacokinetic study, } compared to non-nanoparticle formulation, N beneﬁcial effect of
nanoparticle formulation or nanoparticle formulation fulﬁlled aims of study, . no beneﬁcial effect of nanoparticle formulation/no difference to non-nanoparticle formulation
where compared with free-drug, j adverse effects.
Species Nanoparticle Agent Disease Administration
route
Reference
Cats Emulsion Propofol Anesthesia IV Wiese et al. (2010)d}j.
Cleale et al. (2009)d}4j.
Liposome Muramyl tripeptide Mammary adenocarcinoma IV Fox et al. (1995)d.
Liposome Photosensitiser Squamous cell carcinoma IV Buchholz et al. (2007)djN
Buchholz et al. (2005)dj4}N
Liposome IL-2 DNA Chronic rhinitis Intraperitoneal Veir et al. (2006)djN
Liposome 99 m-technetium Imaging of sarcomas IV Matteucci et al. (2000)dN
Liposome Doxorubicin Soft tissue sarcoma IV Poirier et al. (2002) dj }.
Kleiter et al. (2010)djN
Liposome Ribavirin Feline infectious peritonitis PO, IM, IV Weiss et al. (1993)}.
Magnetic nanoparticle Granulocyte–macrophage
colony stimulating factor,
IL-2, IFN-c
Fibrosarcoma Intratumoural Huttinger et al. (2008)djN
Jahnke et al. (2007)djN
Dogs Emulsion Cyclosporine Immunosuppressive to
prevent transplant rejection
PO Bernsteen et al. (2003)jN
Liposome Hydromorphone Analgesia SC Wunsch et al. (2009)j}N
Smith et al. (2008)4N
Liposome Clodronate Malignant histiocytosis IV Hafeman et al. (2009)dN
Liposome Triﬂuralin Leishmaniosis IV Marques et al. (2008)N
Liposome Meglumine antimoniate Leishmaniosis IV Ribeiro et al. (2008)djN, Schettini et al.
(2005)d4N and Valladares et al. (2001)4}N
Liposome IL-2 DNA Osteosarcoma lung
metastases
IV Dow et al. (2005)djN
Liposome DNA Haemangiosarcoma Intraperitoneal U’Ren et al. (2007)djN
Liposome Clodronate Immune mediated
haemolytic anaemia
IV Mathes et al. (2006)djN
Liposome Doxorubicin Various canine tumours IV Hauck et al. (2006)d4jN
Vail et al. (1997)djN
Liposome Endostatin DNA Soft tissue sarcoma IV Kamstock et al. (2006)djN
Liposome Immunotherapy Atopic dermatitis Intradermal Mueller et al. (2005)djN
Liposome Cisplatin Various tumours and
osteosarcoma
IV Marr et al. (2004)jN
Vail et al. (2002)dj.
Liposome IL-2 Pulmonary neoplasia Inhaled Khanna et al. (1997)djN
Liposome Amphotericin B Blastomycosis IV Krawiec et al. (1996)djN
Liposome Amphotericin B Leishmaniosis IV Oliva et al. (1995)djN
Liposome Muramyl tripeptide Oral melanoma IV MacEwen et al. (1999)dN
Liposome Muramyl tripeptide Osteosarcoma IV Kurzman et al. (1995)dN
Liposome Muramyl tripeptide Splenic haemangiosarcoma IV Vail et al. (1995)dN
Pigs Dendrimer Foot and mouth disease
vaccine
Foot and mouth disease IM Cubillos et al. (2008)}N
Liposome a-tocopherol Vitamin E supplementation PO Bontempo et al. (2000)4}N
Chromium nanocomposite Chromium Chromium
supplementation
PO Wang et al. (2009)}N
Polymeric E. coli ﬁmbriae vaccine E. coli PO Vandamme et al. (2011)}N
Cattle Liposome Streptomycin Brucellosis Intramammary Nicoletti et al. (1989)}N
Liposome Gentamicin S. aureus mastitis Intramammary MacLeod and Prescott, 1988}4.
Liposome Adriamycin Leukaemia IV Onuma et al. (1989)d}N
Niosome Flurbiprofen Analgesic IV Confalonieri et al. (2010)4}N
Ring shaped Human respiratory
syncytial
Bovine respiratory Intranasal, IM Riffault et al. (2010)N
Nanoparticle Virus nucleoprotein Syncytial virus
Liposome Diclofenac Anti-inﬂammatory and
analgesic
Transdermal Lynn et al. (2004)dN
Caldwell et al. (2004)4N, Schleining et al.
(2008)4., and Levine et al. (2009)N
Horses Liposome 99 m-technetium Imaging IV Underwood et al. (2012)jN
Liposome DNA Transfection of equine
spermatozoa
N/A Ball et al. (2008)}N
Liposome Diamidine Treatment of babesiosis IM Timofeev et al. (1994)djN
Micellar microemulsion Propofol Anaesthesia IV Boscan et al. (2010)4
Boscan et al. (2006)jN
Micelle Ivermectin Strongylus vulgaris IM Klei et al. (1984).
Polymer nanospheres Streptococcus equi
antigens
Strangles vaccine Intranasal Florindo et al. (2009)d}N
Water based nanoparticle
adjuvant
Rhodococcus Equi Vap
peptides
R. equi pneumonia vaccine IM Cauchard et al. (2006)d}
Liposome Toxoplasma gondii antigen T. gondii vaccine IM Hiszczynska-Sawicka et al. (2011)N
Sheep Liposome Bovine leukaemia virus Bovine leukaemia virus
vaccine
IM Usui et al. (2003)dN
(continued on next page)
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Table 1 (continued)
Species Nanoparticle Agent Disease Administration
route
Reference
Liposome Staphylococcal antigens Staphylococcal mastitis
vaccine
IM Amorena et al. (1994)d}N
Polystyrene nano-beads Ovalbumin Evaluation of the
nanobeads as an adjuvant
SC, IM,
Intradermal
Scheerlinck et al. (2006)}jN
Polystyrene nano-beads Foot and Mouth Disease
antigens
Foot-and-Mouth disease
vaccine
Intradermal Greenwood et al. (2008)}N
Micelle Fasciola hepatica antigen
Fh12
F. hepatica SC Martinez-Fernandez et al. (2004)dN
DNA chitosan nanospheres Newcastle disease vaccine
and IL-2 gene
Newcastle disease vaccine IM Zhang et al. (2010)dN
Birds Liposome Butorphanol Arthritis in parrots and
conures
SC Paul-Murphy et al. (2009a)N and Paul-Murphy
et al. (2009b)}N
Liposome Avian pathogenic E-coli
vaccine
Avian colibacillosis vaccine Intraocular Yaguchi et al. (2009)djN
Liposome Fimbriae antigens SEF14
and SEF 21
Salmonella enteritidis
vaccine
Intraocular/
nebulised
Li et al. (2004)dN
Fukutome et al. (2001)d}N
Liposome DNA vaccine Newcastle disease virus and
infectious bursal disease
virus vaccine
Transdermal Heckert et al. (2002)N
Liposome M. gallisepticum vaccine M. gallisepticum vaccine SC Barbour and Newman, 1990Nd
Micelle Newcastle disease vaccine Newcastle disease vaccine PO Wambura, 2010dN
Polymer nanoparticle Chlamydophila psittaci
vaccine
C. psittaci vaccine Nebulised Verminnen et al. (2010) and Verminnen
et al.d}N
Chitosan nanoparticles Copper Copper supplementation PO Wang et al. (2011a)N
Fig. 2. Dorsal scintigraphic image of the caudal thigh muscles of a horse with an
area of focal inﬂammation in the right thigh. This image was acquired 21 h post
injection with 99 m-technetium labelled PEG-liposomes. Increased radiopharma-
ceutical uptake is present at the site of focal inﬂammation consistent with liposome
accumulation at that site.
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vants are highly tuneable and can be engineered for reduced dos-
age frequency via a convenient administration route in order to
provoke a speciﬁc immune response, e.g. the intranasal route to
better target mucosal immunity (Morein et al., 2004; Scheerlinck
et al., 2006; Wang et al., 2011b). This makes them highly amenable
to engineering for veterinary species where large numbers of ani-
mals may need to be treated at once in a commercial unit, or when
vaccination by conventional means is inconvenient due to exten-
sive management systems or poor accessibility (e.g. wildlife).
Nanoparticle adjuvants increase the immunogenicity of a vac-
cine in ﬁve (potential) ways (Nordly et al., 2009). Firstly, by mim-
icking pathogen-associated molecular patterns they can activate
pattern recognition receptors, such as Toll-like receptors, and trig-
ger intracellular signalling cascades that initiate the innate im-
mune response, resulting in enhancement of the adaptive
immune response. Secondly, by upregulating co-stimulatory mole-cules on antigen presenting cells, nanoparticle adjuvants increase
the activation of T cells by antigen. Thirdly, nanoparticle adjuvants
can control the residence time, location and dose of antigen re-
leased so as to maintain immunity levels and enhance transloca-
tion of antigen to lymph nodes. Fourthly, they act as a depot to
provide prolonged delivery of antigens. Finally, nanoparticles can
be engineered to produce virus like particles that have similar mor-
phology to virus capsid, and stimulate immune responses without
the infectious genetic material that is responsible for host infection
(Nordly et al., 2009).
Nanoparticle adjuvants that are approved for veterinary use (or
in clinical trials) include emulsions, liposomes, polystyrene nano-
beads, immune-stimulating complexes (ISCOMs) and inorganic
particles (Scheerlinck et al., 2006; Nordly et al., 2009; Vandamme
et al., 2011). For practical veterinary use, nanoparticle adjuvants
need to be inexpensive, stable, easy to administer and biodegrad-
able in species used for human consumption (Aucouturier et al.,
2001). Although use of the more expensive nanoparticle formula-
tions (such as DNA-coated gold nanoparticles) may be cost prohib-
itive, the ﬂexibility and adjustable nature of nanoparticle based
vaccine delivery systems holds great promise for the development
of veterinary vaccines that can be administered via a more conve-
nient route at reduced frequency compared to conventional
counterparts.
To date, more than 40 diseases of animal species including
equine inﬂuenza and Streptococcus equi var. equi infection in
horses (Florindo et al., 2009; Morein et al., 2004), foot-and-mouth
disease, bovine virus diarrhoea virus and Toxoplasma gondii in
ruminants (Harpin et al., 1999; Cubillos et al., 2008; His-
zczynska-Sawicka et al., 2011); Newcastle disease and H5N1
inﬂuenza in poultry (Rimmelzwaan et al., 1999; Zhang et al.,
2010), enterotoxigenic E. coli and atrophic rhinitis in swine (Kang
et al., 2008), and parvovirus and atopic dermatitis in dogs (Morein
et al., 2004; Mueller et al., 2005; Vandamme et al., 2011) have
nanoparticle vaccine delivery systems that are either successfully
developed or under development. A detailed review of nanoparti-
cle based veterinary vaccines is provided by Scheerlinck and
Greenwood (2008).
1 See: www.nanoforum.org.
2 See: http://nhecd.jrc.ec.europa.eu/.
3 See: http://goodnanoguide.org.
4 See: http://www.nanowerk.com/phpscripts/n_dbsearch.php.
5 US Food and Drug Administration; see: www.fda.gov/nanotechnology/.
6 See: http://royalsociety.org/uploadedFiles/Royal_Society_Content/policy/publica-
tions/2004/9693.pdf.
7 See: http://www.oecd.org/document/26/0,3746,en_2649_37015404_
42464730_1_1_1_1,00.html.
8 See: http://www.observatory-nano.eu/project/.
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The unique physicochemical properties of nanoparticles that
potentiate their usefulness for veterinary applications can also re-
sult in adverse effects. Careful and thorough evaluation of these ef-
fects and their implications, not only for the animals receiving the
nanoparticle formulation but also on people in contact with them,
the environment, and of course any residues in food-producing
livestock, is an essential part of nanoparticle development (O’Brien
and Cummins, 2010). Just as the biological properties of nanopar-
ticles vary with their physicochemical properties, the potential
toxicity of nanoparticles can also be affected by a wide range of
factors including chemical composition, charge, size and shape
(Card et al., 2011). Of particular concern are the non-biodegradable
nanoparticle formulations, particularly inorganic nanoparticles,
which are generally associated with more signiﬁcant adverse ef-
fects and have greater potential for accumulation than biodegrad-
able biocompatible nanoparticles such as liposomes and micelles.
Evaluation of the safety of nanoparticle formulations requires a
combination of in vitro and in vivo studies. The preliminary step is
to evaluate in vitro cytotoxicity, genotoxicity and the inﬂuence of
nanoparticles on cell signalling and other cellular functions using
cell culture models and gene expression analyses (Schrand et al.,
2010). Common mechanisms of nanoparticle toxicity at this level
include DNA damage resulting in mutagenesis and potential carci-
nogenesis, oxidative damage, interactions with proteins and en-
zymes, cellular apoptosis, up-regulation of inﬂammatory genes,
mitochondrial damage and cytoskeletal and extracellular matrix
disruption (You et al., 2005; Pernodet et al., 2006; Park et al.,
2008; Zhao and Castranova, 2011).
As different cell types show varying sensitivity to nanoparticle
formulations (Schrand et al., 2010) it is important to use a variety
of cell types with which the nanoparticle is likely to interact based
on biodistribution studies. Whereas in vitro studies provide a bet-
ter understanding of the comparative toxicity of nanoparticles, the
results rarely translate directly into in vivo systems. Therefore
in vivo studies are also essential to characterise fully the biodistri-
bution and potential adverse effects of nanoparticles.
The absorption, distribution, metabolism, accumulation and
excretion of each nanoparticle formulation must be deﬁned by
pharmacokinetic and toxicokinetic studies, and at each stage the
interactions of nanoparticles with ﬂuids, cells and tissues needs
to be considered. In addition to direct toxic effects such as anaphyl-
axisis, hepatotoxicity, nephrotoxicity, inﬂammation and granu-
loma formation (Chen et al., 2006; Ji et al., 2007; Szebeni et al.,
2007; Ho et al., 2011), the persistence and accumulation of non-
biodegradable nanoparticles, such as magnetic silica, in tissues
over prolonged periods of time (Kim et al., 2006), is a concern in
food producing species and raises the potential for environmental
contamination. Moreover, the reproductive and developmental
consequences of nanoparticle formulations must also be consid-
ered in breeding animals. Nanoparticle-induced disruption of
endothelial barriers such as the blood–testis barrier can have
reproductive consequences (Kim et al., 2006; Sharma and Sharma,
2007; Rahman et al., 2009) and developmental defects have been
reported in association with metallic nanoparticles and dendri-
mers (Heiden et al., 2007; Asharani et al., 2008; Browning et al.,
2009).
In addition to the direct effects of intentional nanoparticle
administration, their increasing use in commercial and industrial
applications results in nanoparticle accumulation in the environ-
ment, which can have signiﬁcant impact on veterinary species, par-
ticularly ﬁsh (O’Brien and Cummins, 2010, 2011; Van Hoecke et al.,
2011). Recently there has been increased cohesion between nano-
researchers to address the issue of nanotoxicity, with several web-
databases and forums available to aid selection of approvednanomaterials and to provide information on the environmental
impact and safety of nanoparticles. These include the EU Nanofo-
rum,1 the Nano Health Environment Commented Database project,2
‘The Good Nano Guide’3 and Nanowerk.4
In order to address potential safety issues arising from the use
of nanotechnology, effective regulation of the nanotech industry
is essential. Historically, this has lagged behind nanoparticle appli-
cation not only in the medical ﬁeld, but also in the food, construc-
tion, energy and automotive industries. At present nanoparticle
formulations for veterinary and medical use are approved by the
appropriate regulatory bodies in their respective countries, such
as the FDA.5 The regulatory frameworks are often based primarily
on the properties of substances in bulk rather than nanoparticle
form. However, effective nano-regulation requires an understanding
and consideration of the unique properties of nanoparticle formula-
tions (Eiﬂer et al., 2011). The Royal Society was one of the ﬁrst bodies
to initiate a paradigm shift in the attitude towards regulation of the
nanotechnology industry with their 2004 report ‘Nanoscience and
nanotechnologies: opportunities and uncertainties’.6 But, even by
that time many nanotech formulations were already being marketed
commercially. It was only in October, 2011 that The Nanotechnology
Regulatory Science Act was introduced in the US Senate, to address
the health and safety risks of nanomaterials, by which time over
1300 consumer nanotechnology products were available (Pryor,
2011).
Recently, a number of international bodies have also been
formed to address concerns over nanotoxicity and safety. These in-
clude the OECD Working Party on Manufactured Nanomaterials7
and ObservatoryNANO.8 Whilst some progress has been made, the
stances of the various regulatory bodies worldwide need to be re-
ﬁned to provide a harmonised, dynamic and inclusive approach to
nanoregulation so that they are able to adapt quickly to change in
this rapidly expanding ﬁeld. Detailed information on current nan-
oregulatory bodies is provided in the 2011 ObservatoryNANO report
(ObservatoryNANO, 2011) and the 2011 OECD Working Party on
Manufactured Nanomaterials report (OECD, 2011).Nanoparticle formulations
This section provides a brief synopsis of the most prominent
nanoparticle systems, their applications and limitations, with a
view to familiarising the reader with the basic details of those for-
mulations available for veterinary application. A complete over-
view of each of these systems is beyond the scope of this review
and references to articles that provide a comprehensive analysis
of each nanoparticle system are provided within the text.Polymeric nanoparticles
Polymeric nanoparticles are prepared by combining the active
substance/drug with a polymer. The active components are dis-
solved in, entrapped in, or adsorbed to the surface of the polymer
nanoparticle. Polymeric nanoparticles exist in a variety of forms
ranging from nanospheres to dendrimers (Fig. 3a), and utilise both
natural and synthetic polymers. Polymer delivery characteristics,
surface properties, morphology and composition can be readily tai-
Fig. 3. A schematic diagram of some of the forms of nanoparticle systems discussed
in this article: (a) a polymeric dendrimer typical size range 100–200 nm; (b) a
liposome, typical size range 50–200 nm; (c) a nanoemulsion, typical size range 50–
500 nm; (d) a phospholipid micelle typical size range 5–50 nm.
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patibility, targeting, degradation and controlled release kinetics
(Yang, 2000).
The primary limitations to the development of polymeric nano-
particles include toxicity, irritancy, the need for a biodegradable
soluble material and a lack of large scale production methods
(Muller and Keck, 2004). Several reviews have focused on the
application of polymer materials in drug delivery (Uhrich et al.,
1999; Yuk and Bae, 1999; Paleos et al., 2007) and gene delivery
(Morille et al., 2008; Paleos et al., 2009).Solid lipid nanoparticles
Solid lipid nanoparticles (SLNs) are composed of lipids that are
solid at room temperature, stabilised by surfactant and suspended
in an aqueous solution. The pharmaceutical agent is dissolved or
dispersed within the lipid. SLNs exhibit several advantages over
polymeric nanoparticles. For example, they have comparatively
higher drug entrapment efﬁciency and can be administered by
multiple routes (orally, topically, and IV). Moreover, hydrophobic
drugs are stable in their lipid matrix, they protect sensitive drugs
from the external environment, they have minimal toxicity and
they do not require the use of organic solvents in their production
(which can be easily scaled up to commercial level) (Blasi et al.,
2007; Mishra et al., 2009). Additionally SLNs can provide con-
trolled release formulations lasting up to several weeks, they ad-
here to mucosal surfaces, promote the absorption of orally
administered drugs and have particular potential for drug delivery
to the brain as they are capable of transporting pharmaceuticals
across the blood brain barrier (Muller and Keck, 2004; Blasi et al.,
2009). A thorough review on SLN formulations for drug delivery
is provided by Souto and Doktorová (2009).Liposomes
Liposomes are vesicles in which an aqueous core is encapsu-
lated within one or more phospholipid bilayers (Fig. 3b). They have
been used as drug delivery systems since the 1960s, with their ﬁrst
market appearance in 1986 in a cosmetic formulation by Dior, and
are considered by some to be the archetypical nanoparticle (Muller
and Keck, 2004). Liposomes are highly ﬂexible delivery systems,
able to carry both hydrophobic and hydrophilic substances. They
can be conjugated to antibodies or ligands and have their size,
the number of phospholipid bilayers, lipid composition, surface
characteristics and charge engineered to optimise their suitability
for an intended use.
Liposomes are suitable for topical, IV and IM administration, but
because they are susceptible to degradation in the gastrointestinal
tract they are rarely suitable for oral use. They have been investi-
gated for targeted drug, imaging agent, vaccine and gene delivery
with promising results (Dams et al., 2000; Bakker-Woudenberg
et al., 2005). Several commercially available liposome formulations
are on the market and there are multiple studies on their applica-
tion in the veterinary species (Table 1). However, their application
has been slowed somewhat by stability issues, difﬁcult manufac-
turing techniques and expense. In recent years, the scaling up of
liposome production for commercial applications has resulted in
the availability of liposomes that have a reasonable shelf life and
are an affordable, practical option for use in veterinary medicine.
Liposomes have biodegradable constituents so toxicity is rarely
an issue; however, complement-mediated hypersensitivity reac-
tions may occur in response to IV liposome administration (Muller
and Keck, 2004; Szebeni et al., 2007). The clinical picture of these
complement mediated reactions includes cardiovascular, respira-
tory and cutaneous symptoms, as well as chest and back pain,
hypersalivation, increased urination and defaecation, and even
death (Szebeni et al., 2007). Such reactions only occur in a small
proportion of individuals and can be prevented by slow infusion
and the administration of anti-histamines and anti-inﬂammato-
ries, but they have inhibited the successful application of lipo-
somes in human medical imaging.
Nanoemulsions
Nanoemulsions are dispersions of oil and water where the dis-
persed droplets are stabilised with a surface ﬁlm composed of sur-
factant and co-surfactant. Most commonly, drugs are loaded into
the dispersed phase where the droplet size is typically 20–
200 nm. An oil-in-water emulsion consists of dispersed oil droplets
within an aqueous solution. Water-in-oil emulsions and water-in-
oil-in-water emulsions have also been formulated for biomedical
application.
The advantages of nanoemulsions include simple, inexpensive
preparations, high stability, the ability to solubilise lipophilic sub-
stances and to protect from degradation. Nanoemulsions are versa-
tile and can be prepared by many different aqueous solutions,
surfactant and oil constitutes. According to the properties of their
constituents, they exist in a wide range of compositions and thus
perform a wide variety of tasks.
Low-cost, solvent free nanoemulsions have been produced for
use in veterinary species (Vandamme and Anton, 2010) and prom-
ising results have been achieved using nanoemulsions for drug
delivery, particularly via the oral and transdermal routes (Kawaka-
mi et al., 2002; Kang et al., 2004; Ke et al., 2005). However, nano-
emulsions are relatively new nanoparticles and a considerable
amount of fundamental work needs to be performed to fully estab-
lish their physiochemical behaviour. Additionally the high concen-
trations of solvents, surfactants and co-surfactants in some
nanoemulsion formulations can be toxic to the tissues where they
C. Underwood, A.W. van Eps / The Veterinary Journal 193 (2012) 12–23 19accumulate or are applied, resulting in haemolysis, cellular dam-
age, and tissue inﬂammation (Karasulu et al., 2007; He et al.,
2010). The potential toxicity of the solvents and emulsiﬁers that
are suitable for use have been published by various regulatory
bodies including the World Health Organization9 and the FDA,
and any nanoemulsion formulation for veterinary application would
have to meet similar regulatory standards. Detailed reviews of the
use of nanoemulsions in drug delivery can be found elsewhere
(Lawrence, 2000; Karasulu, 2008; He et al., 2010).
Micelles
Polymeric micelles have a unique structural composition char-
acterised by a hydrophobic core sterically stabilised by a hydro-
philic shell. Due to their hydrophilic shell they are highly water
soluble and evade MPS clearance. Thus, micelles have long circula-
tion times and exhibit the EPR effect. Hydrophobic substances are
stored in the micelle core, where they are solubilised and protected
from enzymatic degradation.
Micelles are divided into four classes, based on the constituents
of their hydrophilic shell: (1) phospholipid micelles, whose shell is
comprised of phospholipids; (2) pluronic micelles, where the shell
is a block copolymer comprised of hydrophilic polyethylene oxide
and hydrophobic polypropylene oxide blocks; (3) poly(L-amino
acid) micelles, and (4) polyester micelles with a shell composed
of biocompatible polymers (Koo et al., 2005).
Micelles can be easily prepared, have low toxicities and have
the potential to be a versatile system for effective delivery of differ-
ent classes of therapeutic agent, with at least six micelle formula-
tions currently being studied in clinical trials (Matsumura and
Kataoka, 2009; Saif et al., 2009). However, careful engineering of
the micelle is necessary to ensure long-term stability and drug
loading capacity (Blanco et al., 2009). Further information on mi-
celles and their clinical application can be found in the reviews
by Blanco et al. (2009), Kim et al. (2010) and Yokoyama (2010).
Inorganic nanoparticles
The most intensively studied inorganic nanoparticles are re-
viewed in brief below. In early studies, inorganic nanoparticles
demonstrated great potential as nanocarriers for therapeutic
agents, vaccines and imaging agents. However, their clinical appli-
cation is limited by concerns over toxicity, lack of biodegradability
and persistent tissue accumulation. Therefore relatively few inor-
ganic nanoparticles have progressed to clinical application. Further
details are available in a review by Fadeel and Garcia-Bennett
(2010) and in the references for the individual nanoparticles.
Ceramic nanomaterials
Ceramic nanoparticles made of materials such as silica, alumina
and titania, have several advantages over polymeric nanoparticle
systems in that they are easy to prepare and engineer to a desired
shape, size and porosity, are biocompatible, have large surface to
volume ratios, have high surface tailorability and are extremely in-
ert. Additionally, they protect the adsorbed particles they carry
against denaturation induced by extreme pH and temperature.
However, titania nanoparticles appear to possess considerable
in vivo toxicity (including causing distress and death in rats) and
detailed toxicological studies of mesoporous silica nanoparticles
are lacking (Fadeel and Garcia-Bennett, 2010).
Carbon nanomaterials9 See: www.who.int.Carbon nanomaterials include fullerenes, carbon nanotubes and
carbon nanohorns, and have been investigated as drug carriers.
They also have potential for vaccine delivery as they amplify the
immunological response (Pantarotto et al., 2003). However, single
walled carbon nanotubes trigger oxidative stress and are cytotoxic
in cultured cell lines (Fadeel and Garcia-Bennett, 2010) and toxic-
ity and biodegradability are a signiﬁcant concern in clinical appli-
cation (Lamprecht, 2009; Surendiran et al., 2009).
Metallic nanomaterials
Various metals have been used to prepare nanoparticles. Gold,
silver and copper are most commonly used, with gold nanoparti-
cles being the most intensively studied (Ghosh et al., 2008; Mishra
et al., 2009). The main applications of metal nanoparticles lie in
biosensing/imaging and cancer thermotherapy, although they are
also being explored for targeted drug delivery (Jain et al., 2007;
Saha et al., 2007).
Metal nanoparticles can easily be synthesised with a range of
sizes (1–150 nm), are stable and can be modiﬁed by conjugation
with various functional groups (Jain et al., 2007). However, they
have a range of toxic effects, including respiratory toxicity, distur-
bances to trace elements in tissues, inhibition of sodium–potas-
sium–ATPase, and oxidative stress which, combined with their
prolonged retention in tissues, is of signiﬁcant concern (Shaw
and Handy, 2011).
Magnetic nanoparticles
Magnetic nanoparticles are commonly composed of iron oxide
due to its high in vivo degradability. They have been investigated
for use as biosensors, for imaging and for drug delivery. In addition
to performing targeted drug delivery by passive and active target-
ing, magnetic nanoparticles can be pulled out of suspension in the
bloodstream and into localised disease sites by application of a
high gradient magnetic ﬁeld over that tissue (Mishima et al.,
2007; Nishijima et al., 2007).
Despite having many characteristics that make them excellent
agents for drug delivery and imaging, concerns over toxicity and
the accumulation of metal-based particles are a signiﬁcant barrier
to the clinical application of magnetic nanoparticles (Veiseh et al.,
2009) at the present time. Banerjee et al. (2010) provide a thorough
review of the biomedical applications of magnetic nanoparticles.
Quantum dots
Quantum dots are semi-conductor nanoparticles that measure
approximately 2–10 nm and ﬂuoresce when stimulated by light.
They are comprised of an inorganic core, an inorganic shell and
an aqueous coating to which biomolecules can be conjugated.
The size of the core determines the colour of light emitted. Bio-
medical applications of quantum dots are primarily focused on
their use as imaging agents (Bentolila et al., 2009). Quantum dots
can be targeted to various biomarkers providing a highly sensitive
diagnostic and research tool (Halfpenny and Wright, 2010). How-
ever, clinical application of quantum dots is limited by their poten-
tial cytotoxicity and slow elimination (Iga et al., 2007; Hauck et al.,
2009).Conclusions
Whilst the hypothesised ‘nano-bot’ that can detect a disease
and release a payload of pharmaceutical treatment is far from clin-
ical reality, it is evident from the studies and results detailed in this
review that the practical application of nanotechnology to veteri-
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underlies the mechanisms by which nanoparticles improve drug
delivery, food supplementation, diagnostics and vaccines. Nano-
particle drug carriers are already enabling veterinarians to revisit
challenging disease entities using a different approach and increas-
ing their pharmaceutical armamentarium. The application of nano-
technology to veterinary medicine provides the opportunity for
improved drug, vitamin, mineral and vaccine delivery by methods
suitable for bulk application to wildlife and extensive production
systems, and quick, sensitive on-site diagnostic tests for many vet-
erinary diseases. This offers potential for improving herd manage-
ment and productivity in food producing animals.
Although challenges remain in nanomedicine application, par-
ticularly relating to toxicity, nanocarrier residues and production
costs, collaboration between various disciplines including human
and veterinary medicine, engineering and materials science will
expand existing knowledge to resolve these issues, increasing their
applicability for veterinary use. Although not yet a dramatic revo-
lution, nanoparticles are edging their way into the veterinary ﬁeld,
and are likely to continue to do so into the future.Conﬂict of interest
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Appendix 2: Ultrafiltration probe placement 
 
Figure II.I Preparation of the foot prior to probe placement. An approximately 20 x 20 
mm piece of hoof has been resected at the dorsal toe. The foot is being scrubbed to remove 
dirt and debris prior to a final sterile prep being performed focused on the resection site. 
 
Figure II.II Placement of the introducer needle showing the hoof # wrapped in an 
antimicrobial surgical incise drape (Ioban, 3M) and the limb was extended cranially and 
placed on a hoof stand.  The custom made introducer has been was inserted into the lamellar 
layer at the centre of the resection and the tip of the introducer is visible exiting at the 
coronary band.  
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Figure II.III Placement of the ultrafiltration probe.  The ultrafiltration probe is shown 
being threaded through the introducer needle. The tubing of the probe was inserted initially at 
the hub of the introducer, and drawn through the introducer until the loops of semipermeable 
membrane (visible in the figure entering the hub of the introducer) lay in the lamellar region. 
The tubing of the probe was marked prior to sterilisation to ensure accurate placement of the 
semipermeable membrane. 
 
Figure II.IV Removal of the introducer. The introducer was removed by retracting it at the 
hub (A) leaving the probe in situ in the lamellar tissue with the tubing exiting at the coronary 
band. 
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Figure II.V Securing the probe. The resection site was packed with sterilised dental putty 
and the plastic tubing of the ultrafiltration probe was secured to the pastern using a white tape 
‘butterfly’ and superglue. The ultrafiltration tubing was connected to a vacutainer using a 
commercially supplied vacutainer holder which was then taped to the metacarpus and 
covered with a stable bandage. In initial studies where the horses were stabled for several 
days the hoof was also covered in a bandage to the level of the metacarpophalangeal joint and 
placed in a hoof boot. This figure shows the limb of a horse in Chapter 5; these horses were 
housed in stocks for the duration of the study hence no further protection was added beyond 
what is shown in the figure. The catheter placed in the lateral palmar digital vein for 
performing RIVI is visible on the lateral (left) side of the pastern.  
 
  
219 
 
Figure II.VI Diagram showing the location of the ultrafiltration probe.  The location of 
the ultrafiltration probe within the lamellar tissue is depicted in red on this longitudinal 
section of a cadaver limb. 
 
 
Figure II.VII Schematic diagram demonstrating the relative positions of the 
ultrafiltration probe and IOIDP cannula in Chapter 3. The ultrafiltration probe was 
inserted 10-20 mm lateral to midline (red dotted line), hence was 10-20 mm lateral cannula 
placement site (yellow circle) which was located 25 mm below the coronary band on midline. 
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Appendix 3: Clinical parameters during and after liposome 
infusion 
Figure III.I Changes in clinical parameters during and immediately following 
intravenous PEG-liposome infusion. There were no significant changes in heart rate, 
respiratory rate or temperature during or immediately after the infusion. Data are expressed as 
median ± interquartile range.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.II Clinical parameters in the 12 h following the start of intravenous PEG-
liposome infusion. There were no significant changes in heart rate, respiratory rate or 
temperature during or immediately after the infusion. Data are expressed as median ± 
interquartile range. 
 
 
 
 
 
 
 
 
 
 
